[go: up one dir, main page]

WO2021146424A1 - Bicyclic heterocycles as fgfr inhibitors - Google Patents

Bicyclic heterocycles as fgfr inhibitors Download PDF

Info

Publication number
WO2021146424A1
WO2021146424A1 PCT/US2021/013438 US2021013438W WO2021146424A1 WO 2021146424 A1 WO2021146424 A1 WO 2021146424A1 US 2021013438 W US2021013438 W US 2021013438W WO 2021146424 A1 WO2021146424 A1 WO 2021146424A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
independently selected
membered heterocycloalkyl
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/013438
Other languages
French (fr)
Inventor
Jeremy ROACH
Artem SHVARTSBART
Michael Witten
Wenqing Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of WO2021146424A1 publication Critical patent/WO2021146424A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the enzyme FGFR and are useful in the treatment of FGFR-associated diseases such as cancer.
  • the Fibroblast Growth Factor Receptors are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands.
  • FGF fibroblast growth factor
  • FGFR1-4 FGFR proteins that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation.
  • the receptors Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins.
  • These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al.
  • carcinomas e.g., bladder, breast, colorectal, endometrial, gastric, head and neck, kidney, lung, ovarian, prostate
  • hematopoietic malignancies e.g., multiple myeloma, acute myelogenous leukemia, and myeloproliferative neoplasms
  • other neoplasms e.g., glioblastoma and sarcomas.
  • FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.
  • compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
  • the present disclosure is further directed to methods of inhibiting an FGFR enzyme (e.g., an FGFR3 enzyme) comprising contacting the enzyme with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • an FGFR enzyme e.g., an FGFR3 enzyme
  • the present disclosure is further directed to a method of treating a disease associated with abnormal activity or expression of an FGFR enzyme (e.g., an FGFR3 enzyme), comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
  • an FGFR enzyme e.g., an FGFR3 enzyme
  • the present disclosure is further directed to compounds of Formula (I) for use in treating a disease associated with abnormal activity or expression of an FGFR enzyme (e.g., an FGFR3 enzyme).
  • an FGFR enzyme e.g., an FGFR3 enzyme
  • the present disclosure is further directed to a method for treating a disorder mediated by an FGFR enzyme (e.g., an FGFR3 enzyme), or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound of Formula (I), or pharmaceutically acceptable composition thereof.
  • the present disclosure is further directed to a method for treating a disorder mediated by an FGFR enzyme (e.g., an FGFR3 enzyme), or a mutant thereof, in a patient in need thereof, comprising the step of administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with another therapy or therapeutic agent as described herein.
  • the present disclosure is further directed to the use of compounds of Formula (I) in the preparation of a medicament for use in therapy.
  • R 1 is selected from OR al , SR al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , NR cl C(0)NR cl R dl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0) 2 R bl , and S(0) 2 NR cl R dl ;
  • R 2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 20 ;
  • R 3 and R 4 are each independently selected from H, D, halo, CN, Ci- 6 alkyl, OR a8 and NR cX R dx ; wherein the Ci- 6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R g ;
  • R 5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 50 ;
  • A is N or CR a ;
  • R A is selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, halo, CN, NO2, OR a , SR a , C(0)R b , C(0)NR c R d , C(0)OR a , OC(0)R b , OC(0)NR c R d , NR c R d , NR c C(0)R b , NR c C(0)OR a , NR c C(0)NR c R d , NR c S(0)R b , NR c S(0) 2 R b , NR c S(0) 2 NR c R d , S(0)R b , S(0)NR c R d , S(0) 2 R b and S(0) 2 NR c R d ; wherein said Ci-e alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally
  • R 6 is selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, halo, CN, NO2, OR a12 , SR a12 , C(0)R b12 , C(0)NR cl2 R d12 , C(0)OR a12 , OC(0)R b12 , 0C(0)NR cl2 R d12 , NR cl2 R d12 , NR cl2 C(0)R b12 , NR cl2 C(0)0R a12 , NR cl2 C(0)NR cl2 R d12 , NR cl2 S(0)R b12 , NR cl2 S(0) 2 R b12 , NR cl2 S(0) 2 R b12 , NR cl2 S(0) 2 NR b12 , NR cl2 S(0) 2 NR cl2 R d
  • the present disclosure provides compounds of Formula (I) , or a pharmaceutically acceptable salt thereof, wherein A is N. In some embodiments, the present disclosure provides compounds of Formula (I) , or a pharmaceutically acceptable salt thereof, wherein A is CH.
  • R 1 is selected from OR al , SR al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , and NR cl C(0)NR cl R dl .
  • R 1 is selected from OR al , SR al , NR cl R dl , NR cl C(0)R bl , and NR cl C(0)0R al .
  • R 1 is selected from OR al and NR cl R dl .
  • R 1 is OR al .
  • each R al is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -ioaryl, 5-10 membered heteroaryl, and C6-10 aryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci- 6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -io aryl, 5-10 membered heteroaryl, and C6-10 aryl-Ci-3 alkylene, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 10 .
  • each R al is independently selected from H, Ci- 6 alkyl, C3-6 cycloalkyl, 5-6 membered heterocycloalkyl, phenyl, and phenyl-Ci-3 alkylene; wherein a ring forming carbon atom of the 5-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci- 6 alkyl, C3-6 cycloalkyl, 5-6 membered heterocycloalkyl, phenyl, and phenyl-Ci-3 alkylene, are each optionally substituted with 1 or 2 substituents independently selected from R 10 .
  • R al is selected from methyl, ethy, isopropyl, cyclobutyl, benzyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, oxetanyl, oxopyrrolidinyl, azetidinyl, and tetrahydropyranyl; wherein methyl, ethy, isopropyl, cyclobutyl, benzyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, oxetanyl, oxopyrrolidinyl, azetidinyl, and tetrahydropyranyl are each optionally substituted with with 1 or 2 substituents independently selected from R 10 .
  • R al is selected from methyl, ethy, isopropyl, 3- cyanocyclobutyl, benzyl, phenyl, methoxy ethyl, dimethylaminoethyl, tetrahydrofuran-3-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, oxetan-3-yl, 2-oxopyrrolidin-3-yl, 1 -methyl -2- oxopyrrolidin-3-yl, l-acetylazetidin-3-yl, and tetrahydo-2H-pyran-4-yl.
  • R al is methyl.
  • R al is tetrahydrofuranyl (e.g., (S)- tetrahydrofuran-3-yl and (R)-tetrahydrofuran-3-yl).
  • each R 10 is independently selected from Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C 6 -ioaryl, 5-10 membered heteroaryl, halo, D, CN, OR a3 , SR a3 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , NR c3 R d3 , and NR c3 C(0)R b3 .
  • each R 10 is independently selected from Ci- 6 alkyl, C6-10 aryl, CN, OR a3 , C(0)R b3 , and NR c3 R d3 .
  • each R 10 is independently selected from methyl, methoxy, methylcarbonyl, CN, phenyl, and amino.
  • each R a3 , R c3 and R d3 is independently selected from H, Ci- 6 alkyl, C2-6 alkenyl, and C2-6 alkynyl.
  • R a3 is H or Ci- 6 alkyl.
  • R a3 is Ci- 6 alkyl.
  • R c3 is H or Ci- 6 alkyl.
  • R c3 is Ci- 6 alkyl.
  • R d3 is H or Ci- 6 alkyl.
  • R d3 is Ci- 6 alkyl.
  • R b3 is selected from Ci- 6 alkyl, C2-6 alkenyl, and C2-6 alkynyl.
  • R b3 is Ci- 6 alkyl.
  • R 1 is NR cl R dl .
  • each R cl and R dl is independently selected from H, Ci- 6 alkyl, Ci - 6 haloalkyl, and 4-10 membered heterocycloalkyl; wherein said Ci- 6 alkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 10 .
  • each R cl and R dl is independently selected from H, Ci- 6 alkyl, and 5-6 membered heterocycloalkyl; wherein said Ci- 6 alkyl and 5-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 substituents independently selected from R 10 .
  • each R cl and R dl is independently selected from H, methyl, and tetrahydrofuranyl; wherein said methyl and tetrahydrofuranyl are each optionally substituted with 1 or 2 substituents independently selected from R 10 .
  • one of R cl and R dl is H and the other is methyl or tetrahydrofuranyl .
  • R bl is Ci- 6 alkyl.
  • R 1 is selected from methoxy, ethoxy, isopropoxy, 3- cyanocyclobutoxy, benzyloxy, phenoxy, 2-methoxyethoxy, (dimethylamino)ethoxy, (tetrahydrofuran-3-yl)oxy, pyrrolidin-3-yloxy, (l-methylpyrrolidin-3-yl)oxy, oxetan-3-yloxy, 2-oxopyrrolidin-3-yloxy, (l-methyl-2-oxopyrrolidin-3-yl)oxy, (1-acetylazeti din-3 -yl)oxy, (tetrahydo-2H-pyran-4-yl)oxy, (tetrahydrofuran-3-yl)amino, and methylamino.
  • R 1 is methoxy. In some embodiments, R 1 is (tetrahydrofuran-3-yl)oxy (e.g., ((S)-tetrahydrofuran-3 -yl)oxy and ((R)-tetrahy drofuran-3 -yl)oxy) .
  • R 2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is C6-10 aryl optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is phenyl optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is phenyl, pyrazolyl, pyridinyl, or pyrazolopyridinyl; and wherein phenyl, pyrazolyl, pyridyl, and pyrazolopyridinyl are each optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is pyrazolyl, pyridinyl, or pyrazolopyridinyl; and wherein pyrazolyl, pyridyl, and pyrazolopyridinyl are each optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is pyrazolyl optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is pyridinyl optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • R 2 is pyrazolyl optionally substituted with 1 or 2 substituents independently selected from R 20 .
  • each R 20 is independently selected from Ci- 6 alkyl, C2- 6 alkenyl, C2- 6 alkynyl, Ci- 6 haloalkyl, C3-1 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -ioaryl, 5-10 membered heteroaryl, C 3 -1 0 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 1 0 aryl -C 1- 3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, OR a2 , SR 32 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , NR c2 R d2 , NR c2 C(0)R b2 , NR c2 C(0)0R a2 , NR c2 C
  • each R 20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl -C 1-3 alkylene, halo, D, CN, OR 32 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , NR c2 R d2 , NR c2 C(0)R b2 , NR C2 C(0)0R 32 , S(0)R b2 , S(0)NR c2 R d2 , S(0) 2 R b2 , and
  • 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R 21 .
  • each R 20 is independently selected from Ci-6 alkyl, C2- 6 alkenyl, C2- 6 alkynyl, Ci-6 haloalkyl, C 3 - 6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl,
  • each R 20 is independently selected from Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, halo, CN, C(0)NR c2 R d2 , and NR c2 C(0)0R a2 ; wherein the 4-6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-6 cycloalkyl,
  • each R a2 , R c2 and R d2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl.
  • each R a2 , R c2 and R d2 is independently selected from H and Ci-
  • each R b2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl.
  • any two adjacent R 20 substituents on R 2 ring taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2,
  • two adjacent R 20 substituents on R 2 ring taken together with the atoms to which they are attached, form a fused C3-6 cycloalkyl ring; and wherein the fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 21 .
  • each R 21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , NR c4 R d4 , NR C4 C(0)R m , NR c4 C(0)0R a4 , S(0)R b4 , S(0)NR c4 R d4 , S(0) 2 R M , and S(0)2NR c4 R d4 ; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said
  • each R 21 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, CN, OR a4 , C(0)R b4 , C(0)NR c4 R d4 , and S(0)2NR c4 R d4 ; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 22 .
  • each R 21 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, CN, OR a4 , C(0)R b4 , C(0)NR c4 R d4 , and S(0)2NR c4 R d4 ; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group.
  • each R a4 , R c4 , and R d4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl. In some embodiments, each R a4 , R c4 , and R d4 is independently selected from H and Ci-6 alkyl. In some embodiments, each R b4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl. In some embodiments, R b4 is Ci-6 alkyl.
  • R 21 is CN, pyridinyl, morpholinyl, hydroxy, methyl, N,N- dimethylaminocarbonyl, acetyl, oxopyrrolidinyl, or A f ,A-dimethylsulfamoyl.
  • R 20 is methyl, isopropyl, propanyl, cyclobutyl, oxetanyl, cyanopropanyl, pyridinylmethyl, morpholinoethyl, CN, pyrrolidinyl, oxopyrrolidinyl, hydroxylcyclohexyl, hydroxypropanyl, fluoro, methylcarbamoyl, methylhydroxypropanyl, methoxycarbonylamino, methylpiperazinyl, dioxidotetrahydrothiophenyl, pyridinyl, methylpiperidinyl, (N,N-dimethylaminocarbonyl)piperidinyl, acetylpiperidinyl, oxopyrrolidinylethyl, or (A f ,A-dimethylsulfamoyl)piperidinyl; or any two adjacent R 20 substituents on R 2 ring, taken together with the
  • R 20 is methyl, isopropyl, propanyl, cyclobutyl, oxetanyl, cyanopropanyl, pyridinylmethyl, morpholinoethyl, CN, pyrrolidinyl, oxopyrrolidinyl, hydroxylcyclohexyl, hydroxypropanyl, fluoro, methylcarbamoyl, methylhydroxypropanyl, methoxycarbonylamino, methylpiperazinyl, dioxidotetrahydrothiophenyl, pyridinyl, methylpiperidinyl, (N,N-dimethylaminocarbonyl)piperidinyl, acetylpiperidinyl, oxopyrrolidinylethyl, or (A f ,A-dimethylsulfamoyl)piperidinyl
  • R 2 is 1 -methyl - l//-pyrazol-4-yl, 6-methylpyri din-3 -yl, 5,6- dihydro-4//-pyrrolo[ 1 ,2-/>]pyrazol-3-yl, 1 -(oxetan-3 -yl)- 1 //-py razol -4-y 1, 1 -isopropyl- ⁇ H- pyrazol-4-yl, 1 -cyclobutyl- 1 //-py razol -4-yl, 1 -(2-cyanopropan-2-yl)- l//-py razol -4-yl, (pyrazolo[ 1 , 5-a]pyri din-3 -yl), 1 -(pyri din-3 -ylmethyl)- l//-py razol -4-yl, 1 -(2- m orphol i noethyl )-l//-pyrazol
  • R 2 is l-methyl-lH-pyrazol-4-yl.
  • R 3 is selected from H, D, halo, CN, and Ci-6 alkyl. In some embodiments, R 3 is selected from H, D, and Ci-6 alkyl. In some embodiments, R 3 is selected from H and Ci-6 alkyl. In some embodiments, R 3 is H.
  • R 4 is selected from H, D, halo, CN, and Ci-6 alkyl. In some embodiments, R 4 is selected from H, D, and Ci-6 alkyl. In some embodiments, R 4 is selected from H and Ci-6 alkyl. In some embodiments, R 4 is H.
  • R 3 and R 4 are both H.
  • R 5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R 50 .
  • R 5 is C6-10 aryl optionally substituted with 1, 2, or 3 substituents independently selected from R 50 . In some embodiments, R 5 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R 50 .
  • R 5 is 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-10 membered heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R 50 .
  • R 5 is 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-6 membered heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R 50 .
  • R 5 is pyridinyl, quinolinyl, indazolyl, or benzoisoxazolyl; and wherein pyridinyl, quinolinyl, indazolyl, benzoisoxazolyl, and isoindolinonyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R 50 .
  • each R 50 is independently selected from Ci- 6 alkyl, C2- 6 alkenyl, C2- 6 alkynyl, Ci- 6 haloalkyl, C3-1 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -ioaryl, 5-10 membered heteroaryl, C 3 -1 0 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C 6 - 1 0 aryl -C 1- 3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, OR a9 , SR a9 , C(0)R b9 , C(0)NR c9 R d9 , C(0)OR a9 , NR c9 R d9 , NR c9 C(0)R b9 , NR c9 C(0)0R a9 , NR
  • each R 50 is independently selected from Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, halo, D, CN, NO2, OR a9 , SR a9 , C(0)R b9 , C(0)NR c9 R d9 , C(0)0R a9 , NR c9 R d9 , NR c9 C(0)R b9 , S(0)R b9 , S(0)NR c9 R d9 , S(0) 2 R b9 , and S(0) 2 NR c9 R d9 ; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 4-6
  • each R 50 is independently selected from Ci- 6 alkyl, Ci- 6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, halo, D, CN, OR a9 , C(0)NR c9 R d9 , NR c9 R d9 , NR c9 C(0)R b9 , and S(0)2NR c9 R d9 ; wherein said Ci- 6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl-Ci-3 alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R 51 .
  • each R a9 , R c9 and R d9 is independently selected from H, Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C 1-6 haloalkyl. In some embodiments, each R a9 , R c9 and R d9 is independently selected from H, Ci- 6 alkyl, and Ci- 6 haloalkyl. In some embodiments, each R b9 is independently selected from Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci- 6 haloalkyl.
  • any two adjacent R 50 substituents on the R 5 ring taken together with the atoms to which they are attached, form a fused 4-, 5-, or 6-membered heterocycloalkyl ring; wherein each fused 4-, 5-, or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, or 6- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R 51 .
  • each R 50 is independently selected from methyl, propanyl, cyclopropyl, morpholinyl, phenyl, triazolyl, pyrrolidinylmethyl, pyrazolyl, fluoro, methoxy, ethyoxy, CN, methylaminocarbonyl, methylcarbonylamino, dimethylamino, (2,2,2- trifluoroethyljaminocarbonyl, difluoromethyl, and methylaminosulfonyl; wherein said methyl, propanyl, cyclopropyl, morpholinyl, phenyl, triazolyl, pyrrolidinylmethyl, pyrazolyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R 51 ; or any two adjacent R 50 substituents on the R 5 ring, taken together with the atoms to which they are attached, form a fused oxopyrrolidinyl; and wherein the fused ox
  • each R 51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR al °, SR al °, C(0)R bl °, C(O)NR cl0 R dl °, C(0)OR al °, NR cl0 R dl °, and NR cl0 C(O)R bl °.
  • each R 51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, and OR al °. In some embodiments, each R 51 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, halo, D, CN, and OR al °.
  • each R al °, R cl ° and R dl ° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C 1-6 haloalkyl. In some embodiments, each R al °, R cl ° and R dl ° is independently selected from H and Ci-6 alkyl. In some embodiments, each R bl ° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl.
  • each R 51 is independently selected from methyl, pyrrolidinyl, fluoro, CN, or hydroxy.
  • the present disclosure provides compounds of Formula Ila: or a pharmaceutically acceptable salt thereof, wherein R al , R 2 , R 3 , R 4 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula lib: or a pharmaceutically acceptable salt thereof, wherein R cl , R dl , R 2 , R 3 , R 4 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula Ilia: or a pharmaceutically acceptable salt thereof, wherein R al , R 2 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula Illb: or a pharmaceutically acceptable salt thereof, wherein R cl , R dl , R 2 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula IVa: or a pharmaceutically acceptable salt thereof, wherein R 10 , R 2 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula IVb: or a pharmaceutically acceptable salt thereof, wherein R 2 and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula IVc: or a pharmaceutically acceptable salt thereof, wherein R 10 , R 2 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula Va: or a pharmaceutically acceptable salt thereof, wherein R al , R 20 , and R 5 are as defined herein.
  • the present disclosure provides compounds of Formula Vb: or a pharmaceutically acceptable salt thereof, wherein R al , R 20 , and R 5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Vc: or a pharmaceutically acceptable salt thereof, wherein R al , R 20 , and R 5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Via: or a pharmaceutically acceptable salt thereof, wherein R al , R 2 , and R 50 are as defined herein. In one aspect, the present disclosure provides compounds of Formula VIb: or a pharmaceutically acceptable salt thereof, wherein R al , R 2 , and R 50 are as defined herein.
  • the present disclosure provides compounds of Formula Vila: or a pharmaceutically acceptable salt thereof, wherein R al , R 2 , and R 50 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Vllb: or a pharmaceutically acceptable salt thereof, wherein R al , R 2 , and R 50 are as defined herein.
  • R 1 is selected from OR al , SR al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , NR cl C(0)NR cl R dl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0) 2 R bl , and S(0) 2 NR cl R dl ;
  • R 2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 20 ;
  • R 3 and R 4 are each independently selected from H, D, halo, CN, Ci-6 alkyl, OR a8 and NR cX R dx ; wherein the Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R g ;
  • R 5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 50 ;
  • each R 10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, OR a3 , SR a3 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)0R a3 , NR c3 S(0)R b3 , NR c3 S(0) 2 R b3 , NR c3 S(0) 2 NR c3 R d3 , S(0)R b3 , S(0)NR c3 R d3 , and S(0)2NR c3 R d3 ; wherein said Ci-6 alky
  • R 1 is selected from OR al , SR al , 0C(0)R bl , 0C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)0R al , NR cl C(0)NR cl R dl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0) 2 R bl , and S(0) 2 NR cl R dl ;
  • R 2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 20 ;
  • R 3 and R 4 are each independently selected from H, D, halo, CN, and Ci-6 alkyl;
  • R 5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 50 ;
  • each R 10 is independently selected from Ci-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, OR a3 , SR a3 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)0R a3 , NR c3 S(0)R b3 , NR c3 S(0) 2 R b3 , NR c3 S(0) 2 NR c3 R d3 , S(0)R b3 , S(0)NR c3 R d3 , and S(0) 2 NR c3 R d3 ; each
  • R 1 is selected from OR al , and NR cl R dl ;
  • R 2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 20 ;
  • R 3 and R 4 are each H
  • R 5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 50 ; Ais N; each R 10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, OR
  • 6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 21 ; each R 21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , NR c4 R d4 , NR c4 C(0)R M
  • each R 51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 3 -1 0 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C 3 -1 0 cycloalkyl-Ci- 3 alkylene, 4-10 membered heterocycloalkyl-Ci- 3 alkylene, C 6 - 1 0 aryl-C 1- 3 alkylene, 5-10 membered heteroaryl-C 1- 3 alkylene, halo, D, CN, OR al °, SR al °, C(0)R bl °, C(O)NR cl0 R dl °, C(0)OR al °, NR cl0 R dl
  • R 1 is selected from OR al , and NR cl R dl ;
  • R 2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 20 ;
  • R 3 and R 4 are each H
  • R 5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 50 ; Ais N; each R 10 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, OR a3 , SR a3 , C(0)R b
  • 6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 21 ; each R 21 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)0R a4 , NR C4 S(0) 2 R m , NR c4 S(0) 2 NR c4 R d4 , S(0) 2 R M , and S(0) 2 NR c4 R d4 ; wherein a ring-forming carbon atom of the 4-10 member
  • each R 51 is independently selected from Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, halo, D, CN, OR al °, C(0)R bl °, C(O)NR cl0 R dl °, C(0)OR al °, NR cl0 R dl °, NR cl0 C(O)R bl °, and S(0) 2 R bl °; each R al , R cl , and R dl is independently selected from H, Ci- 6 alkyl, C 1-6 haloalkyl, C3- 10 cycloalkyl, 4-10
  • R 1 is selected from OR al , and NR cl R dl ;
  • R 2 is selected from phenyl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the phenyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ;
  • R 3 and R 4 are each H
  • R 5 is selected from phenyl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the phenyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R 50 ;
  • each R 10 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, phenyl, halo, D,
  • each R 20 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, halo, D, CN, OR 32 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , NR c2 R d2 , NR c2 C(0)R b2 , and NR c2 C(0)0R a2 ; wherein the 4-6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
  • 6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, or 3 substituents independently selected from R 21 ; each R 21 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)0R a4 , NR c4 S(0) 2 R M , S(0) 2 R M , and S(0) 2 NR c4 R d4 ; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl
  • each R 51 is independently selected from Ci-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR al °, C(0)R bl °, C(O)NR cl0 R dl °, C(0)OR al °, NR cl0 R dl °, NR cl0 C(O)R bl °, and S(0) 2 R bl °; each R al , R cl , and R dl is independently selected from H, Ci- 6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR al °, C(0)R b
  • substituents of compounds of the disclosure are disclosed in groups or in ranges. It is specifically intended that the disclosure include each and every individual subcombination of the members of such groups and ranges.
  • the term “Ci- 6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and Ce alkyl.
  • aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency.
  • a pyridine ring or “pyridinyl” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.
  • n-membered where n is an integer typically describes the number of ring forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5-membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • each variable can be a different moiety independently selected from the group defining the variable.
  • the two R groups can represent different moieties independently selected from the group defined for R.
  • substituted means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group.
  • substituted refers to any level of substitution, e.g, mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted.
  • the substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
  • a single divalent substituent e.g., oxo, can replace two hydrogen atoms.
  • Ci-j As used herein, the term “Ci-j, ” where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range.
  • Ci- 6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
  • alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched.
  • An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
  • the alkyl group contains 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, /e/7-butyl, «-pentyl, 2-methyl- 1 -butyl, 3-pentyl, «-hexyl, 1,2,2- trimethylpropyl, and the like.
  • the alkyl group is methyl, ethyl, or propyl.
  • Ci-j alkylene employed alone or in combination with other terms, means a saturated divalent linking hydrocarbon group that may be straight-chain or branched, having i to j carbons.
  • the alkylene group contains from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or from 1 to 2 carbon atoms.
  • alkylene moieties include, but are not limited to, chemical groups such as methylene, ethylene, 1,1- ethylene, 1,2-ethylene , 1,3 -propylene, 1,2-propylene, 1,1 -propylene, isopropylene, and the like.
  • alkenyl refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon double bonds.
  • An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound.
  • the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • Example alkenyl groups include, but are not limited to, ethenyl, «-propenyl, isopropenyl, «-butenyl, .sfc-butenyl, and the like.
  • alkynyl refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon triple bonds.
  • An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
  • the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn- 2-yl, and the like.
  • carbamoyl and “carbamyl” interchangeably refer to a group of formula -C(0)NH2.
  • cyano or "nitrile” refers to a group of formula -CoN, which also may be written as -CN.
  • C1-3 alkoxy-Ci-3 alkyl refers to a group of formula -(C1- 3 alkylene)-(Ci-3 alkoxy).
  • C1- 3 alkoxy-Ci- 3 alkoxy refers to a group of formula -(C1- 3 alkoxylene)-(Ci-3 alkoxy).
  • HO-C1- 3 alkoxy refers to a group of formula -(C1- 3 alkoxylene)-OH.
  • HO-C1- 3 alkyl refers to a group of formula -(C1- 3 alkylene)-OH.
  • cyano-Ci- 3 alkyl refers to a group of formula -(C1- 3 alkylene)-CN.
  • H2N-C1- 3 alkyl refers to a group of formula -(C1- 3 alkylene)-NH2.
  • Cn-m alkylamino refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-m alkoxy carbonyl refers to a group of formula -C(0)0- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-m alkylcarbonyl refers to a group of formula -C(O)- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. As used herein, the term “Cn-m alkylcarbonylamino” refers to a group of formula -NHC(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn- m alkylcarbonyloxy refers to a group of formula - 0C(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminocarbonyloxy refers to a group of formula - 0C(0)NH 2.
  • Cn-malkylaminocarbonyloxy refers to a group of formula -OC(0)NH-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-malkylsulfonylamino refers to a group of formula -NHS(0)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminosulfonyl refers to a group of formula -S(0)2NH2.
  • Cn-m alkylaminosulfonyl refers to a group of formula -S(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(Cn-m alkyl)aminosulfonyl refers to a group of formula -S(0)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms.
  • each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminosulfonylamino refers to a group of formula - NHS(0) 2 NH 2.
  • Cn-m alkylaminosulfonylamino refers to a group of formula -NHS(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(Cn-m alkyl)aminosulfonylamino refers to a group of formula -NHS(0)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminocarbonylamino employed alone or in combination with other terms, refers to a group of formula -NHC(0)NH2.
  • Cn-m alkylaminocarbonylamino refers to a group of formula -NHC(0)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(Cn-m alkyl)aminocarbonylamino refers to a group of formula -NHC(0)N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-m alkylcarbamyl refers to a group of formula -C(O)- NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(Cn-m-alkyl)carbamyl refers to a group of formula - C(0)N(alkyl)2, wherein the two alkyl groups each has, independently, n to m carbon atoms.
  • each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • thio refers to a group of formula -SH.
  • Cn-m alkylthio refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-malkylsulfmyl refers to a group of formula -S(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-malkylsulfonyl refers to a group of formula -S(0)2- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • halo or “halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. In some embodiments, halo is F.
  • haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom, having up to the full valency of halogen atom substituents, which may either be the same or different.
  • the halogen atoms are fluoro atoms.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Example haloalkyl groups include CF3, C2F5, CHF2, CCh, CHCI2, C2CI5, and the like.
  • alkoxy employed alone or in combination with other terms, refers to a group of formula -O-alkyl.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, alkoxy is methoxy.
  • haloalkoxy employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl).
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • An example haloalkoxy group is -OCF3.
  • amino employed alone or in combination with other terms, refers to NEb.
  • alkylamino refers to a group of formula -NH(alkyl).
  • the alkylamino group has 1 to 6 or 1 to 4 carbon atoms.
  • Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.
  • alkylthio employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • cycloalkyl refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups.
  • Cn-m cycloalkyl refers to a cycloalkyl that has n to m ring member carbon atoms.
  • Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems.
  • cycloalkyl moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane.
  • a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
  • Ring forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo.
  • Cycloalkyl groups also include cycloalkylidenes.
  • the term “cycloalkyl” also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like).
  • bridgehead cycloalkyl groups e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl
  • spirocycloalkyl groups e.g., non-aromatic hydrocarbon moieties
  • the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7 monocyclic cycloalkyl group.
  • Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcamyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like.
  • the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • heterocycloalkyl refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus, and which has 4-14 ring members, 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7- membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) or spirocyclic ring systems.
  • the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
  • moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like.
  • Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-l-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like).
  • the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or 3 to 8 ring forming atoms.
  • the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms.
  • the carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quatemized.
  • the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group.
  • the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring.
  • the heterocycloalkyl is a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.
  • the heterocycloalkyl is 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.
  • aryl refers to a monocyclic or polycyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1 -naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl.
  • heteroaryl or “heteroaromatic” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
  • Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[l,2-b]thiazolyl, pyridone, or the like.
  • the carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved.
  • the heteroaryl group is a 5 to 10 membered heteroaryl group.
  • the heteroaryl group is a 5 to 6 membered heteroaryl group.
  • the heteroaryl is a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.
  • the heteroaryl is a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, no more than 2 heteroatoms of a 5 -membered heteroaryl moiety are N.
  • a five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
  • Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
  • a six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more ( e.g ., 1, 2 or 3) ring atoms are independently selected from N, O and S.
  • Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, isoindolyl, and pyridazinyl.
  • oxo refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N- oxide group.
  • oxidized in reference to a ring-forming N atom refers to a ring-forming N-oxide.
  • oxidized in reference to a ring-forming S atom refers to a ring-forming sulfonyl or ring-forming sulfmyl.
  • aromatic refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i.e., having (4n + 2) delocalized p (pi) electrons where n is an integer).
  • the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3 -position.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms. Resolution of racemic mixtures of compounds can be carried out by methods known in the art.
  • An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids.
  • resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g ., S and R for s, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2- diaminocyclohexane, and the like.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • an optically active resolving agent e.g., dinitrobenzoylphenylglycine
  • Suitable elution solvent composition can be determined by one skilled in the art.
  • the compounds of the disclosure have the (//(-configuration In other embodiments, the compounds have the ( ⁇ -configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2, 4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Compounds of the disclosure also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • One or more constituent atoms of the compounds of the disclosure can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance.
  • the compound includes at least one deuterium atom.
  • one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium.
  • the compound includes two or more deuterium atoms.
  • the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms.
  • Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744- 7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.
  • compound as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted.
  • the term is also meant to refer to compounds of the disclosure, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
  • All compounds, and pharmaceutically acceptable salts thereof can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated.
  • the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates.
  • the compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
  • the compounds of the disclosure, or salts thereof are substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in the compounds of the disclosure.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the disclosure, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the present disclosure also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present disclosure include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
  • non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
  • ACN acetonitrile
  • the compounds provided herein can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
  • the reactions for preparing compounds of the disclosure can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
  • suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected by the skilled artisan.
  • Preparation of compounds of the disclosure can involve the protection and deprotection of various chemical groups.
  • the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
  • the chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis , 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
  • Reactions can be monitored according to any suitable method known in the art.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 'H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 'H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry
  • chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
  • HPLC high performance liquid chromatography
  • intermediates 1-1 include Z groups that afford the opposite regioselectivity
  • a palladium catalyst such as [ 1,1’- bis(diphenylphosphino)ferrocene]dichloropalladium(II)
  • heterocycles of the formula 1-1 are commercially available or known in the literature. Alternatively, some can be prepared as shown in Scheme 3. Heterocycles 3-1 can be deprotonated under strongly basic conditions (e.g., with a lithium base, like n- BuLi, LDA, or LiHMDS, or with a /b//w-Hauser base, like 2,2,6,6-tetramethylpiperidinylmagnesium chloride, lithium chloride complex) and treated with a suitable halogenating agent (e.g., NCS, NBS, NIS, hexachloroethane) at cryogenic temperatures.
  • a suitable halogenating agent e.g., NCS, NBS, NIS, hexachloroethane
  • Cross-coupling of heterocycles 4-2 with a suitable M-R 2 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) affords intermediates 4-3
  • Halogenation of these intermediates 4-3 with a suitable halogenating reagent e.g., NBS, NCS, etc.) affords intermediates 4 4 , which can undergo subsequent cross-coupling with M- R 5 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu) 3 , or Zn) under standard Suzuki conditions
  • heterocycles of the formula 5-1 are commercially available or known in the literature. Alternatively, some can be prepared as shown in Scheme 7. Heterocycles 7-1 can be can be treated with alpha-halo carbonyl compounds at elevated temperatures to provide imidazo[l,2-Z>]pyridazines 5-1.
  • Compounds of the present disclosure can inhibit the activity of the FGFR enzyme.
  • compounds of the present disclosure can be used to inhibit activity of an FGFR enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient.
  • Compounds of the present disclosure can be used to inhibit activity of the FGFR3 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient.
  • Compounds of the present disclosure can be used to inhibit activity of the FGFR2 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient.
  • Compounds of the present disclosure can be selective for the inhibition of FGFR2 and/or FGFR3 enzymes over the inhibition of FGFR1 and/or FGFR4 enzymes.
  • the compounds of the present disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR enzyme or FGFR ligands.
  • Compounds which inhibit FGFR will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that compounds of the present disclosure will prove useful in treating or preventing proliferative disorders such as cancers.
  • tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.
  • the disclosure provides a method for treating a FGFR- mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound according to the disclosure, or a pharmaceutically acceptable composition thereof.
  • diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
  • Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), 8pll myeloproliferative syndrome), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, adult
  • Exemplary sarcomas include chondrosarcoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, lymphosarcoma, leiomyosarcoma, and teratoma.
  • Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.
  • NSCLC non-small cell lung cancer
  • small cell lung cancer bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.
  • Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (exocrine pancreatic carcinoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, gall bladder cancer and anal cancer.
  • esophagus squa
  • Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma) and urothelial carcinoma.
  • kidney adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma
  • bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma
  • prostate adenocarcinoma, sarcoma
  • testis se
  • liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
  • Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors
  • osteogenic sarcoma osteosarcoma
  • fibrosarcoma malignant fibrous histiocytoma
  • chondrosarcoma chondrosarcoma
  • Ewing's sarcoma malignant lymphoma
  • multiple myeloma malignant giant cell tumor chordoma
  • osteochronfroma osteocart
  • Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, neuro-ectodermal tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), neuroblastoma, Lhermitte-Duclos disease and pineal tumors.
  • skull osteoma, hemangioma, granuloma,
  • Exemplary gynecological cancers include cancers of the breast (ductal carcinoma, lobular carcinoma, breast sarcoma, triple-negative breast cancer, HER2-positive breast cancer, inflammatory breast cancer, papillary carcinoma), uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (car
  • Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
  • Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and parathyroid cancers, tumors of the eye, tumors of the lips and mouth and squamous head and neck cancer.
  • the compounds of the present disclosure can also be useful in the inhibition of tumor metastases.
  • the compounds of the disclosure are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare- Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.
  • the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder.
  • compounds described herein can be used to treat Alzheimer’s disease, HIV, or tuberculosis.
  • 8pl 1 myeloproliferative syndrome is meant to refer to myeloid/lymphoid neoplasms associated with eosinophilia and abnormalities of FGFR1.
  • an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal.
  • an in vitro cell can be a cell in a cell culture.
  • an in vivo cell is a cell living in an organism such as a mammal.
  • contacting refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
  • “contacting” the FGFR enzyme with a compound described herein includes the administration of a compound described herein to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound described herein into a sample containing a cellular or purified preparation containing the FGFR enzyme.
  • the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent such as an amount of any of the solid forms or salts thereof as disclosed herein that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • An appropriate "effective" amount in any individual case may be determined using techniques known to a person skilled in the art.
  • phrases "pharmaceutically acceptable” is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the phrase "pharmaceutically acceptable carrier or excipient” refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, non-toxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. In some embodiments, each component is "pharmaceutically acceptable” as defined herein.
  • treating refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. dinner arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. termed reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
  • One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g .,
  • IL2, GM-CSF, etc), and/or tyrosine kinase inhibitors can be used in combination with compounds described herein for treatment of FGFR-associated diseases, disorders or conditions, or diseases or conditions as described herein.
  • the agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
  • a combination can include one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-PR, Pirn, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFpR, CSFIR, KIT, FLK-II, KDR/FLK- 1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2,
  • the compounds and pharmaceutically acceptable salts thereof as described herein can be combined with inhibitors of kinases associated with the PIK3/Akt/mTOR signaling pathway, such as PI3K, Akt (including Aktl, Akt2 and Akt3) and mTOR kinases.
  • inhibitors of kinases associated with the PIK3/Akt/mTOR signaling pathway such as PI3K, Akt (including Aktl, Akt2 and Akt3) and mTOR kinases.
  • compounds described herein can be used in combination with one or more inhibitors of the enzyme or protein receptors such as HPK1, SBLB, TUT4, A2A/A2B, CD47, CDK2, STING, ALK2, LIN28, ADAR1, MAT2a, RIOK1, HDAC8, WDR5, SMARCA2, and DCLK1 for the treatment of diseases and disorders.
  • exemplary diseases and disorders include cancer, infection, inflammation and neurodegenerative disorders.
  • compouds described herein can be used in combination with a therapeutic agent that targets an epigenetic regulator.
  • epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases.
  • Histone deacetylase inhibitors include, e.g, vorinostat.
  • JAK kinase inhibitors Rosolitinib, additional JAK1/2 and JAK 1- selective, baricitinib or INCB39110
  • Pirn kinase inhibitors e.g., LGH447, INCB053914 and SGI-1776
  • PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors (e.g., INCB50465 and INCB54707), PI3K- gamma inhibitors such as PI3K-gamma selective inhibitors, MEK inhibitors, CSF1R inhibitors (e.g., PLX3397 and LY3022855), TAM receptor tyrosine kinases inhibitors (Tyro- 3, Axl, and Mer; e.g., INCB81776), angiogenesis inhibitors, interleukin receptor inhibitors, Cyclin Dependent
  • compounds described herein can be used in combination with targeted therapies such as, e.g., c-MET inhibitors (e.g., capmatinib), an anti-CD19 antibody (e.g., tafasitamab), an ALK2 inhibitor (e.g., INCB00928); or combinations thereof.
  • targeted therapies such as, e.g., c-MET inhibitors (e.g., capmatinib), an anti-CD19 antibody (e.g., tafasitamab), an ALK2 inhibitor (e.g., INCB00928); or combinations thereof.
  • chemotherapeutic agents e.g., agonists or antagonists of nuclear receptors, or other anti -proliferative agents.
  • Compounds described herein can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g ., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.
  • a medical therapy such as surgery or radiotherapy, e.g ., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.
  • chemotherapeutic agents include any of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amidox, amsacrine, anastrozole, aphidicolon, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bendamustine, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, camptosar, capecitabine, carboplatin, carmustine, cediranib, cetuximab, chlorambucil, cisplatin, cladribine, clofar
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, 0X40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3 (e g., INCAGN2385), TIM3 (e g., INCB2390), VISTA, PD-1, PD-L1 and PD-L2.
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, 0X40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS,
  • the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40 (e.g., INCAGN1949), GITR (e.g., INCAGN1876) and CD137.
  • the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA.
  • the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRbeta inhibitors.
  • the inhibitor of an immune checkpoint molecule is a small molecule PD-L1 inhibitor.
  • the small molecule PD-L1 inhibitor has an IC50 less than 1 mM, less than 100 nM, less than 10 nM or less than 1 nM in a PD-L1 assay described in US Patent Publication Nos. US 20170107216, US 20170145025, US 20170174671, US 20170174679, US 20170320875, US 20170342060, US 20170362253, and US 20180016260, each of which is incorporated by reference in its entirety for all purposes.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti -PD-1 monoclonal antibody.
  • the anti -PD-1 monoclonal antibody is MGA012, nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, ipilumimab or AMP -224.
  • the anti- PD-1 monoclonal antibody is nivolumab or pembrolizumab.
  • the anti- PD1 antibody is pembrolizumab.
  • the anti-PDl antibody is nivolumab.
  • the anti-PD-1 monoclonal antibody is MGA012.
  • MGA012 is also known as retifanlimab.
  • the anti-PDl antibody is SHR-1210.
  • Other anti-cancer agent(s) include antibody therapeutics such as 4-1BB (e.g. urelumab, utomilumab).
  • the compounds of the disclosure can be used in combination with INCB086550.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody.
  • the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C.
  • the anti-PD-Ll monoclonal antibody is MPDL3280A or MEDI4736.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
  • the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody.
  • the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody.
  • the anti-TEVB antibody is INCAGN2390, MBG453, or TSR-022.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody.
  • the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.
  • the inhibitor of an immune checkpoint molecule is an agonist of 0X40, e.g., 0X40 agonist antibody or OX40L fusion protein.
  • the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS- 986178.
  • the OX40L fusion protein is MEDI6383.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody.
  • the anti-CD20 antibody is obinutuzumab or rituximab.
  • the compounds of the present disclosure can be used in combination with bispecific antibodies.
  • one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, 0X40, TIM3, LAG3, CD137, ICOS, CD3 or TGFp receptor.
  • the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors.
  • the metabolic enzyme inhibitor is an inhibitor of IDO 1, TDO, or arginase.
  • IDO 1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
  • the compounds described herein can be used in combination with one or more agents for the treatment of diseases such as cancer.
  • the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
  • an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine.
  • the proteasome inhibitor is carfilzomib.
  • the corticosteroid is dexamethasone (DEX).
  • the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
  • Suitable antiviral agents contemplated for use in combination with compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
  • NRTIs nucleoside and nucleotide reverse transcriptase inhibitors
  • NRTIs non-nucleoside reverse transcriptase inhibitors
  • protease inhibitors and other antiviral drugs.
  • Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fluoro-cytidene); DAPD, ((- )-beta-D-2, 6, -diamino-purine dioxolane); and lodenosine (FddA).
  • ZT zidovudine
  • ddl didanosine
  • ddC zalcitabine
  • stavudine d4T
  • NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B.
  • Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549.
  • Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.
  • Suitable agents for use in combination with compounds described herein for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy.
  • Compounds described herein may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors.
  • Suitable examples are anti -estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant).
  • Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds described herein.
  • anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone).
  • LHRH luteinizing hormone-releasing hormone
  • LHRH antagonists e.g. degarelix
  • androgen receptor blockers e.g. enzalutamide
  • agents that inhibit androgen production e.g. abiraterone.
  • the compounds described herein may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the
  • These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk.
  • Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib.
  • Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab.
  • Inhibitors of c- Met may be used in combination with FGFR inhibitors.
  • Agents against Abl include imatinib, dasatinib, nilotinib, and ponatinib and those against Aik (or EML4-ALK) include crizotinib.
  • Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti -angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib
  • agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance.
  • agents that may be combined with compounds described herein include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.
  • Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib.
  • Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors.
  • Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors).
  • Inhibitors of one or more JAKs e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds described herein.
  • the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.
  • Suitable agents for use in combination with compounds described herein include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
  • chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
  • Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
  • alkylating agents including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes
  • alkylating agents including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoure
  • steroids including 17 alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, and medroxy proge steroneacetate .
  • DTIC dacarbazine
  • BCNU carmustine
  • Dartmouth regimen which consists of DTIC
  • BCNU cisplatin and tamoxifen
  • a combination of cisplatin, vinblastine, and DTIC or temozolomide.
  • Compounds described herein may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in.
  • cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in.
  • Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.
  • antimetabolites including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors
  • methotrexate including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors
  • methotrexate including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors
  • Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara- C, paclitaxel (TAXOLTM), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
  • certain natural products and their derivatives for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins
  • vinblastine vincristine, vindesine
  • bleomycin dactinomycin
  • daunorubicin daunor
  • cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafme, cyclophosphamide, ifosamide, and droloxafme.
  • cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
  • anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB, PD-L1 and PD-1 antibodies, or antibodies to cytokines (IL-10, TGF-b, etc.).
  • trastuzumab Herceptin
  • costimulatory molecules such as CTLA-4, 4- IBB, PD-L1 and PD-1 antibodies
  • cytokines IL-10, TGF-b, etc.
  • anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
  • anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
  • Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
  • tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
  • HPV Human Papilloma Viruses
  • HCV Hepatitis Viruses
  • KHSV Kaposi's Herpes Sarcoma Virus
  • tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
  • the compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
  • the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
  • compositions which refers to a combination of one or more compounds described herein, and at least one pharmaceutically acceptable carrier or excipient.
  • compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary ( e.g ., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral.
  • Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
  • Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • compositions which contain, as the active ingredient, one or more compounds described herein in combination with one or more pharmaceutically acceptable carriers or excipients.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the composition is suitable for topical administration.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
  • the compounds of the disclosure may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the disclosure can be prepared by processes known in the art see, e.g ., WO 2002/000196.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof.
  • SMCC silicified microcrystalline cellulose
  • the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
  • the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide.
  • the composition further comprises magnesium stearate or silicon dioxide.
  • the microcrystalline cellulose is Avicel PHI 02TM.
  • the lactose monohydrate is Fast-flo 316TM.
  • the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g, Methocel K4 M PremierTM) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g, Methocel K00LVTM).
  • the polyethylene oxide is polyethylene oxide WSR 1105 ( e.g ., Poly ox WSR 1105TM).
  • a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
  • compositions can be formulated in a unit dosage form, each dosage containing from, for example, about 5 mg to about 1000 mg, about 5 mg to about 100 mg, about 100 mg to about 500 mgor about 10 to about 30 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade).
  • the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration.
  • suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good Manufacturing Practice regulations of the U.S. Food and Drug Administration.
  • the active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the therapeutic dosage of a compound of the present disclosure can vary according to, e.g, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g, hydrophobicity), and the route of administration.
  • the compounds of the disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day.
  • the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of one or more compounds described herein.
  • a solid pre-formulation composition containing a homogeneous mixture of one or more compounds described herein.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present disclosure.
  • the tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • liquid forms in which the compounds, or compositions as described herein can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • Topical formulations can contain one or more conventional carriers.
  • ointments can contain water and one or more hydrophobic carriers selected from, e.g ., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like.
  • Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g. , glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol.
  • Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g. , glycerol, hydroxy ethyl cellulose, and the like.
  • topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the disclosure.
  • the topical formulations can be suitably packaged in tubes of, e.g. , 100 g which are optionally associated with instructions for the treatment of the select indication, e.g. , psoriasis or other skin condition.
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of a compound of the present disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of the compounds in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • compounds of the present disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day.
  • the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.
  • Compounds described herein can also be formulated in combination with one or more additional active ingredients, which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.
  • Another aspect of the present disclosure relates to labeled compounds of the disclosure (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo , for localizing and quantitating FGFR3 protein in tissue samples, including human, and for identifying FGFR3 ligands by inhibition binding of a labeled compound.
  • Substitution of one or more of the atoms of the compounds of the present disclosure can also be useful in generating differentiated ADME (Adsorption, Distribution, Metabolism and Excretion).
  • the present disclosure includes FGFR binding assays that contain such labeled or substituted compounds.
  • the present disclosure further includes isotopically-labeled compounds of the disclosure.
  • An “isotopically” or “radio-labeled” compound is a compound of the disclosure where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present disclosure include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), U C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 13 C I.
  • one or more hydrogen atoms in a compound of the present disclosure can be replaced by deuterium atoms (e.g., one or more hydrogen atoms of a Ci-6 alkyl group of Formula (I) can be optionally substituted with deuterium atoms, such as -CD3 being substituted for -CFb).
  • alkyl groups in Formula (I) can be perdeuterated.
  • the compound includes at least one deuterium atom.
  • the compound includes two or more deuterium atoms.
  • the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms.
  • all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.
  • substitution with heavier isotopes may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances (see e.g., A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210; R. Xu et. al. J. Label Compd. Radiopharm. 2015, 58, 308-312).
  • substitution at one or more metabolism sites may afford one or more of the therapeutic advantages.
  • radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro adenosine receptor labeling and competition assays, compounds that incorporate 3 H, 14 C,
  • a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide.
  • the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1, 35 S and 82 Br.
  • the present disclosure can further include synthetic methods for incorporating radio isotopes into compounds of the disclosure. Synthetic methods for incorporating radio isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of disclosure.
  • a labeled compound of the disclosure can be used in a screening assay to identify and/or evaluate compounds.
  • a newly synthesized or identified compound i.e., test compound
  • a test compound which is labeled can be evaluated for its ability to bind an FGFR3 protein by monitoring its concentration variation when contacting with the FGFR3, through tracking of the labeling.
  • a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a FGFR3 protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the FGFR3 protein directly correlates to its binding affinity.
  • the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
  • kits useful for example, in the treatment or prevention of FGFR-associated diseases or disorders, such as cancer and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure.
  • kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
  • Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
  • the flow rate used with the 30 x 100 mm column was 60 mL/minute.
  • pH 10 purifications: Waters XBridge Cis 5 pm, 19 x 100 mm column, eluting with mobile phase A: 0.15% MLOH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See “Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J Comb. Chem ., 6, 874-883 (2004)].
  • the flow rate used with 30 x 100 mm column was 60 mL/minute.
  • Step 3 4-Difluoro-N-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzamide
  • a sample of 3-bromo-4,5-difluoro-/V-methylbenzamide (402 mg, 1.6 mmol) was suspended in toluene and treated with potassium acetate (316 mg, 3.22 mmol) and bis(pinacolato)diboron (694 mg, 2.73 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (16 ml) was added and the mixture was stirred to dissolve. The solution was degassed by bubbling with nitrogen for 5 mins.
  • Step 3 4-Fluoro-N, 3-dimethyl-5-( 4, 4, 5, 5-tetramethyl-l , 3, 2-dioxaborolan-2-yl)benzamide
  • a sample of 3-bromo-4-fluoro-/V,5-dimethylbenzamide (95 mg, 0.39 mmol) was suspended in toluene and treated with potassium acetate (114 mg, 1.16 mmol) and bis(pinacolato)diboron (147 mg, 0.58 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (3.9 ml) was added and the mixture was stirred to dissolve.
  • Step 3 4’-Difluoro-5-(6-methoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)-N-methyl-[ 1, 1 ’-biphenyl] -3-carboxamide
  • Step 1 4-Fluoro-3-( 6-methoxy- 7-(l -methyl-lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3- yl)benzoic acid
  • Tetrakis(triphenylphosphine)palladium(0) (0.451 g, 0.391 mmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 16 hours, LCMS indicated -85% conversion. The solution was cooled to room temperature and quenched with aqueous NH4CI, and extracted with EtOAc, then 25% /.s -propanol in chloroform. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo.
  • Step 1 tert-Butyl (S)-3-((3-bromo-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-6- yl)oxy)pyrrolidine-l-carboxylate
  • a sample of 3 -bromo-6-chloro-7-( 1 -methyl- li7-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazine (15 mg, 0.048 mmol, see Example 15, Step 5) was dissolved in DMF (0.8 ml) and was treated with cesium carbonate (47 mg, 0.14 mmol) and /cvV-butyl fV)-3-hydroxypyrrolidine-l - carboxylate (45 mg, 0.24 mmol).
  • Step 3 4-Difluoro-5-( 6-(2-methoxyethoxy)-7-( 1 -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2- b]pyridazin-3-yl)-N-methylbenzamide
  • LCMS indicated consumption of the starting material.
  • the solution was cooled to room temperature, diluted with DCM, and filtered through a SiliaPrep Thiol cartridge.
  • the solution was cooled to room temperature, diluted with EtOAc, filtered through a SiliaPrep Thiol cartridge, and the filtrate was concentrated in vacuo.
  • the concentrate was dissolved in dioxane (1.5 mL) and treated with HC1 in dioxane (4N, 1.5 mL). The solution was stirred at room temperature for 48 hours, at which point LCMS indicated consumption of the intermediate.
  • Step 1 l-(4-(3-Bromo-6-chloroimidazo[ l,2-b]pyridazin-7-yl)-lH-pyrazol-l-yl)-2- methylpropan-2-ol
  • Tetrakis(triphenylphosphine)palladium(0) (135 mg, 0.12 mmol) was added, the vial was capped, and the solution was stirred at 120 °C. After 2 hours, LCMS indicated complete conversion to the product. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo.
  • the solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and the filtrate was concentrated in vacuo.
  • the concentrate was dissolved in DCM (7.5 mL) and treated with HC1 in dioxane (4N, 10 mL). The solution was stirred at room temperature for 20 minutes, at which point LCMS indicated consumption of the intermediate.
  • Tetrakis(triphenylphosphine)palladium(0) 44 mg, 0.038 mmol was added, the vial was capped, and the solution was stirred at 120 °C. After 1.5 hours, LCMS indicated complete conversion to the product. The solution was cooled to room temperature and quenched with aqueous NLLCl, and extracted with EtOAc, then 25% /.s -propanol in chloroform. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo.
  • the inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET measurements to detect product formation. Inhibitors were serially diluted in DMSO and a volume of 0.2 pL was transferred to the wells of a 384-well plate.
  • a 5 pL/well volume of enzyme isoforms of FGFR (-1, -2, -3 wild-type and mutant isoforms, -4) including phosphorylated and un- phosphorylated proteins diluted in assay buffer (50 mM HEPES, 10 mM MgCh, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated with inhibitor for 5 to 15 minutes at ambient temperature. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate.
  • assay buffer 50 mM HEPES, 10 mM MgCh, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5
  • the reaction was initiated by the addition of a 5 pL/well volume containing both biotinylated EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP in assay buffer.
  • the 10 pL/well reaction concentration of the peptide substrate was 500 nM whereas the ATP concentration was maintained near or below the ATP Km.
  • the ATP Km values were pre-determined in a separate series of experiments.
  • the reaction plate was incubated at 25 °C for 1 hr and the reactions were ended with the addition of 5 pL/well of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 45 mM EDTA, 600 nM staurosporin, with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin).
  • quench solution 50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 45 mM EDTA, 600 nM staurosporin, with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin.
  • the plate was allowed to equilibrate for ⁇ 10 minutes at ambient temperature before scanning on a PheraStar plate reader (BMG Labtech) instrument. Either GraphPad prism or X
  • IC50 values were derived by fitting the data to a four parameter logistic equation producing a sigmoidal dose- response curve with a variable Hill coefficient.
  • Prism equation: Y Bottom + (Top- Bottom)/(l+10 A ((LogIC5o-X)*Hill slope));
  • XLfit equation: Y (A+((B-A)/(1+((X/C) A D)))) where X is the logarithm of inhibitor concentration and Y is the response.
  • Compounds having an IC50 of 1 mM or less are considered active.
  • Table 1 provides IC50 data for compounds of the disclosure assayed in the FGFR Enzymatic Assay after dilution in assay buffer, added to the plate and pre-incubated for 4 hours.
  • Example B Luminescent Viability Assay
  • RT112 cells are purchased from ATCC (Manassas, VA) and maintained in RPMI,
  • FBS 10% FBS (Gibco/Life Technologies).
  • the cells are plated with RPMI 10 % FBS (5xl0 3 cells/well/in 50 pL) into black 96-well Greiner polystyrene in the presence or absence of 50ul of a concentration range of test compounds. After 3 days, lOOul of CellTiter-Glo Reagent (Promega) is added. Luminescence is read with a TopCount (PerkinElmer). ICso determination is performed by fitting the curve of percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
  • Example C pFGFR2 and pFGFRl,3 Functional Cell HTRF Assay
  • KATOIII cells Human Gastric Carcinoma
  • FBS Gibco/Life Technologies
  • KATOIII cells are plated overnight in 5% FBS and Iscove’s medium at 5xl0 4 cells/well into Corning 96-well flat- bottom tissue culture treated plates. The next morning, 50 m ⁇ of fresh media with 0.5% FBS is incubated in the presence or absence of a concentration range of test compounds also at 50ul, for 1 hour at 37°C, 5% C02.
  • BAF3-TEL-FGFR1 or BAF3-TEL-FGFR3 are maintained in RPMI with 10% FBS and lug/ml puromycin (Gibco/Life Technologies).
  • 12nl of BAF3- TEL-FGFR1 or BAF3-TEL-FGFR3 cells in serum free and puromycin free RPMI media at 1 x 10 6 cell/ml are added to 384 Greiner white plate already containing 20nl dots of compounds at a concentration range.
  • the plates are gently shaken (100 rpm) for 2 minutes at room temperature to mix well and incubate for 2 hours in a single layer at 37°C, 5% C02. 4 pl/well of 1/25 dilution of lysis buffer #3 (Cis Bio) is added with standard Protease inhibitors and shaken at 200 rpm at room temperature for 20 minutes. 4 m ⁇ total of the Cis Bio Tb-pFGFR Ab (10ng) and d2-FGFR3 (lng) together are added to the lysate and mixed well. The plates are sealed and incubated at room temperature overnight in the dark. The plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. ICso determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
  • Example D pFGFR3 Functional Whole Blood HTRF Assay
  • BAF3-TEL-FGFR3 phosphorylated Fibroblast Growth Factor Receptor 3 (FGFR3) in a whole blood assay
  • BAF3-TEL-FGFR3 are maintained in RPMI with 10% FBS and 1 pg/ml puromycin (Gibco/Life Technologies).
  • lOOul BAF3-TEL- FGFR3 cells in 10% FBS and puromycin free RPMI media at 5 x 10 4 cell/well are added to fibronectin coated 96 well tissue culture plate (5ug/ml) overnight at 37°C, 5% C02.
  • serum is separated from the top of the blood by a low speed spin, 1200, RPM, and heat inactivated by incubating at 56°C for 15 minutes.
  • KATO III cells are purchased from ATCC and maintained in Iscove’s medium with 20% FBS (Gibco/Life Technologies).
  • Iscove a medium with 20% FBS
  • FBS Gibco/Life Technologies
  • the cells are resuspended with Iscove’s, 0.2 % FBS at 5xl0 6 cells/ml. 50 ⁇ L of the cells are then spiked into a 96-deep well 2 ml polypropylene assay block (Costar,) in the presence or absence of a concentration range of test compounds and 300ul human heparinized whole blood (Biological Specialty Corp, Colmar PA).
  • the red cells are lysed using Qiagen EL buffer and the cell lysates are resuspended in lysis buffer (Cell Signaling) containing standard protease inhibitor cocktail (Calbiochem/EMD,) and PMSF (Sigma) for 30 minutes ice.
  • the lysates are transferred to a standard V bottom propylene tissue culture plate and frozen overnight at -80°C. Samples are tested an in an R & D Systems DuoSet IC Human Phospho- FGF R2a ELISA and the plate is measured using a SpectraMax M5 microplate set to 450 nm with a wavelength correction of 540. ICso determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

Description

BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
FIELD
The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the enzyme FGFR and are useful in the treatment of FGFR-associated diseases such as cancer.
BACKGROUND
The Fibroblast Growth Factor Receptors (FGFR) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFR1-4) that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation. Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005, 16 , 139-149). Aberrant activation of this pathway either through overexpression of FGF ligands or FGFR or activating mutations in the FGFRs can lead to tumor development, progression, and resistance to conventional cancer therapies. In human cancer, genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand-independent receptor activation have been described (Reviewed in Knights and Cook, Pharmacology & Therapeutics, 2010, 125, 105-117; Turner and Grose, Nature Reviews Cancer, 2010, 10, 116-129). Large scale DNA sequencing of thousands of tumor samples has revealed that FGFR genes are altered in many cancers (Helsten et al. Clin Cancer Res. 2016, 22, 259-267). Some of these activating mutations are identical to germline mutations that lead to skeletal dysplasia syndromes (Gallo et al. Cytokine & Growth Factor Reviews 2015, 26, 425-449). Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities. Therefore, development of inhibitors targeting FGFR may be useful in the clinical treatment of diseases that have elevated FGF or FGFR activity.
The cancer types in which FGF/FGFRs are implicated include, but are not limited to: carcinomas (e.g., bladder, breast, colorectal, endometrial, gastric, head and neck, kidney, lung, ovarian, prostate); hematopoietic malignancies (e.g., multiple myeloma, acute myelogenous leukemia, and myeloproliferative neoplasms); and other neoplasms (e.g., glioblastoma and sarcomas). In addition to a role in oncogenic neoplasms, FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.
There is a continuing need for the development of new drugs for the treatment of cancer, and the FGFR inhibitors described herein help address this need.
SUMMARY
The present disclosure is directed to compounds having Formula (I):
Figure imgf000003_0001
I or pharmaceutically acceptable salts thereof, wherein constituent variables are defined herein.
The present disclosure is further directed to pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
The present disclosure is further directed to methods of inhibiting an FGFR enzyme (e.g., an FGFR3 enzyme) comprising contacting the enzyme with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
The present disclosure is further directed to a method of treating a disease associated with abnormal activity or expression of an FGFR enzyme (e.g., an FGFR3 enzyme), comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
The present disclosure is further directed to compounds of Formula (I) for use in treating a disease associated with abnormal activity or expression of an FGFR enzyme (e.g., an FGFR3 enzyme).
The present disclosure is further directed to a method for treating a disorder mediated by an FGFR enzyme (e.g., an FGFR3 enzyme), or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound of Formula (I), or pharmaceutically acceptable composition thereof. The present disclosure is further directed to a method for treating a disorder mediated by an FGFR enzyme (e.g., an FGFR3 enzyme), or a mutant thereof, in a patient in need thereof, comprising the step of administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with another therapy or therapeutic agent as described herein.
The present disclosure is further directed to the use of compounds of Formula (I) in the preparation of a medicament for use in therapy.
DETAILED DESCRIPTION
Compounds
In one aspect, the present disclosure provides compounds of Formula (I):
Figure imgf000004_0001
I or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from ORal, SRal, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(0)NRclRdl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each independently selected from H, D, halo, CN, Ci-6 alkyl, ORa8 and NRcXRdx; wherein the Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50;
A is N or CRa;
RA is selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, halo, CN, NO2, ORa, SRa, C(0)Rb, C(0)NRcRd, C(0)ORa, OC(0)Rb, OC(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)ORa, NRcC(0)NRcRd, NRcS(0)Rb, NRcS(0)2Rb, NRcS(0)2NRcRd, S(0)Rb, S(0)NRcRd, S(0)2Rb and S(0)2NRcRd; wherein said Ci-e alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R6;
R6 is selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, halo, CN, NO2, ORa12, SRa12, C(0)Rb12, C(0)NRcl2Rd12, C(0)ORa12, OC(0)Rb12, 0C(0)NRcl2Rd12, NRcl2Rd12, NRcl2C(0)Rb12, NRcl2C(0)0Ra12, NRcl2C(0)NRcl2Rd12, NRcl2S(0)Rb12, NRcl2S(0)2Rb12, NRcl2S(0)2NRcl2Rd12, S(0)Rb12, S(0)NRcl2Rd12, S(0)2Rb12 and S(0)2NRcl2Rd12; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)0Ra3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each R11 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)0Ra5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 memberedheterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)0Ra2, 0C(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NORa2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl- Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on the R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)RM, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- lo aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each R22 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)0Ra6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, C(=NRe9)Rb9, C(=NORa9)Rb9, C(=NRe9)NRc9Rd9, NRc9C(=NRe9)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- io aryl-Ci-3 alkylene, 5-10 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, NRcl0C(O)ORal°, NRcl0S(O)Rbl°, NRcl0S(O)2Rbl°, NRcl0S(O)2NRcl0Rdl°, S(0)Rbl°, S(O)NRcl0Rdl°, S(0)2Rbl°, and S(O)2NRcl0Rdl°; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each R52 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORa11, SRa11, C(0)Rbu, C(0)NRcllRdu, C(0)ORa11, NRcllRdu, NRcllC(0)Rbu, NRcllC(0)ORa11, NRcllS(0)Rbu, NRcllS(0)2Rbu, NRcllS(0)2NRcllRdu, S(0)Rbu, S(0)NRcllRdu, S(0)2Rbu, and S(0)2NRcllRdu; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-C 1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra, Rc, and Rd is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R6; each Rb is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R6; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 4-10 membered heterocycloalkyl-Ci-3 alkylene is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Re2 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R11; each Rb3 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R22; each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each Ra5, Rc5 and Rd5 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and Ci-6haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rb5 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra6, Rc6 and Rd6 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rc6 and Rd6 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rb6 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra8, Rc8 and Rd8 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Re9 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R52; each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each Ral1, Rcl1 and Rdu is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rcl1 and Rdu attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rbu is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ral2, Rcl2, and Rdl2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2- 6 alkynyl, and Ci-6 haloalkyl,; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rbl2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; and each Rg is independently selected from D, OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Ci-2 alkylene, Ci-6 alkoxy, Ci-6haloalkoxy, C1-3 alkoxy-Ci-3 alkyl, C1-3 alkoxy-Ci-3 alkoxy, HO-C1-3 alkoxy, HO- Ci-3 alkyl, cyano-Ci-3 alkyl, H2N-C1-3 alkyl, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, Ci-6 alkylthio, Ci-6 alkylsulfmyl, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci-6 alkyl carbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci-6 alkoxycarbonylamino, Ci-6 alkylcarbonyloxy, aminocarbonyloxy, Ci-6 alkylaminocarbonyloxy, di(Ci-6 alkyl)aminocarbonyloxy, Ci-6 alkylsulfonylamino, aminosulfonyl, Ci-6 alkylaminosulfonyl, di(Ci-6 alkyl)aminosulfonyl, aminosulfonylamino, Ci-6 alkylaminosulfonylamino, di(Ci-6 alkyl)aminosulfonylamino, aminocarbonylamino, Ci-6 alkylaminocarbonylamino, and di(Ci-6 alkyl)aminocarbonylamino; provided that a compound of Formula I is other than
3-(2-benzofuranyl)-6-[3-(methylsulfonyl)propoxy]-7-phenyl-imidazo[l,2-b]pyridazine; 2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]propanoic acid;
2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]-propanoic acid, ethyl ester;
4-[6-( 1 -cyanoethoxy)-7-( 1 -methyl- lH-pyrazol-4-yl)imidazo[ 1 ,2-a]pyri din-3 -yl]-N- cyclopropyl-2-(difluoromethoxy)-6-methoxy-benzamide;
N-cyclopropyl-2-(difluoromethoxy)-6-methoxy-4-[7-(l-methyl-lH-pyrazol-4-yl)-6-
(phenylmethoxy)imidazo[l,2-a]pyridin-3-yl]-benzamide;
2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]-acetic acid; and
2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]-acetic acid, ethyl ester.
In some embodiments, the present disclosure provides compounds of Formula (I) , or a pharmaceutically acceptable salt thereof, wherein A is N. In some embodiments, the present disclosure provides compounds of Formula (I) , or a pharmaceutically acceptable salt thereof, wherein A is CH.
In some embodiments, R1 is selected from ORal, SRal, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, and NRclC(0)NRclRdl. In some embodiments, R1 is selected from ORal, SRal, NRclRdl, NRclC(0)Rbl, and NRclC(0)0Ral. In some embodiments, R1 is selected from ORal and NRclRdl.
In some embodiments, R1 is ORal.
In some embodiments, each Ral is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, and C6-10 aryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, and C6-10 aryl-Ci-3 alkylene, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10.
In some embodiments, each Ral is independently selected from H, Ci-6 alkyl, C3-6 cycloalkyl, 5-6 membered heterocycloalkyl, phenyl, and phenyl-Ci-3 alkylene; wherein a ring forming carbon atom of the 5-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 5-6 membered heterocycloalkyl, phenyl, and phenyl-Ci-3 alkylene, are each optionally substituted with 1 or 2 substituents independently selected from R10.
In some embodiments, Ral is selected from methyl, ethy, isopropyl, cyclobutyl, benzyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, oxetanyl, oxopyrrolidinyl, azetidinyl, and tetrahydropyranyl; wherein methyl, ethy, isopropyl, cyclobutyl, benzyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, oxetanyl, oxopyrrolidinyl, azetidinyl, and tetrahydropyranyl are each optionally substituted with with 1 or 2 substituents independently selected from R10.
In some embodiments, Ral is selected from methyl, ethy, isopropyl, 3- cyanocyclobutyl, benzyl, phenyl, methoxy ethyl, dimethylaminoethyl, tetrahydrofuran-3-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, oxetan-3-yl, 2-oxopyrrolidin-3-yl, 1 -methyl -2- oxopyrrolidin-3-yl, l-acetylazetidin-3-yl, and tetrahydo-2H-pyran-4-yl. In some embodiments, Ral is methyl. In some embodiments, Ralis tetrahydrofuranyl (e.g., (S)- tetrahydrofuran-3-yl and (R)-tetrahydrofuran-3-yl).
In some embodiments, each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-ioaryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, and NRc3C(0)Rb3.
In some embodiments, each R10 is independently selected from Ci-6 alkyl, C6-10 aryl, CN, ORa3, C(0)Rb3, and NRc3Rd3.
In some embodiments, each R10 is independently selected from methyl, methoxy, methylcarbonyl, CN, phenyl, and amino.
In some embodiments, each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl. In some embodiments, Ra3 is H or Ci-6 alkyl. In some embodiments, Ra3 is Ci-6 alkyl. In some embodiments, Rc3 is H or Ci-6 alkyl. In some embodiments, Rc3 is Ci-6 alkyl. In some embodiments, Rd3 is H or Ci-6 alkyl. In some embodiments, Rd3 is Ci-6 alkyl. In some embodiments, Rb3 is selected from Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl. In some embodiments, Rb3 is Ci-6 alkyl.
In some embodiments, R1 is NRclRdl.
In some embodiments, each Rcl and Rdl is independently selected from H, Ci-6 alkyl, Ci -6 haloalkyl, and 4-10 membered heterocycloalkyl; wherein said Ci-6 alkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10.
In some embodiments, each Rcl and Rdl is independently selected from H, Ci-6 alkyl, and 5-6 membered heterocycloalkyl; wherein said Ci-6 alkyl and 5-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 substituents independently selected from R10.
In some embodiments, each Rcl and Rdl is independently selected from H, methyl, and tetrahydrofuranyl; wherein said methyl and tetrahydrofuranyl are each optionally substituted with 1 or 2 substituents independently selected from R10.
In some embodiments, one of Rcl and Rdl is H and the other is methyl or tetrahydrofuranyl .
In some embodiments, Rbl is Ci-6 alkyl.
In some embodiments, R1 is selected from methoxy, ethoxy, isopropoxy, 3- cyanocyclobutoxy, benzyloxy, phenoxy, 2-methoxyethoxy, (dimethylamino)ethoxy, (tetrahydrofuran-3-yl)oxy, pyrrolidin-3-yloxy, (l-methylpyrrolidin-3-yl)oxy, oxetan-3-yloxy, 2-oxopyrrolidin-3-yloxy, (l-methyl-2-oxopyrrolidin-3-yl)oxy, (1-acetylazeti din-3 -yl)oxy, (tetrahydo-2H-pyran-4-yl)oxy, (tetrahydrofuran-3-yl)amino, and methylamino. In some embodiments, R1 is methoxy. In some embodiments, R1 is (tetrahydrofuran-3-yl)oxy (e.g., ((S)-tetrahydrofuran-3 -yl)oxy and ((R)-tetrahy drofuran-3 -yl)oxy) .
In some embodiments, R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, R2 is C6-10 aryl optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, R2 is phenyl optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, R2 is 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, R2 is 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, R2 is phenyl, pyrazolyl, pyridinyl, or pyrazolopyridinyl; and wherein phenyl, pyrazolyl, pyridyl, and pyrazolopyridinyl are each optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, R2 is pyrazolyl, pyridinyl, or pyrazolopyridinyl; and wherein pyrazolyl, pyridyl, and pyrazolopyridinyl are each optionally substituted with 1 or 2 substituents independently selected from R20. In some embodiments, R2 is pyrazolyl optionally substituted with 1 or 2 substituents independently selected from R20. In some embodiments, R2 is pyridinyl optionally substituted with 1 or 2 substituents independently selected from R20. In some embodiments, R2 is pyrazolyl optionally substituted with 1 or 2 substituents independently selected from R20.
In some embodiments, each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R21; or any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1 or 2 substituents independently selected from R21.
In some embodiments, each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl -C 1-3 alkylene, halo, D, CN, OR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, NRc2Rd2, NRc2C(0)Rb2, NRC2C(0)0R32, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring- forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the
4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R21.
In some embodiments, each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl,
5-6 membered heteroaryl, C3-6 cycloalkyl-Ci-3 alkylene, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, NRc2Rd2, NRc2C(0)Rb2, and NRc2C(0)0Ra2; wherein the 4-6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C3-6 cycloalkyl-C 1-3 alkylene, 4-6 membered heterocycloalkyl-C 1-3 alkylene, phenyl-Ci-3 alkylene and 5-6 membered heteroaryl- Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R21.
In some embodiments, each R20 is independently selected from Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, halo, CN, C(0)NRc2Rd2, and NRc2C(0)0Ra2; wherein the 4-6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, and phenyl-Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R21.
In some embodiments, each Ra2, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl.
In some embodiments, each Ra2, Rc2 and Rd2 is independently selected from H and Ci-
6 alkyl.
In some embodiments, each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl.
In some embodiments, any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2,
3 or 4 substituents independently selected from R21.
In some embodiments, any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heterocycloalkyl ring; wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring forming carbon atom and 1 or 2 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6- membered heterocycloalkyl ring are each optionally substituted with 1 or 2 substituents independently selected from R21.
In some embodiments, two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused C3-6 cycloalkyl ring; and wherein the fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21.
In some embodiments, each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRC4C(0)Rm, NRc4C(0)0Ra4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R22.
In some embodiments, each R21 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, CN, ORa4, C(0)Rb4, C(0)NRc4Rd4, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R22.
In some embodiments, each R21 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, CN, ORa4, C(0)Rb4, C(0)NRc4Rd4, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group.
In some embodiments, each Ra4, Rc4, and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl. In some embodiments, each Ra4, Rc4, and Rd4 is independently selected from H and Ci-6 alkyl. In some embodiments, each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6haloalkyl. In some embodiments, Rb4 is Ci-6 alkyl.
In some embodiments, R21is CN, pyridinyl, morpholinyl, hydroxy, methyl, N,N- dimethylaminocarbonyl, acetyl, oxopyrrolidinyl, or Af,A-dimethylsulfamoyl.
In some embodiments, R20 is methyl, isopropyl, propanyl, cyclobutyl, oxetanyl, cyanopropanyl, pyridinylmethyl, morpholinoethyl, CN, pyrrolidinyl, oxopyrrolidinyl, hydroxylcyclohexyl, hydroxypropanyl, fluoro, methylcarbamoyl, methylhydroxypropanyl, methoxycarbonylamino, methylpiperazinyl, dioxidotetrahydrothiophenyl, pyridinyl, methylpiperidinyl, (N,N-dimethylaminocarbonyl)piperidinyl, acetylpiperidinyl, oxopyrrolidinylethyl, or (Af,A-dimethylsulfamoyl)piperidinyl; or any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused cyclopentyl ring or a fused piperidinyl.
In some embodiments, R20 is methyl, isopropyl, propanyl, cyclobutyl, oxetanyl, cyanopropanyl, pyridinylmethyl, morpholinoethyl, CN, pyrrolidinyl, oxopyrrolidinyl, hydroxylcyclohexyl, hydroxypropanyl, fluoro, methylcarbamoyl, methylhydroxypropanyl, methoxycarbonylamino, methylpiperazinyl, dioxidotetrahydrothiophenyl, pyridinyl, methylpiperidinyl, (N,N-dimethylaminocarbonyl)piperidinyl, acetylpiperidinyl, oxopyrrolidinylethyl, or (Af,A-dimethylsulfamoyl)piperidinyl
In some embodiments, any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused cyclopentyl ring or a fused piperidinyl.
In some embodiments, R2 is 1 -methyl - l//-pyrazol-4-yl, 6-methylpyri din-3 -yl, 5,6- dihydro-4//-pyrrolo[ 1 ,2-/>]pyrazol-3-yl, 1 -(oxetan-3 -yl)- 1 //-py razol -4-y 1, 1 -isopropyl- \H- pyrazol-4-yl, 1 -cyclobutyl- 1 //-py razol -4-yl, 1 -(2-cyanopropan-2-yl)- l//-py razol -4-yl, (pyrazolo[ 1 , 5-a]pyri din-3 -yl), 1 -(pyri din-3 -ylmethyl)- l//-py razol -4-yl, 1 -(2- m orphol i noethyl )-l//-pyrazol -4-yl, 3-cyano-4-methylphenyl, 6-(pyrrolidin-l-yl)pyri din-3 -yl, 6-(2-oxopyrrolidin-l-yl)pyri din-3 -yl, ( 1 /,4,V)-4-hy droxy cy cl ohexy 1 - 1 //-py razol -4-y 1 , 6-(2- hydroxypropan-2-yl)pyridin-3-yl, 3-fluoro-4-(methylcarbamoyl)phenyl, l-(2-methyl-2- hydroxypropanyl)- lH-pyrazol-4-yl, 4-(methoxycarbonylamino)phenyl, 4-(4-methylpiperazin- 1 -yl)phenyl, 1 -( 1 , 1 -dioxidotetrahydrothiophen-3 -yl)- lH-pyrazol-4-yl, 1 -(pyridin-2-yl)- 1 H- pyrazol-4-yl, 1 -(1 -m ethyl pi peri din-4-yl)-l//-pyrazol -4-yl, pyridin-4-yl, 1-((N,N- dimethylaminocarbonyl)piperidin-4-yl)-lH-pyrazol-4-yl, l-(acetylpiperidin-4-yl)-lH- pyrazol-4-yl, 1 -(2-(2-oxopyrrolidin-l -yl)ethyl)-l//-py razol -4-yl, or l-(l-(N,N- di methyl sulfamoyl )pi peri din-4-yl)-l//-pyrazol -4-yl.
In some embodiments, R2 is l-methyl-lH-pyrazol-4-yl.
In some embodiments, R3 is selected from H, D, halo, CN, and Ci-6 alkyl. In some embodiments, R3 is selected from H, D, and Ci-6 alkyl. In some embodiments, R3 is selected from H and Ci-6 alkyl. In some embodiments, R3 is H.
In some embodiments, R4 is selected from H, D, halo, CN, and Ci-6 alkyl. In some embodiments, R4 is selected from H, D, and Ci-6 alkyl. In some embodiments, R4 is selected from H and Ci-6 alkyl. In some embodiments, R4 is H.
In some embodiments, R3 and R4 are both H.
In some embodiments, R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R50.
In some embodiments, R5 is C6-10 aryl optionally substituted with 1, 2, or 3 substituents independently selected from R50. In some embodiments, R5 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R50.
In some embodiments, R5 is 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-10 membered heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R50.
In some embodiments, R5 is 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-6 membered heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R50.
In some embodiments, R5 is pyridinyl, quinolinyl, indazolyl, or benzoisoxazolyl; and wherein pyridinyl, quinolinyl, indazolyl, benzoisoxazolyl, and isoindolinonyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R50.
In some embodiments, each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R51; or any two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, or 6-membered heterocycloalkyl ring; wherein each fused 4-, 5-, or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R51. In some embodiments, each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)0Ra9, NRc9Rd9, NRc9C(0)Rb9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl-C 1-3 alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R51.
In some embodiments, each R50 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, halo, D, CN, ORa9, C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl-Ci-3 alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R51.
In some embodiments, each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C 1-6 haloalkyl. In some embodiments, each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, and Ci-6 haloalkyl. In some embodiments, each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl.
In some embodiments, any two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, or 6-membered heterocycloalkyl ring; wherein each fused 4-, 5-, or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, or 6- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R51.
In some embodiments, each R50 is independently selected from methyl, propanyl, cyclopropyl, morpholinyl, phenyl, triazolyl, pyrrolidinylmethyl, pyrazolyl, fluoro, methoxy, ethyoxy, CN, methylaminocarbonyl, methylcarbonylamino, dimethylamino, (2,2,2- trifluoroethyljaminocarbonyl, difluoromethyl, and methylaminosulfonyl; wherein said methyl, propanyl, cyclopropyl, morpholinyl, phenyl, triazolyl, pyrrolidinylmethyl, pyrazolyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R51; or any two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused oxopyrrolidinyl; and wherein the fused oxopyrrolidinyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R51.
In some embodiments, each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, and NRcl0C(O)Rbl°. In some embodiments, each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, and ORal°. In some embodiments, each R51 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, halo, D, CN, and ORal°.
In some embodiments, each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C 1-6 haloalkyl. In some embodiments, each Ral°, Rcl° and Rdl° is independently selected from H and Ci-6 alkyl. In some embodiments, each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl.
In some embodiments, each R51 is independently selected from methyl, pyrrolidinyl, fluoro, CN, or hydroxy.
In one aspect, the present disclosure provides compounds of Formula Ila:
Figure imgf000024_0001
or a pharmaceutically acceptable salt thereof, wherein Ral, R2, R3, R4, and R5 are as defined herein.
In one aspect, the present disclosure provides compounds of Formula lib:
Figure imgf000024_0002
or a pharmaceutically acceptable salt thereof, wherein Rcl, Rdl, R2, R3, R4, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Ilia:
Figure imgf000025_0001
or a pharmaceutically acceptable salt thereof, wherein Ral, R2, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Illb:
Figure imgf000025_0002
or a pharmaceutically acceptable salt thereof, wherein Rcl, Rdl, R2, and R5 are as defined herein.
In one aspect, the present disclosure provides compounds of Formula IVa:
Figure imgf000025_0003
or a pharmaceutically acceptable salt thereof, wherein R10, R2, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula IVb:
Figure imgf000025_0004
or a pharmaceutically acceptable salt thereof, wherein R2 and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula IVc:
Figure imgf000025_0005
or a pharmaceutically acceptable salt thereof, wherein R10, R2, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Va:
Figure imgf000026_0001
or a pharmaceutically acceptable salt thereof, wherein Ral, R20, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Vb:
Figure imgf000026_0002
or a pharmaceutically acceptable salt thereof, wherein Ral, R20, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Vc:
Figure imgf000026_0003
or a pharmaceutically acceptable salt thereof, wherein Ral, R20, and R5 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Via:
Figure imgf000026_0004
or a pharmaceutically acceptable salt thereof, wherein Ral, R2, and R50 are as defined herein. In one aspect, the present disclosure provides compounds of Formula VIb:
Figure imgf000026_0005
or a pharmaceutically acceptable salt thereof, wherein Ral, R2, and R50 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Vila:
Figure imgf000027_0001
or a pharmaceutically acceptable salt thereof, wherein Ral, R2, and R50 are as defined herein. In one aspect, the present disclosure provides compounds of Formula Vllb:
Figure imgf000027_0002
or a pharmaceutically acceptable salt thereof, wherein Ral, R2, and R50 are as defined herein.
In some embodiments, wherein:
R1 is selected from ORal, SRal, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(0)NRclRdl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each independently selected from H, D, halo, CN, Ci-6 alkyl, ORa8 and NRcXRdx; wherein the Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50;
Ais N; each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)0Ra3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, and S(0)2NRc3Rd3; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each R11 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)0Ra5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NORa2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl- Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)RM, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each R22 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)0Ra6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 memberedheterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)0Ra9, 0C(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, C(=NRe9)Rb9, C(=NORa9)Rb9, C(=NRe9)NRc9Rd9, NRc9C(=NRe9)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-C 1-3 alkylene, 5-10 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, NRcl0C(O)ORal°, NRcl0S(O)Rbl°, NRcl0S(O)2Rbl°, NRcl0S(O)2NRcl0Rdl°, S(0)Rbl°, S(O)NRcl0Rdl°, S(0)2Rbl°, and S(O)2NRcl0Rdl°; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each R52 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORa11, SRa11, C(0)Rbu,
Figure imgf000031_0001
S(0)2NRcllRdu; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 memberedheterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 4-10 membered heterocycloalkyl-Ci-3 alkylene is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Re2 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R11; each Rb3 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R22; each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each Ra5, Rc5 and Rd5 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rb5 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra6, Rc6 and Rd6 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rc6 and Rd6 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rb6 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra8, Rc8 and Rd8 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and Ci-6haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Re9 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R52; each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each Ral1, Rcl1 and Rdu is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rcl1 and Rdu attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rbu is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; and each Rg is independently selected from D, OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C 1-2 alkylene, Ci-6 alkoxy, Ci-6haloalkoxy, C1-3 alkoxy-Ci-3 alkyl, C1-3 alkoxy-Ci-3 alkoxy, HO-C1-3 alkoxy, HO- Ci-3 alkyl, cyano-Ci-3 alkyl, H2N-C1-3 alkyl, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, Ci-6 alkylthio, Ci-6 alkylsulfmyl, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci-6 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci-6 alkoxycarbonylamino, Ci-6 alkylcarbonyloxy, aminocarbonyloxy, Ci-6 alkylaminocarbonyloxy, di(Ci-6 alkyl)aminocarbonyloxy, Ci-6 alkylsulfonylamino, aminosulfonyl, Ci-6 alkylaminosulfonyl, di(Ci-6 alkyl)aminosulfonyl, aminosulfonylamino, Ci-6 alkylaminosulfonylamino, di(Ci-6 alkyl)aminosulfonylamino, aminocarbonylamino, Ci-6 alkylaminocarbonylamino, and di(Ci-6 alkyl)aminocarbonylamino. In some embodiments, wherein:
R1 is selected from ORal, SRal, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(0)NRclRdl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each independently selected from H, D, halo, CN, and Ci-6 alkyl;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50;
Ais N; each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)0Ra3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, and S(0)2NRc3Rd3; each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, N02, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NORa2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl- Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)RM, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, C(=NRe9)Rb9, C(=NORa9)Rb9, C(=NRe9)NRc9Rd9, NRc9C(=NRe9)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- lo aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-C 1-3 alkylene, 5-10 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, NRcl0C(O)ORal°, NRcl0S(O)Rbl°, NRcl0S(O)2Rbl°, NRcl0S(O)2NRcl0Rdl°, S(0)Rbl°, S(O)NRcl0Rdl°, S(0)2Rbl°, and S(O)2NRcl0Rdl°; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 4-10 membered heterocycloalkyl-Ci-3 alkylene is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 memberedheterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Re2 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb3 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Re9 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene.
In some embodiments, wherein:
R1 is selected from ORal, and NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each H;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50; Ais N; each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)0Ra3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, and S(0)2NRc3Rd3; each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring,; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)2Rm, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-C 1-3 alkylene, 5-10 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, NRcl0C(O)ORal°, NRcl0S(O)2Rbl°, NRcl0S(O)2NRcl0Rdl°, S(0)2Rbl°, and S(O)2NRcl0Rdl°; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 4-10 membered heterocycloalkyl-Ci-3 alkylene is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 memberedheterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb3 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 memberedheterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene.
In some embodiments, wherein:
R1 is selected from ORal, and NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each H;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50; Ais N; each R10 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, and NRc3C(0)Rb3; each R20 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring,; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; each R50 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6- lo aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, halo, D, CN, ORal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, and S(0)2Rbl°; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3- 10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5- 10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb3 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb4 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5- 10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and each Rbl° is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl.
In some embodiments, wherein:
R1 is selected from ORal, and NRclRdl;
R2 is selected from phenyl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the phenyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R20;
R3 and R4 are each H;
R5 is selected from phenyl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the phenyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R50;
Ais N; each R10 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, phenyl, halo, D,
CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, and NRc3C(0)Rb3; each R20 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, halo, D, CN, OR32, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, NRc2Rd2, NRc2C(0)Rb2, and NRc2C(0)0Ra2; wherein the 4-6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-6 cycloalkyl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring,; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, or 3 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)2RM, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; each R50 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl, are each optionally substituted with 1, 2, or 3 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, ORal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, and S(0)2Rbl°; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl, are each optionally substituted with 1, 2, or 3 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl and Ci-6haloalkyl; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, and Ci-6haloalkyl; wherein said Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl and Ci-6haloalkyl; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb3 is independently selected from Ci-6 alkyl and Ci-6haloalkyl; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, and Ci-6haloalkyl; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb4 is independently selected from Ci-6 alkyl and Ci-6haloalkyl; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, and Ci-6haloalkyl; wherein said Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl and Ci-6haloalkyl; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, and Ci-6 haloalkyl; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and each Rbl° is independently selected from Ci-6 alkyl and Ci-6 haloalkyl.
It is further appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the disclosure which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
At various places in the present specification, substituents of compounds of the disclosure are disclosed in groups or in ranges. It is specifically intended that the disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term “Ci-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and Ce alkyl.
At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term “a pyridine ring” or “pyridinyl” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.
The term “n-membered” where n is an integer typically describes the number of ring forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
For compounds of the disclosure in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R.
As used herein, the phrase “optionally substituted” means unsubstituted or substituted.
The term "substituted" means that an atom or group of atoms formally replaces hydrogen as a "substituent" attached to another group. The term "substituted", unless otherwise indicated, refers to any level of substitution, e.g, mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms.
As used herein, the term “Ci-j, ” where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, Ci-6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
As used herein, the term “alkyl,” employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkyl group contains 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, /e/7-butyl, «-pentyl, 2-methyl- 1 -butyl, 3-pentyl, «-hexyl, 1,2,2- trimethylpropyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl.
As used herein, the term "Ci-j alkylene," employed alone or in combination with other terms, means a saturated divalent linking hydrocarbon group that may be straight-chain or branched, having i to j carbons. In some embodiments, the alkylene group contains from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or from 1 to 2 carbon atoms. Examples of alkylene moieties include, but are not limited to, chemical groups such as methylene, ethylene, 1,1- ethylene, 1,2-ethylene , 1,3 -propylene, 1,2-propylene, 1,1 -propylene, isopropylene, and the like.
As used herein, “alkenyl,” employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon double bonds. An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, «-propenyl, isopropenyl, «-butenyl, .sfc-butenyl, and the like. As used herein, “alkynyl,” employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon triple bonds. An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn- 2-yl, and the like.
As used herein, the terms “carbamoyl” and “carbamyl” interchangeably refer to a group of formula -C(0)NH2.
As used herein, the term “carboxy” refers to a group of formula -C(0)0H.
The term "cyano" or "nitrile" refers to a group of formula -CºN, which also may be written as -CN.
As used herein, the term “C1-3 alkoxy-Ci-3 alkyl” refers to a group of formula -(C1-3 alkylene)-(Ci-3 alkoxy).
As used herein, the term “C1-3 alkoxy-Ci-3 alkoxy” refers to a group of formula -(C1-3 alkoxylene)-(Ci-3 alkoxy).
As used herein, the term “HO-C1-3 alkoxy” refers to a group of formula -(C1-3 alkoxylene)-OH.
As used herein, the term “HO-C1-3 alkyl” refers to a group of formula -(C1-3 alkylene)-OH.
As used herein, the term “cyano-Ci-3 alkyl” refers to a group of formula -(C1-3 alkylene)-CN.
As used herein, the term “H2N-C1-3 alkyl” refers to a group of formula -(C1-3 alkylene)-NH2.
As used herein, the term “Cn-m alkylamino” refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “Cn-m alkoxy carbonyl” refers to a group of formula -C(0)0- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “Cn-m alkylcarbonyl” refers to a group of formula -C(O)- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. As used herein, the term “Cn-m alkylcarbonylamino” refers to a group of formula -NHC(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term "Cn-malkylcarbonyloxy” refers to a group of formula - 0C(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term "aminocarbonyloxy” refers to a group of formula - 0C(0)NH2.
As used herein, the term "Cn-malkylaminocarbonyloxy” refers to a group of formula -OC(0)NH-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “Cn-malkylsulfonylamino” refers to a group of formula -NHS(0)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “aminosulfonyl” refers to a group of formula -S(0)2NH2.
As used herein, the term “Cn-m alkylaminosulfonyl” refers to a group of formula -S(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “di(Cn-m alkyl)aminosulfonyl” refers to a group of formula -S(0)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms.
In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “aminosulfonylamino” refers to a group of formula - NHS(0)2NH2.
As used herein, the term “Cn-m alkylaminosulfonylamino” refers to a group of formula -NHS(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “di(Cn-m alkyl)aminosulfonylamino” refers to a group of formula -NHS(0)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “aminocarbonylamino”, employed alone or in combination with other terms, refers to a group of formula -NHC(0)NH2. As used herein, the term “Cn-m alkylaminocarbonylamino” refers to a group of formula -NHC(0)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “di(Cn-m alkyl)aminocarbonylamino” refers to a group of formula -NHC(0)N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “Cn-m alkylcarbamyl” refers to a group of formula -C(O)- NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “di(Cn-m-alkyl)carbamyl” refers to a group of formula - C(0)N(alkyl)2, wherein the two alkyl groups each has, independently, n to m carbon atoms.
In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “thio” refers to a group of formula -SH.
As used herein, the term “Cn-m alkylthio” refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “Cn-malkylsulfmyl” refers to a group of formula -S(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, the term “Cn-malkylsulfonyl” refers to a group of formula -S(0)2- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
As used herein, “halo” or “halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. In some embodiments, halo is F.
As used herein, the term “haloalkyl,” employed alone or in combination with other terms, refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom, having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms.
In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCh, CHCI2, C2CI5, and the like. As used herein, the term “alkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-alkyl. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, alkoxy is methoxy.
As used herein, “haloalkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. An example haloalkoxy group is -OCF3.
As used herein, “amino,” employed alone or in combination with other terms, refers to NEb.
As used herein, the term “alkylamino,” employed alone or in combination with other terms, refers to a group of formula -NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms. Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.
As used herein, the term “alkylthio,” employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term “cycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. The term "Cn-m cycloalkyl" refers to a cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Ring forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term “cycloalkyl” also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7 monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcamyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, the term “heterocycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus, and which has 4-14 ring members, 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7- membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) or spirocyclic ring systems.
In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-l-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quatemized. In some embodiments, the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring. In some embodiments, the heterocycloalkyl is a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heterocycloalkyl is 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.
As used herein, the term “aryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1 -naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl.
As used herein, the term “heteroaryl” or “heteroaromatic” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[l,2-b]thiazolyl, pyridone, or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In some embodiments the heteroaryl group is a 5 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 5 to 6 membered heteroaryl group. In some embodiments, the heteroaryl is a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heteroaryl is a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, no more than 2 heteroatoms of a 5 -membered heteroaryl moiety are N.
A five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S. Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
A six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more ( e.g ., 1, 2 or 3) ring atoms are independently selected from N, O and S. Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, isoindolyl, and pyridazinyl.
The term "oxo" refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N- oxide group. In some embodiments, heterocyclic groups may be optionally substituted by 1 or 2 oxo (=0) substituents.
The term “oxidized” in reference to a ring-forming N atom refers to a ring-forming N-oxide.
The term “oxidized” in reference to a ring-forming S atom refers to a ring-forming sulfonyl or ring-forming sulfmyl.
The term "aromatic" refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i.e., having (4n + 2) delocalized p (pi) electrons where n is an integer).
At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3 -position.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms. Resolution of racemic mixtures of compounds can be carried out by methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine ( e.g ., S and R for s, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2- diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
In some embodiments, the compounds of the disclosure have the (//(-configuration In other embodiments, the compounds have the (^-configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
Compounds of the disclosure also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2, 4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the disclosure also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the disclosure can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744- 7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.
Substitution with heavier isotopes such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. (A. Kerekes et.al. J. Med. Chem. 2011, 54 , 201-210; R. Xu et.al. J. Label Compd. Radiopharm. 2015, 58, 308-312).
The term, “compound,” as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted. The term is also meant to refer to compounds of the disclosure, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated. When in the solid state, the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates. The compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
In some embodiments, the compounds of the disclosure, or salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the disclosure. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the disclosure, or salt thereof. Methods for isolating compounds and their salts are routine in the art. The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present disclosure include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences , 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science , 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
The following abbreviations may be used herein: AcOH (acetic acid); AC2O (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (/-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc (calculated); d (doublet); dd (doublet of doublets); DCM (dichloromethane); DEAD (diethyl azodi carboxyl ate); DIAD (A, A -diisopropyl azidodi carboxyl ate); DIPEA (A,A-diisopropylethylamine); DMF (A,A-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (A,A,A',A'-tetramethyl-0- (7-azabenzotriazol-l-yl)uronium hexafluorophosphate); HC1 (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography - mass spectrometry); m (multiplet); M (molar); wCPBA (3- chloroperoxybenzoic acid); MgSCri (magnesium sulfate); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); NaHCCh (sodium bicarbonate); NaOH (sodium hydroxide); Na2SC>4 (sodium sulfate); NH4CI (ammonium chloride); NH4OH (ammonium hydroxide); NIS (N-iodosuccinimide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM (picomolar); PMB (para-methoxybenzyl), POCh (phosphoryl chloride); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); SEM (2- trimethylsilylethoxymethyl); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); /-Bu (/er/-butyl); TFA (trifluoroacetic acid); THF (tetrahydrofuran); pg (microgram(s)); pL (microliter(s)); pM (micromolar); wt% (weight percent).
Synthesis
As will be appreciated by those skilled in the art, the compounds provided herein, including salts and stereoisomers thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
The reactions for preparing compounds of the disclosure can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of compounds of the disclosure can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis , 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 'H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography. The expressions, “ambient temperature,” “room temperature,” and “r.t ”, as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.
Compounds of Formula I, wherein A = N, can be prepared as shown in Scheme 1. Selective cross-coupling of heterocycles 1-1 (wherein Z = halogen (F, Cl, Br, I) or pseudohalogen (e.g., OTf), with Z chosen appropriately to afford regioselectivity) with a suitable M-R2 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) affords intermediates 1-2. Buchwald-Hartwig coupling (Chem. Sci. 2011, 2, 27-50) with benzophenone imine under standard conditions (e.g., in the presence of a palladium catalyst, such as [I,G- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane and a base, such as cesium carbonate) affords imine intermediates 1-3. Treatment of intermediates 1-3 with aqueous acid (e.g., hydrochloric acid) provides amines 1-4. Cyclization of the 3- aminopyridazines (e.g., with chloroacetaldehyde) affords imidazo[l,2-Z>]pyridazine intermediates 1-5. Halogenation of these intermediates 1-5 with a suitable halogenating reagent (e.g., NBS, NCS, etc.) affords intermediates 1-6 , which can undergo subsequent cross-coupling with M-R5 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) under standard Suzuki conditions (Tetrahedron 2002, 58, 9633-9695) (e.g., in the presence of a palladium catalyst, such as [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane or chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'- biphenyl)[2-(2'-amino-l,l'-biphenyl)]palladium(II), and abase, such as a carbonate base or cesium fluoride), or standard Stille conditions (ACS Catalysis 2015, 5, 3040-3053) (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)-palladium(0)), or standard Negishi conditions (ACS Catalysis 2016, 6, 1540-1552) (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [ 1,1’- bis(diphenylphosphino)ferrocene]-dichloropalladium (II)) to afford compounds of the Formula I. Scheme 1.
Figure imgf000067_0001
1-4 cyclization
T 5
Figure imgf000067_0002
Alternatively, when intermediates 1-1 include Z groups that afford the opposite regioselectivity, compounds of Formula I (wherein A = N) can be prepared as shown in Scheme 2. Selective Buchwald-Hartwig coupling of heterocycles 1-1 (wherein Z = halogen (F, Cl, Br, I) or pseudohalogen (e.g., OTf)) with benzophenone imine under standard conditions (e.g., in the presence of a palladium catalyst, such as [ 1,1’- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane and a base, such as cesium carbonate) affords imine intermediates 2-1. Analogous to the above procedure, treatment of intermediates 2-1 with aqueous acid (e.g., hydrochloric acid) provides amines 2-2. Cyclization of the 3-aminopyridazines 2-2 (e.g., with chloroacetaldehyde) affords imidazo[l,2-Z>]pyridazine intermediates 2-3. Halogenation of these intermediates 2-3 with a suitable halogenating reagent (e.g., NBS, NCS, etc.) affords intermediates 2-4, which can undergo subsequent cross-coupling with M-R5 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane or chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'- biphenyl)[2-(2'-amino-l,l'-biphenyl)]palladium(II), and abase, such as a carbonate base or cesium fluoride), or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)-palladium(0)), or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [l,r-bis(diphenylphosphino)ferrocene]-dichloropalladium (II)) to afford intermediates 2-5. Finally, cross-coupling of heterocycles 2-5 with a suitable M-R2 (wherein M is B(OH)2,
BPin, BF3K, Sn(Bu)3, or Zn) under standard conditions as described above affords compounds of the Formula I.
Scheme 2.
Figure imgf000068_0001
Formula I
Some heterocycles of the formula 1-1 are commercially available or known in the literature. Alternatively, some can be prepared as shown in Scheme 3. Heterocycles 3-1 can be deprotonated under strongly basic conditions (e.g., with a lithium base, like n- BuLi, LDA, or LiHMDS, or with a /b//w-Hauser base, like 2,2,6,6-tetramethylpiperidinylmagnesium chloride, lithium chloride complex) and treated with a suitable halogenating agent (e.g., NCS, NBS, NIS, hexachloroethane) at cryogenic temperatures. For heterocycles 3-1 wherein R3 = H, this method may be most effective for groups R1 that offer a stronger directing effect than the chosen Z group. Scheme 3.
Figure imgf000069_0001
Some compounds of Formula I, wherein A = CRA, can be prepared as shown in Scheme 4. Commercially available 2-aminopyri dines 4-1 (wherein Z = halogen (F, Cl, Br, I) or pseudohalogen (e.g., OTf)) can be cyclized (e.g., with chloroacetaldehyde) to afford imidazo[l,2-a]pyridine intermediates 42 Cross-coupling of heterocycles 4-2 with a suitable M-R2 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) affords intermediates 4-3 Halogenation of these intermediates 4-3 with a suitable halogenating reagent (e.g., NBS, NCS, etc.) affords intermediates 4 4 , which can undergo subsequent cross-coupling with M- R5 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as [ 1,1’- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane or chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)[2-(2'-amino-l,l'- biphenyl)]palladium(II), and a base, such as a carbonate base or cesium fluoride), or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)-palladium(0)), or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [ 1,1’- bis(diphenylphosphino)ferrocene]-dichloropalladium (II)) to afford compounds of the Formula I.
Scheme 4.
Figure imgf000070_0001
Compounds of Formula I, wherein A = N, can also be prepared as shown in Scheme 5. Halogenation of commercially available heterocycles 5-1 (wherein Z = halogen (F, Cl, Br,
I) or pseudohalogen (e.g., OTf)) with a suitable halogenating reagent (e.g., NBS, NCS, etc.) affords intermediates 5 2 Nucleophilic aromatic substitution with ammonia then selectively affords amines 5 3 , which can undergo selective halogenation to provide intermediates 5-4 Conversion of the amino group under diazotization reaction conditions (e.g., alkyl nitrite in an appropriate solvent at elevated temperature, under reducing conditions or with the appropriate copper(I) salt) affords intermediates 5-5, which can undergo selective cross coupling with M-R2 (wherein M is B(OH)2, BPin, BF3K, Sn(Bu)3, or Zn) to give intermediates 5 6 Nucleophilic aromatic substitution (e.g., with HORal or HNRclRdl) provides intermediates 5-7, which can undergo cross-coupling with M-R5 under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as [ 1,1’- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane or chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)[2-(2'-amino-l,l'- biphenyl)]palladium(II), and a base, such as a carbonate base or cesium fluoride), or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)-palladium(0)), or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [ 1,1’- bis(diphenylphosphino)ferrocene]-dichloropalladium (II)), to afford compounds of the Formula I. Scheme 5.
Figure imgf000071_0001
Alternatively, when intermediates 5-5 include Z groups that afford the opposite regioselectivity, compounds of Formula I (wherein A = N) can be prepared as shown in
Scheme 6. From intermediates 5-5 (as prepared in Scheme 5), with Z groups chosen appropriately, nucleophilic aromatic substitution (e.g., with HORal or HNRclRdl) provides intermediates 6 1 , which can undergo selective cross-coupling with M-R5 (under conditions as described above) to afford compounds 6 2 Cross coupling of 6-2 with M-R2 (under conditions as described above) can then afford compounds of Formula I.
Scheme 6.
Figure imgf000072_0004
M-R2 cross-coupling
Figure imgf000072_0001
Figure imgf000072_0002
Formula I
Some heterocycles of the formula 5-1 are commercially available or known in the literature. Alternatively, some can be prepared as shown in Scheme 7. Heterocycles 7-1 can be can be treated with alpha-halo carbonyl compounds at elevated temperatures to provide imidazo[l,2-Z>]pyridazines 5-1.
Scheme 7. o
RJGZ
Figure imgf000072_0003
Methods of Use
Compounds of the present disclosure can inhibit the activity of the FGFR enzyme. For example, compounds of the present disclosure can be used to inhibit activity of an FGFR enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient. Compounds of the present disclosure can be used to inhibit activity of the FGFR3 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient. Compounds of the present disclosure can be used to inhibit activity of the FGFR2 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient. Compounds of the present disclosure can be selective for the inhibition of FGFR2 and/or FGFR3 enzymes over the inhibition of FGFR1 and/or FGFR4 enzymes.
As FGFR inhibitors, the compounds of the present disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR enzyme or FGFR ligands. Compounds which inhibit FGFR will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that compounds of the present disclosure will prove useful in treating or preventing proliferative disorders such as cancers. In particular, tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.
In certain embodiments, the disclosure provides a method for treating a FGFR- mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound according to the disclosure, or a pharmaceutically acceptable composition thereof.
In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), 8pll myeloproliferative syndrome), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, adult T-cell leukemia, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, marginal zone lymphoma, chronic myelogenic lymphoma and Burkitf s lymphoma.
Exemplary sarcomas include chondrosarcoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, lymphosarcoma, leiomyosarcoma, and teratoma.
Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.
Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (exocrine pancreatic carcinoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, gall bladder cancer and anal cancer.
Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma) and urothelial carcinoma.
Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors
Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, neuro-ectodermal tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), neuroblastoma, Lhermitte-Duclos disease and pineal tumors.
Exemplary gynecological cancers include cancers of the breast (ductal carcinoma, lobular carcinoma, breast sarcoma, triple-negative breast cancer, HER2-positive breast cancer, inflammatory breast cancer, papillary carcinoma), uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).
Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and parathyroid cancers, tumors of the eye, tumors of the lips and mouth and squamous head and neck cancer.
The compounds of the present disclosure can also be useful in the inhibition of tumor metastases.
In addition to oncogenic neoplasms, the compounds of the disclosure are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare- Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes. In some embodiments, the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder.
In some embodiments, compounds described herein can be used to treat Alzheimer’s disease, HIV, or tuberculosis.
As used herein, the term “8pl 1 myeloproliferative syndrome” is meant to refer to myeloid/lymphoid neoplasms associated with eosinophilia and abnormalities of FGFR1.
As used herein, the term “cell” is meant to refer to a cell that is in vitro , ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.
As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” the FGFR enzyme with a compound described herein includes the administration of a compound described herein to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound described herein into a sample containing a cellular or purified preparation containing the FGFR enzyme.
As used herein, the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent such as an amount of any of the solid forms or salts thereof as disclosed herein that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. An appropriate "effective" amount in any individual case may be determined using techniques known to a person skilled in the art.
The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, the phrase "pharmaceutically acceptable carrier or excipient" refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, non-toxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. In some embodiments, each component is "pharmaceutically acceptable" as defined herein. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et ak, Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed. ; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009.
As used herein, the term "treating" or "treatment" refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.„ arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.„ reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the disclosure which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
Combination Therapy
One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy ( e.g .,
IL2, GM-CSF, etc), and/or tyrosine kinase inhibitors can be used in combination with compounds described herein for treatment of FGFR-associated diseases, disorders or conditions, or diseases or conditions as described herein. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
Compounds described herein can be used in combination with one or more other kinase inhibitors for the treatment of diseases, such as cancer, that are impacted by multiple signaling pathways. For example, a combination can include one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-PR, Pirn, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFpR, CSFIR, KIT, FLK-II, KDR/FLK- 1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Additionally, the compounds and pharmaceutically acceptable salts thereof as described herein can be combined with inhibitors of kinases associated with the PIK3/Akt/mTOR signaling pathway, such as PI3K, Akt (including Aktl, Akt2 and Akt3) and mTOR kinases.
In some embodiments, compounds described herein can be used in combination with one or more inhibitors of the enzyme or protein receptors such as HPK1, SBLB, TUT4, A2A/A2B, CD47, CDK2, STING, ALK2, LIN28, ADAR1, MAT2a, RIOK1, HDAC8, WDR5, SMARCA2, and DCLK1 for the treatment of diseases and disorders. Exemplary diseases and disorders include cancer, infection, inflammation and neurodegenerative disorders.
In some embodiments, compouds described herein can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. Histone deacetylase inhibitors include, e.g, vorinostat.
For treating cancer and other proliferative diseases, compounds described herein can be used in combination with targeted therapies, including JAK kinase inhibitors (Ruxolitinib, additional JAK1/2 and JAK 1- selective, baricitinib or INCB39110), Pirn kinase inhibitors (e.g., LGH447, INCB053914 and SGI-1776), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors (e.g., INCB50465 and INCB54707), PI3K- gamma inhibitors such as PI3K-gamma selective inhibitors, MEK inhibitors, CSF1R inhibitors (e.g., PLX3397 and LY3022855), TAM receptor tyrosine kinases inhibitors (Tyro- 3, Axl, and Mer; e.g., INCB81776), angiogenesis inhibitors, interleukin receptor inhibitors, Cyclin Dependent kinase inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (Bortezomib, Carfilzomib), HD AC -inhibitors (panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors, such as OTX015, CPI- 0610, INCB54329 or INCB57643), LSD1 inhibitors (e.g., GSK2979552, INCB59872 and INCB60003), arginase inhibitors (e.g., INCB1158), indoleamine 2,3 -di oxygenase inhibitors (e.g., epacadostat, NLG919 or BMS-986205), PARP inhibiors (e.g., olaparib or rucaparib), and inhibitors of BTK such as ibrutinib. In addition, for treating cancer and other proliferative diseases, compounds described herein can be used in combination with targeted therapies such as, e.g., c-MET inhibitors (e.g., capmatinib), an anti-CD19 antibody (e.g., tafasitamab), an ALK2 inhibitor (e.g., INCB00928); or combinations thereof. For treating cancer and other proliferative diseases, compounds described herein can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti -proliferative agents. Compounds described herein can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g ., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.
Examples of suitable chemotherapeutic agents include any of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amidox, amsacrine, anastrozole, aphidicolon, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bendamustine, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, camptosar, capecitabine, carboplatin, carmustine, cediranib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dacomitinib, dactinomycin, dalteparin sodium, dasatinib, dactinomycin, daunorubicin, decitabine, degarelix, denileukin, denileukin diftitox, deoxycoformycin, dexrazoxane, didox, docetaxel, doxorubicin, droloxafme, dromostanolone propionate, eculizumab, enzalutamide, epidophyllotoxin, epirubicin, epothilones, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, idelalisib, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lonafarnib, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mithramycin, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, navelbene, necitumumab, nelarabine, neratinib, nilotinib, nilutamide, niraparib, nofetumomab, oserelin, oxaliplatin, paclitaxel, pamidronate, panitumumab, panobinostat, pazopanib, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pilaralisib, pipobroman, plicamycin, ponatinib, porfimer, prednisone, procarbazine, quinacrine, ranibizumab, rasburicase, regorafenib, reloxafme, revlimid, rituximab, rucaparib, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, tegafur, temozolomide, teniposide, testolactone, tezacitabine, thalidomide, thioguanine, thiotepa, tipifarnib, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, triapine, trimidox, triptorelin, uracil mustard, valrubicin, vandetanib, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, veliparib, talazoparib, and zoledronate. In some embodiments, compounds described herein can be used in combination with immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, 0X40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3 (e g., INCAGN2385), TIM3 (e g., INCB2390), VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40 (e.g., INCAGN1949), GITR (e.g., INCAGN1876) and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRbeta inhibitors.
In some embodiments, the inhibitor of an immune checkpoint molecule is a small molecule PD-L1 inhibitor. In some embodiments, the small molecule PD-L1 inhibitor has an IC50 less than 1 mM, less than 100 nM, less than 10 nM or less than 1 nM in a PD-L1 assay described in US Patent Publication Nos. US 20170107216, US 20170145025, US 20170174671, US 20170174679, US 20170320875, US 20170342060, US 20170362253, and US 20180016260, each of which is incorporated by reference in its entirety for all purposes.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti -PD-1 monoclonal antibody. In some embodiments, the anti -PD-1 monoclonal antibody is MGA012, nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, ipilumimab or AMP -224. In some embodiments, the anti- PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti- PD1 antibody is pembrolizumab. In some embodiments, the anti-PDl antibody is nivolumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. MGA012 is also known as retifanlimab. In some embodiments, the anti-PDl antibody is SHR-1210. Other anti-cancer agent(s) include antibody therapeutics such as 4-1BB (e.g. urelumab, utomilumab).
In some embodiments, the compounds of the disclosure can be used in combination with INCB086550.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is MPDL3280A or MEDI4736.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody. In some embodiments, the anti-TEVB antibody is INCAGN2390, MBG453, or TSR-022.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.
In some embodiments, the inhibitor of an immune checkpoint molecule is an agonist of 0X40, e.g., 0X40 agonist antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS- 986178. In some embodiments, the OX40L fusion protein is MEDI6383.
In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.
The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, 0X40, TIM3, LAG3, CD137, ICOS, CD3 or TGFp receptor.
In some embodiments, the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO 1, TDO, or arginase. Examples of IDO 1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
In some embodiments, the compounds described herein can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
Suitable antiviral agents contemplated for use in combination with compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fluoro-cytidene); DAPD, ((- )-beta-D-2, 6, -diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.
Suitable agents for use in combination with compounds described herein for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy. Compounds described herein may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors. Suitable examples are anti -estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds described herein. These include anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone). The compounds described herein may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c- Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Aik (or EML4-ALK) include crizotinib.
Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti -angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib
Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds described herein include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.
Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds described herein. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.
Other suitable agents for use in combination with compounds described herein include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
Other suitable agents for use in combination with compounds described herein include steroids including 17 alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, and medroxy proge steroneacetate .
Other suitable agents for use in combination with compounds described herein include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the “Dartmouth regimen,” which consists of DTIC,
BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compounds described herein may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in.
Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.
Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara- C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafme, cyclophosphamide, ifosamide, and droloxafme. Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB, PD-L1 and PD-1 antibodies, or antibodies to cytokines (IL-10, TGF-b, etc.).
Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.
As provided throughout, the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
Pharmaceutical Formulations and Dosage Forms
When employed as pharmaceuticals, compounds described herein can be administered in the form of pharmaceutical compositions which refers to a combination of one or more compounds described herein, and at least one pharmaceutically acceptable carrier or excipient. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary ( e.g ., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
This disclosure also includes pharmaceutical compositions which contain, as the active ingredient, one or more compounds described herein in combination with one or more pharmaceutically acceptable carriers or excipients. In making the compositions described herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is suitable for topical administration.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh. The compounds of the disclosure may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the disclosure can be prepared by processes known in the art see, e.g ., WO 2002/000196.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
In some embodiments, the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PHI 02™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g, Methocel K4 M Premier™) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g, Methocel K00LV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 ( e.g ., Poly ox WSR 1105™).
In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
The compositions can be formulated in a unit dosage form, each dosage containing from, for example, about 5 mg to about 1000 mg, about 5 mg to about 100 mg, about 100 mg to about 500 mgor about 10 to about 30 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration. For example, suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good Manufacturing Practice regulations of the U.S. Food and Drug Administration.
The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
The therapeutic dosage of a compound of the present disclosure can vary according to, e.g, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g, hydrophobicity), and the route of administration. For example, the compounds of the disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of one or more compounds described herein. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present disclosure.
The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the compounds, or compositions as described herein can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g ., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g. , glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g. , glycerol, hydroxy ethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the disclosure. The topical formulations can be suitably packaged in tubes of, e.g. , 100 g which are optionally associated with instructions for the treatment of the select indication, e.g. , psoriasis or other skin condition.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of a compound of the present disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of the compounds in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, compounds of the present disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.
Compounds described herein can also be formulated in combination with one or more additional active ingredients, which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.
Labeled Compounds and Assay Methods
Another aspect of the present disclosure relates to labeled compounds of the disclosure (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo , for localizing and quantitating FGFR3 protein in tissue samples, including human, and for identifying FGFR3 ligands by inhibition binding of a labeled compound. Substitution of one or more of the atoms of the compounds of the present disclosure can also be useful in generating differentiated ADME (Adsorption, Distribution, Metabolism and Excretion). Accordingly, the present disclosure includes FGFR binding assays that contain such labeled or substituted compounds.
The present disclosure further includes isotopically-labeled compounds of the disclosure. An “isotopically” or “radio-labeled” compound is a compound of the disclosure where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present disclosure include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), UC, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36C1, 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I and 13 CI. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced by deuterium atoms (e.g., one or more hydrogen atoms of a Ci-6 alkyl group of Formula (I) can be optionally substituted with deuterium atoms, such as -CD3 being substituted for -CFb). In some embodiments, alkyl groups in Formula (I) can be perdeuterated.
One or more constituent atoms of the compounds presented herein can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms. In some embodiments, all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.
Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton- Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can be used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.
Substitution with heavier isotopes, such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances (see e.g., A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210; R. Xu et. al. J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolism sites may afford one or more of the therapeutic advantages.
The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro adenosine receptor labeling and competition assays, compounds that incorporate 3H, 14C,
82Br, 125I, 131I or 35S can be useful. For radio-imaging applications UC, 18F, 125I, 123I, 124I, 131I, 75Br, 76Br or 77Br can be useful. It is understood that a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide. In some embodiments, the radionuclide is selected from the group consisting of 3H, 14C, 1251, 35S and 82Br.
The present disclosure can further include synthetic methods for incorporating radio isotopes into compounds of the disclosure. Synthetic methods for incorporating radio isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of disclosure.
A labeled compound of the disclosure can be used in a screening assay to identify and/or evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind an FGFR3 protein by monitoring its concentration variation when contacting with the FGFR3, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a FGFR3 protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the FGFR3 protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
Kits
The present disclosure also includes pharmaceutical kits useful, for example, in the treatment or prevention of FGFR-associated diseases or disorders, such as cancer and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
The disclosure will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the disclosure in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of FGFR3 as described below.
EXAMPLES
Experimental procedures for compounds of the invention are provided below. Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass-directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g., “Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification”, K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity analysis under the following conditions: Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ Cis 5 pm, 2.1 x 50 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL/minute.
Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse- phase high performance liquid chromatography (RP-HPLC) column conditions are as follows: pH = 2 purifications: Waters Sunfire™ Cix 5 pm, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute. pH = 10 purifications: Waters XBridge Cis 5 pm, 19 x 100 mm column, eluting with mobile phase A: 0.15% MLOH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J Comb. Chem ., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute.
Intermediate A. 3,4-Difluoro-A-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzamide
Figure imgf000095_0001
Step 1. 3-Bromo-4,5-difluorobenzoic Acid
Figure imgf000095_0002
A sample of 3,4-difluorobenzoic acid (2.0 g, 12.7 mmol) was dissolved in sulfuric acid (25 ml) and treated with NBS (2.49 g, 14.0 mmol). The solution was warmed to 60 °C and stirred for 16 hours. The reaction was poured into ice water (250 mL) and diluted with EtOAc (250 mL). The layers were separated and the aqueous portion was extracted with additional EtOAc. The organic fractions were combined, dried with magnesium sulfate, filtered, and concentrated in vacuo. The resulting material (initially an oil, crystallizes over several days) was collected to provide crude 3-bromo-4,5-difluorobenzoic acid (1.27 g, 5.4 mmol, 42% yield). Compound does not ionize by LCMS and structure was confirmed by subsequent steps.
Step 2. 3-Bromo-4,5-difluoro-N-methylbenzamide
Figure imgf000095_0003
A sample of 3-bromo-4,5-difluorobenzoic acid (1.27 g, 5.4 mmol) was dissolved in DCM (27 ml) in a round-bottomed flask with a stir bar. This solution was treated with DIPEA (1.9 ml, 10.7 mmol), and HATU (2.24 g, 5.9 mmol), and stirred for 15 minutes. Lastly, methylamine (8.0 ml, 2M in THF, 16.0 mmol) was added and the mixture was stirred at 22 °C. After 40 minutes, the reaction mixture was treated with saturated aqueous ammonium chloride (50 mL) and diluted with EtOAc (100 mL). The layers were separated and the aqueous layer was extracted with additional EtOAc. The organic fractions were combined, dried with magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (0-15% EtOAc/DCM) to provide 3-bromo-4,5- difluoro-A-methylbenzamide (0.403 g, 1.61 mmol, 30% yield). LCMS calculated for CsHvBrFiNO (M+H)+: m/z = 250.0; found: 249.9.
Step 3. 3, 4-Difluoro-N-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzamide A sample of 3-bromo-4,5-difluoro-/V-methylbenzamide (402 mg, 1.6 mmol) was suspended in toluene and treated with potassium acetate (316 mg, 3.22 mmol) and bis(pinacolato)diboron (694 mg, 2.73 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (16 ml) was added and the mixture was stirred to dissolve. The solution was degassed by bubbling with nitrogen for 5 mins. [l,l'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (131 mg, 0.16 mmol) was added and the reaction was warmed to 100 °C and stirred for 2 hours. After cooling to room temperature, the reaction was diluted with DCM and filtered to remove the potassium acetate. The filtrate was concentrated in vacuo , and the residue was purified by flash chromatography
(0-100% EtOAc/DCM) to afford 3, 4-difluoro-A-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3,2- dioxaborolan-2-yl)benzamide (500 mg, 1.7 mmol, mass was over theoretical yield, so quantitative yield was assumed). The following data is reported for the corresponding boronic acid, which was the only observable species by LCMS. LCMS calculated for C8H9BF2NO3 (M+H)+: m/z = 216.1; found: 216.1.
Intermediate B. 4-Fluoro-A,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzamide
Figure imgf000097_0001
Step 1. 3-Bromo-4-fluoro-5-methylbenzoic Acid
Figure imgf000097_0002
A sample of 4-fluoro-3-methylbenzoic acid (2.0 g, 13 mmol) was dissolved in sulfuric acid (26 ml) and treated with NBS (2.6 g, 14.5 mmol). The solution was warmed to 60 °C and stirred for 16 hours. The reaction was poured into ice water (500 mL) and stirred for an hour. The sample was filtered and the solid was collected to provide crude 3-bromo-4-fluoro- 5-methylbenzoic acid (3.3 g, 14.1 mmol, mass was over theoretical yield, so quantitative yield was assumed). Compound does not ionize by LCMS and structure was confirmed by subsequent steps; subsequent steps also indicate an unidentified dibrominated product.
Step 2. 3-Bromo-4-fluoro-N,5-dimethylbenzamide
Figure imgf000097_0003
A sample of crude 3-bromo-4-fluoro-5-methylbenzoic acid (3.3 g, 14.1 mmol) was suspended in DCM (71 ml) in a round-bottomed flask with a stir bar. This suspension was treated with DIPEA (4.93 ml, 28.2 mmol), causing complete dissolution of the starting material. The solution was then treated with HATU (5.90 g, 15.5 mmol), and stirred for 15 minutes. Lastly, methylamine (21.2 ml, 2M in THF, 42.4 mmol) was added and the mixture was stirred at 22 °C. After 40 minutes, the reaction mixture was treated with saturated aqueous ammonium chloride (50 mL) and diluted with EtOAc (100 mL). The layers were separated and the aqueous layer was extracted with additional EtOAc. The organic fractions were combined, dried with magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (0-100% EtO Ac/hexanes) to provide 3-bromo- 4-fluoro-Af,5-dimethylbenzamide (1.4 g, 5.7 mmol, 40% yield). LCMS calculated for CiHioBrFNO (M+H)+: m/z = 246.0; found: 245.9.
Step 3. 4-Fluoro-N, 3-dimethyl-5-( 4, 4, 5, 5-tetramethyl-l , 3, 2-dioxaborolan-2-yl)benzamide A sample of 3-bromo-4-fluoro-/V,5-dimethylbenzamide (95 mg, 0.39 mmol) was suspended in toluene and treated with potassium acetate (114 mg, 1.16 mmol) and bis(pinacolato)diboron (147 mg, 0.58 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (3.9 ml) was added and the mixture was stirred to dissolve. The solution was degassed by bubbling with nitrogen for 5 minutes. [l,r-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (47 mg, 0.06 mmol) was added and the reaction was warmed to 110 °C and stirred for 2 hours. The reaction was diluted with DCM and filtered to remove solid potassium acetate. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography (0-100% EtOAc/DCM) to provide 4-fluoro-Af,3-di methyl -5-(4, 4,5, 5-tetramethyl- l ,3,2-dioxaborolan-2- yl)benzamide (99 mg, 0.34 mmol, 87% yield). The following data is reported for the corresponding boronic acid, which was the only observable species by LCMS. LCMS calculated for C9H12BFNO3 (M+H)+: m/z = 212.1; found: 212.2.
Intermediate C. 3-(Difluoromethyl)-4-fluoro-A-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3, 2- dioxaborolan-2-yl)benzamide
Figure imgf000098_0001
Step 1. 3-Bromo-4-fluoro-5-formylbenzoic Acid
Figure imgf000098_0002
A sample of 4-fluoro-3-formylbenzoic acid (2.07 g, 12.3 mmol) was dissolved in sulfuric acid (25 ml) and treated with NBS (2.41 g, 13.5 mmol). The solution was warmed to 60 °C and stirred for 16 hours. The reaction was poured into ice water (500 mL) and stirred for 1 hour. The sample was filtered and the solid was collected to provide 3-bromo-4-fluoro- 5-formylbenzoic acid (2.63 g, 10.7 mmol, 86% yield). Compound does not ionize by LCMS and structure was confirmed by subsequent steps.
Step 2. 3-Bromo-4-fluoro-5-formyl-N-methylbenzamide
Figure imgf000099_0001
To a solution of 3-bromo-4-fluoro-5-formylbenzoic acid (400 mg, 1.62 mmol) and HATU (739 mg, 1.94 mmol) in DMF (6 ml) was added DIPEA (0.42 mL, 2.43 mmol), and the reaction mixture was stirred at room temperature for 5 min. Methylamine (2M/THF) (1.2 mL, 2.43 mmol) was added and stirring was continued for an additional 30 min. The reaction mixture was partitioned between water and EtOAc, and the layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The product was purified by flash chromatography (0-100% EtOAc/hexanes) to afford the title compound (176 mg, 0.68 mmol, 42% yield). LCMS calculated for CiHsBrFNOi (M+H)+: m/z = 260.0; found: 260.0.
Step 3. 3-Bromo-5-(difluoromethyl)-4-fluoro-N-methylbenzamide
Figure imgf000099_0002
To a solution of 3-bromo-4-fluoro-5-formyl-/V-methylbenzamide (176 mg, 0.68 mmol) in DCM (4 ml) was added DAST (179 mΐ, 1.35 mmol) at 0 °C, and the reaction mixture was allowed to warm to room temp. After 30 min, more DAST (179 mΐ, 1.35 mmol) was added and stirring was continued for 1 h. The reaction mixture was cooled to 0 °C, carefully quenched with saturated aqueous NaHCCh, and extracted with DCM. The layers were separated and the organic layer was washed with brine, dried over MgSCri, filtered and concentrated. The product was purified by flash chromatography (0-100% EtOAc/hexanes) to afford the title compound (180 mg, 0.64 mmol, 94% yield). LCMS calculated for CiHsBrFsNO (M+H)+: m/z = 282.0; found: 282.0. Step 4. 3-(Difluoromethyl)-4-fluoro-N-methyl-5-( 4, 4, 5, 5-tetramethyl-l , 3, 2-dioxaborolan-2- yl)benzamide
3-Bromo-5-(difluoromethyl)-4-fluoro-Af-methylbenzamide (191 mg, 0.68 mmol) was combined with bis(pinacolato)diboron (430 mg, 1.69 mmol), dichloro[l,T- bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (27.6 mg, 0.034 mmol) and potassium acetate (199 mg, 2.03 mmol) in dioxane (5 ml) and the mixture was sparged with N2, then heated to 100 °C for 6 h. The reaction mixture was diluted with EtOAc, filtered, and concentrated. The residue was purified by flash chromatography (0-100%
EtO Ac/hexanes) to afford the title compound (223 mg, 0.68 mmol, 100% yield). The following data is reported for the corresponding boronic acid, which was the only observable species by LCMS. LCMS calculated for C9H10BF3NO3 (M+H)+: m/z = 248.1; found: 248.1.
Intermediate D. 3-Chloro-4-fluoro-A-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan- 2-yl)benzamide
Figure imgf000100_0001
Step 1. 3-Bromo-5-chloro-4-fluorobenzoic Acid
Figure imgf000100_0002
A sample of 3-chloro-4-fluorobenzoic acid (1.71 g, 9.80 mmol) was dissolved in sulfuric acid (19.59 ml) and treated with NBS (1.92 g, 10.8 mmol). The solution was stirred for 16 hours at room temperature. The reaction was poured into ice water (250 mL) and stirred for an hour. The sample was filtered and the solid was collected to provide crude 3- bromo-5-chloro-4-fluorobenzoic acid (2.48 g, 9.78 mmol, 100% yield). Compound does not ionize by LCMS and structure was confirmed by subsequent steps; subsequent steps also indicate an unidentified dibrominated product. Step 2. 3-Bromo-5-chloro-4-fluoro-N-methylbenzamide
Figure imgf000101_0001
A sample of crude 3-bromo-5-chloro-4-fluorobenzoic acid (600 mg, 2.37 mmol) was suspended in DCM (11.8 ml) and was treated with Hiinig's base (827 mΐ, 4.73 mmol), causing complete dissolution of the starting material. The solution was then treated with HATU (990 mg, 2.60 mmol), and stirred for 15 minutes. Lastly, methylamine (11.8 ml, 2M in THF, 23.6 mmol) was added and the mixture was stirred at 22 °C. After 1 hour, the reaction mixture was treated with saturated aqueous NFLCl (50 mL) and diluted with EtOAc (100 mL). The layers were separated and the aqueous layer was extracted with additional EtOAc. The organic fractions were combined, dried with magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (0-100% EtOAc/DCM) to provide 3- bromo-5-chloro-4-fluoro-/V-methylbenzamide (240 mg, 0.901 mmol, 38% yield). LCMS calculated for CsHeBrCIFNO (M+H)+: m/z = 265.9, 267.9; found: 265.9, 267.9.
Step 3. 3-chloro-4-fluoro-N-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2- yl)benzamide
A sample of 3-bromo-5-chloro-4-fluoro-/V-methylbenzamide (240 mg, 0.901 mmol) was suspended in toluene and treated with potassium acetate (265 mg, 2.70 mmol) and bis(pinacolato)diboron (457 mg, 1.80 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (9 ml) was added and the mixture was stirred to dissolve. The solution was degassed by bubbling with nitrogen for 5 minutes. [l,l'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (110 mg, 0.135 mmol) was added and the reaction was warmed to 90 °C and stirred for 16 hours, at which point LCMS indicated complete consumption of the starting material. The reaction was cooled to room temperature, diluted with DCM and filtered to remove solid potassium acetate. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography (0-100% EtOAc/DCM) to provide 3-chloro-4-fluoro-/V-methyl-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (229 mg, 0.730 mmol, 81% yield). The following data is reported for the corresponding boronic acid, which was the only observable species by LCMS. LCMS calculated for CuHsBClFNOs (M+H)+: m/z = 232.0; found: 232.0. Intermediate E. 3-(Cyanomethyl)-4-fluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzamide
Figure imgf000102_0001
Step 1. 3-Bromo-4-fluoro-5-(hydroxymethyl)-N-methylbenzamide
Figure imgf000102_0002
A sample of 3-bromo-4-fluoro-5-formyl-/V-methylbenzamide (531 mg, 2.04 mmol, see Intermediate C, Step 2) was suspended in methanol (4 ml) and stirred at 22 °C. This suspension was treated with NaBFE (386 mg, 10.2 mmol) in three portions, added over 15 minutes. After 15 additional minutes, the solution had become homogeneous, and LCMS indicated complete conversion to the product. The solution was concentrated in vacuo , and the residue was dissolved in EtOAc and aqueous NFECl. The layers were separated, and the aqueous layer was extracted with additional EtOAc. The combined organic fractions were dried over MgS04, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography (0-100% EtOAc/DCM, then 0-10% MeOH/DCM) to provide 3-bromo-4-fluoro-5-(hydroxymethyl)-A-methylbenzamide (444 mg, 1.69 mmol, 83% yield) LCMS calculated for CiHioBrFNOi (M+H)+: m/z = 262.0, 264.0. Found: 262.0, 263.9.
Step 2. 3-Bromo-5-(bromomethyl)-4-fluoro-N-methylbenzamide
Figure imgf000102_0003
A sample of 3-bromo-4-fluoro-5-(hydroxymethyl)-/V-methylbenzamide (444 mg, 1.69 mmol) was suspended in DCM (17 ml) and stirred at 22 °C. This suspension was treated with triphenylphosphine (667 mg, 2.54 mmol) and carbon tetrabromide (843 mg, 2.54 mmol). The solution became homogeneous quickly, and acquired a yellow color. The solution was stirred at 22 °C for an hour, at which point LCMS indicated complete conversion to the product. The solution was adsorbed onto silica directly, the excess solvent was removed in vacuo , and the sample was purified by flash column chromatography (0-60% EtOAc/DCM) to provide 3- bromo-5-(brornomethyl)-4-fluoro-/V-methylbenzamide (485 mg, 1.49 mmol, 88% yield). LCMS calculated for CifLBnFNO (M+H)+: m/z = 323.9, 325.9, 327.9. Found: 323.8, 325.8, 327.9.
Step 3. 3-Bromo-5-(cyanomethyl)-4-fluoro-N-methylbenzamide
Figure imgf000103_0001
A sample of 3-bromo-5-(bromomethyl)-4-fluoro-/V-methylbenzamide (485 mg, 1.492 mmol) was disolved in DMF (14.92 ml) and treated with potassium cyanide (389 mg, 5.97 mmol). The solution was stirred at 22 °C. After 30 mins, LCMS indicated complete conversion to the product. The reaction was quenched with aqueous NaHCCb and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (0-100% EtOAc/DCM) to provide 3-bromo-5-(cyanomethyl)-4-fluoro-A-methylbenzamide (211 mg, 0.778 mmol, 52% yield). LCMS calculated for CiofLBrFNiO (M+H)+: m/z = 271.0, 273.0. Found: 270.9, 272.9.
Step 4. 3-(Cyanomethyl)-4-fluoro-N-methyl-5-( 4, 4, 5, 5-tetramethyl-l , 3, 2-dioxaborolan-2- yl)benzamide
Figure imgf000103_0002
A sample of 3-bromo-5-(cyanomethyl)-4-fluoro-/V-methylbenzamide (211 mg, 0.778 mmol) was suspended in toluene and treated with potassium acetate (229 mg, 2.33 mmol) and bis(pinacolato)diboron (395 mg, 1.56 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (3.9 ml) was added and the mixture was stirred to dissolve. The solution was de-gassed by bubbling with nitrogen for 5 mins. [l,T-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (95 mg, 0.117 mmol) was added and the reaction was stirred at 100 °C. After 3 hours, LCMS indicated complete conversion to the product. The solution was cooled to room temperature, diluted with EtOAc, filtered to remove KOAc, and concentrated in vacuo. The residue was purified by flash column chromatography (0-100% EtOAc/DCM) to provide 3-(cyanomethyl)-4-fluoro-A- methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (110 mg, 0.346 mmol, 44% yield). The following data is reported for the corresponding boronic acid, which was the only observable species by LCMS. LCMS calculated for C10H11BFN2O3 (M+H)+: m/z = 237.1; found: 237.0.
Intermediate F. 4-Fluoro-/V-methyl-3-(pyrrolidin-l-ylmethyl)-5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)benzamide
Figure imgf000104_0001
Step 1. 3-Bromo-4-fluoro-N-methyl-5-(pyrrolidin-l-ylmethyl) benzamide
Figure imgf000104_0002
A sample of 3-bromo-4-fluoro-5-formyl-/V-methylbenzamide (100 mg, 0.385 mmol) was dissolved in DCE (3.9 ml) and treated with pyrrolidine (48 mΐ, 0.58 mmol) and acetic acid (44 mΐ, 0.77 mmol). Once the solution was homogeneous, sodium triacetoxyborohydride (122 mg, 0.58 mmol) was added and the mixture was stirred at 22 °C. After 16 hours, LCMS indicated complete conversion to the product. The reaction was quenched with aqueous NaHC03 and extracted with DCM. The combined organic fractions were dried over MgS04, filtered, and concentrated in vacuo to provide 3-bromo-4-fluoro-A-methyl-5-(pyrrolidin-l - ylmethyl)benzamide (125 mg, 0.40 mmol, mass was over theoretical yield, so quantitative yield was assumed). The crude material was used without purification. Step 2. 4-Fluoro-N-methyl-3-(pyrrolidin-l-ylmethyl)-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl) benzamide
A sample of 3-bromo-4-fluoro-/V-methyl-5-(pyrrolidin-l-ylmethyl)benzamide (125 mg, 0.40 mmol) was suspended in toluene and treated with potassium acetate (117 mg, 1.19 mmol) and bis(pinacolato)diboron (201 mg, 0.793 mmol). The solvent was removed in vacuo , and the residue was azeotroped twice more with toluene. Anhydrous dioxane (4 ml) was added and the mixture was stirred to dissolve. The solution was degassed by bubbling with nitrogen for 5 minutes. [l,T-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (48.6 mg, 0.059 mmol) was added and the reaction was warmed to 100 °C and stirred for 16 hours, at which point LCMS indicated complete consumption of the starting material. The reaction was cooled to room temperature, diluted with DCM and filtered to remove solid potassium acetate. The filtrate was concentrated in vacuo to provide crude 4-fluoro-A- methyl-3-(pyrrolidin-l-ylmethyl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (yield not determined). The crude material could be used in subsequent reactions. The following data is reported for the corresponding boronic acid, which was the only observable species by LCMS. LCMS calculated for C13H19BFN2O3 (M+H)+: m/z = 281.2; found: 281.1.
Example 1.
3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-«|pyridine-3-yl)-/V- methylbenzamide
Figure imgf000105_0001
4-Chloro-5-methoxypyridin-2-amine (236 mg, 1.49 mmol) was dissolved in ethanol (2.48 ml), and 2-chloroacetaldehyde (832 mΐ, 7.44 mmol, 50% w/w aqueous) was added. The mixture was refluxed for 3.5 hours. The mixture was concentrated in vacuo , dissolved in DCM and washed with NaHCCb, then brine. The organic layer was dried with MgSCL, filtered, and concentrated in vacuo. The crude material was purified via flash column chromatography (0- 100% EtOAc/DCM) on a 24 g silica column to give 7-chloro-6-methoxyimidazo[l,2- ajpyridine (225 mg, 0.86 mmol, 82% yield). LCMS calculated for CxHxCINiO (M+H)+: m/z = 183.0; found: 183.1.
Figure imgf000106_0001
A sample of 7-chloro-6-methoxyimidazo[l,2-a]pyridine (216 mg, 1.18 mmol) was dissolved in dioxane (4.93 ml) and was treated with K2CO3 (327 mg, 2.37 mmol), l-methyl-4- (4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)- l//-pyrazole (418 mg, 2.01 mmol) and water (1.0 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (93 mg, 0.118 mmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 40 mins, the solution was cooled to room temperature, quenched with aqueous NH4CI, extracted with EtOAc, and then 25% /.s -propanol in chloroform. The combined organic layers were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to give 6-m ethoxy - 7-(l-methyl-lif-pyrazol-4-yl)imidazo[l,2-a]pyridine (163 mg, 0.714 mmol, 60% yield). LCMS calculated for C12H13N4O (M+H)+: m/z = 229.1; found: 229.1.
Step 3. 3-Bromo-6-methoxy- 7-( l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-a]pyridine
Figure imgf000106_0002
A solution of 6-methoxy-7-( 1 -methyl -l//-pyrazol-4-yl)i mi dazo[ l ,2-r/]pyridine (162 mg, 0.710 mmol) in acetonitrile (1.8 ml) was stirred at 0 °C. To this solution was added a cold solution of NBS (139 mg, 0.781 mmol) in additional acetonitrile (1.8 ml). The solution was allowed to warm to room temperature, stirred for an hour, then filtered and concentrated in vacuo to give 3-bromo-6-methoxy-7-( l -methyl - l//-pyrazol-4-yl)i mi dazo[ l ,2-r/]pyridine (102 mg, 0.331 mmol, 47% yield). The obtained product was used without further purification. LCMS calculated for CiiHiiBrNr (M+H)+: m/z = 307.0; found: 306.9. Step 4. 3-( 6-Methoxy- 7-( 1 -methyl-lH-pyrazol-4-yl)imidazo[ 1, 2-a]pyridine-3-yl)-N- methylbenzamide
A crude sample of 3-bromo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- ajpyridine (25 mg, 0.081 mmol) was dissolved in dioxane (1.4 ml) and was treated with K2CO3 (22.5 mg, 0.163 mmol), (3-(methylcarbamoyl)phenyl)boronic acid (23.3 mg, 0.130 mmol) and water (0.27 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (6.4 mg, 8.1 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 30 mins, the solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 3-(6-methoxy-7-(l-methyl- li7-pyrazol-4-yl)imidazo[l,2-a]pyridine-3-yl)-/V-methylbenzamide (12.5 mg, 0.035 mmol, 43% yield). ¾ NMR (600 MHz, DMSO- e) d 8.66 (q, J = 4.6 Hz, 1H), 8.49 (s, 1H), 8.33 (s, 1H), 8.22 (s, 2H), 8.19 (s, 1H), 8.16 (s, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.74 (t, J = 7.7 Hz, 1H), 4.00 (s, 3H), 3.94 (s, 3H), 2.84 (d, J = 4.5 Hz, 3H). LCMS calculated for C20H20N5O2 (M+H)+: m/z = 362.2; found: 362.2.
Example 2.
3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo|l,2-/>|pyridazin-3-yl)-/V- methylbenzamide
Figure imgf000107_0001
Step 1. 6-Chloro-3-methoxy-4-( 1 -methyl-lH-pyrazol-4-yl)pyridazine
Figure imgf000107_0002
A sample of 6-chloro-4-iodo-3-methoxypyridazine (2.66 g, 9.84 mmol) was dissolved in dioxane (41 ml) and was treated with K2CO3 (2.72 g, 19.7 mmol), l-methyl-4-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-l//-pyrazole (2.66 g, 12.8 mmol) and water (8.2 ml). This solution was degassed with bubbling nitrogen for 5 minutes. [1,T- Bis(diphenylphosphino)ferrocene]dichloro-palladium(II), dichloromethane adduct (0.803 g, 0.984 mmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic layers were dried over MgSCri, filtered, and concentrated in vacuo. The sample was purified by flash chromatography in 0-100% EtOAc/hexanes to provide 6-chloro-3-methoxy-4-(l- methyl-liT-pyrazol-4-yl)pyridazine (1.07 g, 4.76 mmol, 48% yield). LCMS calculated for C9H10CIN4O (M+H)+: m/z = 225.1; found: 225.0.
Step 2. N-(6-Methoxy-5-(l-methyl-lH-pyrazol-4-yl)pyridazin-3-yl)-l, 1-diphenylmethanimine
Figure imgf000108_0001
A sample of 6-chloro-3-methoxy-4-(l -methyl- liT-pyrazol-4-yl)pyridazine (1.07 g,
4.76 mmol) was dissolved in dioxane (19 ml) and was treated with CS2CO3 (3.10 g, 9.53 mmol) and benzophenone imine (0.879 ml, 5.24 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Xantphos (0.276 g, 0.476 mmol) and Pd2(dba)3 (0.218 g, 0.238 mmol) were added, the vial was capped, and the solution was stirred at 120 °C. After 16 hours, LCMS indicated 80% consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NEECl, and extracted with EtOAc. The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/hexanes to provide A-(6-methoxy-5-(l - methyl-liT-pyrazol-4-yl)pyridazin-3-yl)-l, 1-diphenylmethanimine (923 mg, 2.50 mmol, 53% yield). LCMS calculated for C22H20N5O (M+H)+: m/z = 370.2; found: 370.2.
Figure imgf000108_0002
A sample of /V-(6-methoxy-5-(l-methyl-li7-pyrazol-4-yl)pyridazin-3-yl)-l,l- diphenylmethanimine (923 mg, 2.50 mmol) was dissolved in THF (12.5 ml) and stirred at 22 °C. This solution was treated with 4N aq. HC1 (4.25 ml, 17 mmol) and stirred for 5 mins. LCMS indicated consumption of the starting material. The solution was diluted with Et20 and water, and the layers were separated (organic layer contains only benzophenone and impurities). The aqueous layer was quenched with 4N aq. NaOH (4.67 ml, 18.7 mmol) and extracted with 25% /.s -propanol in chloroform until the product was fully extracted. The combined organic fractions were dried with MgSCri, and concentrated in vacuo to provide crude 6-methoxy-5-(l- methyl-liT-pyrazol-4-yl)pyridazin-3-amine (500 mg, 2.44 mmol, 98% yield). The product was used without further purification. LCMS calculated for C9H12N5O (M+H)+: m/z = 206.1; found: 206.1.
Figure imgf000109_0001
A crude sample of 6-methoxy-5-(l-methyl-li7-pyrazol-4-yl)pyridazin-3-amine (500 mg, 2.44 mmol) was dissolved in 2-propanol (16 ml) and stirred at 22 °C. This solution was treated with 2-chloroacetaldehyde (3.2 ml, 25 mmol, 50% w/w aqueous) and stirred at 90 °C. After 24 hours, the reaction was cooled to room temperature, quenched with aqueous NELCl, extracted with 25% /.s -propanol in chloroform, dried over MgSCri, and concentrated in vacuo. The sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide 6-methoxy-7-( l -methyl - l//-pyrazol-4-yl)i mi dazo[ l ,2-/ ]pyridazine (307 mg, 1.34 mmol, 54% yield). LCMS calculated for C11H12N5O (M+H)+: m/z = 230.1; found: 230.0.
Step 5. 3-Bromo-6-methoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazine
Figure imgf000109_0002
A solution of 6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2-Z>]pyridazine (307 mg, 1.34 mmol) in DCE (6.7 ml) was stirred at 0 °C. This solution was treated with a cold solution of NBS (262 mg, 1.47 mmol) in acetonitrile (6.7 ml). This solution was stirred at 0 °C for 15 minutes, at which point an aliquot quenched with sodium thiosulfate demonstrated consumption of starting material. Saturated aqueous sodium thiosulfate (5 mL) was added, followed by DCM and aqueous NaElCCh. The layers were separated, and the aqueous layer was extracted with DCM and 10% /.s -propanol in DCM. The combined organic portions were dried over MgSCri, filtered, and concentrated in vacuo to provide 3-bromo-6-methoxy-7-(l- m ethyl- li7-pyrazol-4-yl)imidazo[l,2-/>]pyridazine (379 mg, 1.23 mmol, 92% yield). The product was used without further purification. LCMS calculated for CiiHnBrNsO (M+H)+: m/z = 308.0; found: 307.9.
Step 6. 3-( 6-Methoxy- 7-( 1 -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3-yl)-N- methylbenzamide
A crude sample of 3-bromo-6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- bjpyridazine (6 mg, 0.019 mmol) was dissolved in dioxane (0.33 ml) and was treated with K2CO3 (6 mg, 0.04 mmol), (3-(methylcarbamoyl)phenyl)boronic acid (6 mg, 0.03 mmol) and water (0.07 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (1.5 mg, 1.9 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 3-(6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2-/>]pyridazin- 3-yl)-/V-methylbenzamide (0.7 mg, 1.9 pmol, 10% yield). LCMS calculated for C19H19N6O2 (M+H)+: m/z = 363.2; found: 363.2.
Example 3.
6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)-3-(5-methylpyridin-3-yl)imidazo[l,2-
6]pyridazine
Figure imgf000110_0001
A sample of 3-bromo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.068 mmol), (5-methylpyridin-3-yl)boronic acid (15 mg, 0.11 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 6-methoxy-7-( l -methyl - l//-pyrazol-4-yl)- 3-(5-methylpyridin-3-yl)imidazo[l,2-/>]pyridazine (0.9 mg, 2.8 pmol, 12% yield). LCMS calculated for C17H17N6O (M+H)+: m/z = 321.2; found: 321.1.
Example 4. 5-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-A- methylnicotinamide
Figure imgf000111_0001
A sample of 3-bromo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.07 mmol), A-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)nicotinamide (30 mg, 0.12 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 5- (6-methoxy-7-( 1 -methyl- 17T-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazin-3 -yl)-/V- methylnicotinamide (3.8 mg, 10 pmol, 46% yield). LCMS calculated for Ci8Hi8Nv02(M+H)+: m/z = 364.2; found: 364.1. Example 5.
6-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)quinoline
Figure imgf000111_0002
A sample of 3-bromo-6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- Z>]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.068 mmol), 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)quinoline (29 mg, 0.11 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 6-(6- methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2-Z>]pyridazin-3-yl)quinoline (5.0 mg, 0.014 mmol, 62% yield). LCMS calculated for C20H17N6O (M+H)+: m/z = 357.2; found: 357.1. Example 6.
4-(3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3- yl)phenyl)morpholine
Figure imgf000112_0001
A sample of 3-bromo-6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- />]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.068 mmol), 4-(3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)morpholine (33 mg, 0.11 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 4- (3 -(6-methoxy-7-( 1 -methyl- 17T-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazin-3- yl)phenyl)morpholine (2.9 mg, 7.4 pmol, 33% yield). LCMS calculated for C21H23 N6O2 (M+H)+: m/z = 391.2; found: 391.2.
Ill Example 7.
2-(3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3- yl)phenyl)acetonitrile
Figure imgf000113_0001
A sample of 3-bromo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.068 mmol), 2-(3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)acetonitrile (28 mg, 0.11 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 2- (3-(6-methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-Z>]pyridazin-3- yl)phenyl)acetonitrile (4.5 mg, 0.013 mmol, 58% yield). LCMS calculated for C19H17 N6O (M+H)+: m/z = 345.2; found: 345.2.
Example 8.
3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-/>|pyridazin-3-yl)-/V- methylbenzenesulfonamide
Figure imgf000113_0002
A sample of 3-bromo-6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.068 mmol), (3-(/V-methylsulfamoyl)phenyl)boronic acid (24 mg, 0.11 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 3-(6-methoxy-7-(l-methyl- l//-pyrazol-4-yl)imidazo[l ,2-/)]pyridazin-3-yl)-Af-methylbenzenesulfonamide (3.5 mg, 8.8 pmol, 39% yield). LCMS calculated for C18H19N6O3S (M+H)+: m/z = 399.1; found: 399.1.
Example 9.
2-(3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3- yl)phenyl)propan-2-ol
Figure imgf000114_0001
A sample of 3-bromo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (7 mg, 0.023 mmol, see Example 2, Step 5) was dissolved in dioxane (0.38 ml) and was treated with K2CO3 (9.4 mg, 0.068 mmol), 2-(3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)propan-2-ol (30 mg, 0.11 mmol) and water (0.076 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.6 mg, 4.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 16 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide 2- (3-(6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2-Z>]pyridazin-3-yl)phenyl)propan-2- ol (3.5 mg, 9.6 pmol, 42% yield). LCMS calculated for C20H22N5O2 (M+H)+: m/z = 364.2; found: 364.2.
Example 10.
/V-(3-(6-Methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3- yl)phenyl)acetamide
Figure imgf000115_0001
Step 1. 3-Iodo-6-methoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazine
Figure imgf000115_0002
A solution of 6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2-b]pyridazine (680 mg, 2.97 mmol, see Example 2, Step 4) in DMF (27 ml) was stirred at 0 °C. To this solution was added a cold solution of NIS (934 mg, 4.15 mmol) in additional DMF (27.0 ml). The solution was allowed to warm to room temperature and stirred for 1 hour. The solution was poured into water and stirred at room temperature for 30 mins, at which point it was filtered. The solid was dried with continued air flow to provide the title compound (512 mg, 1.44 mmol, 49% yield). The product was used without further purification. LCMS calculated for C11H11IN5O (M+H)+: m/z = 356.0; found: 356.0.
Step 2. N-(3-( 6-Methoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3- yl)phenyl)acetamide
A crude sample of 3-iodo-6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (10 mg, 0.028 mmol) was dissolved in DMF (0.25 ml) and was treated with K2CO3 (12 mg, 0.084 mmol), (3-acetamidophenyl)boronic acid (15 mg, 0.084 mmol) and water (0.047 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.3 mg, 4.2 pmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 1.5 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide /V-(3-(6-methoxy-7-( 1 -methyl - l//-pyrazol-4-yl)i mi dazo[l ,2-/ ]pyridazin- 3-yl)phenyl)acetamide (7.8 mg, 0.022 mmol, 76% yield). LCMS calculated for C19H19N6O2 (M+H)+: m/z = 363.2; found: 363.1. Example 11.
2,,4,-Difluoro-5-(6-methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-
A^-methyl-fl^’-biphenylJ-S-carboxamide
Figure imgf000116_0001
Step 1. 3-Chloro-5-(6-methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)benzoic acid
Figure imgf000116_0002
A sample of 3-iodo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (100 mg, 0.282 mmol, see Example 10, Step 1 ) was dissolved in DMF (2.4 ml) and was treated with K2CO3 (195 mg, 1.41 mmol), water (0.47 ml), and 3-borono-5- chlorobenzoic acid (169 mg, 0.845 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (33 mg, 0.042 mmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 90 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, quenched with pH 4 aqueous buffer, and extracted with EtOAc followed by 25% /.so-propanol in chloroform. The combined organic fractions were dried over MgSCL, filtered, and concentrated in vacuo to provide crude 3 -chloro- 5-(6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2-Z>]pyridazin-3-yl)benzoic acid (187 mg, .486 mmol, mass was over theoretical yield, so quantitative yield was assumed). LCMS calculated for C18H15CIN5O3 (M+H)+: m/z = 384.1; found: 384.3. Step 2. 3-Chloro-5-( 6-methoxy- 7-( l -methyl- lH-pyrazol-4-yl)imidazo[ l, 2-b ]pyridazin-3-yl)- N-methylbenzamide
Figure imgf000117_0001
A crude sample of 3-chloro-5-(6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazin-3-yl)benzoic acid (187 mg, 0.486 mmol) was dissolved in DMF (4.9 ml) and treated with Hiinig's base (213 mΐ, 1.22 mmol) and HATU (204 mg, 0.536 mmol). The solution was stirred at 22 °C for 15 minutes. At this point, methylamine (731 mΐ, 1.462 mmol, 2.0 M in THF) was added and the mixture was stirred at 22 °C. After 45 mins, LCMS indicated consumption of the starting material. The reaction was quenched with aqueous MLCl, and the mixture was extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide the title compound (43 mg, 0.11 mmol, 39% yield over two steps). LCMS calculated for C19H18CIN6O2 (M+H)+: m/z = 397.1; found: 397.3.
Step 3. 2 4’-Difluoro-5-(6-methoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)-N-methyl-[ 1, 1 ’-biphenyl] -3-carboxamide
A sample of 3-chloro-5-(6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- />]pyridazin-3-yl)-/V-methylbenzamide (10 mg, 0.025 mmol) was dissolved in DMF (0.30 ml) and was treated with K2CO3 (11 mg, 0.076 mmol), (2,4-difluorophenyl)boronic acid (8 mg, 0.05 mmol) and water (0.060 ml). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3 mg, 3.8 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide 2’,4’- difluoro-5-(6-methoxy-7-(l -methyl- li7-pyrazol-4-yl)imidazo[l,2-/>]pyridazin-3-yl)-/V- methyl-[l,l’-biphenyl]-3-carboxamide (2.1 mg, 4.4 pmol, 18% yield). LCMS calculated for C25H21F2N6O2 (M+H)+: m/z = 475.2; found: 475.0. Example 12.
4-Methoxy-3-(6-methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-/V- methylbenzamide
Figure imgf000118_0001
Step 1. 4-Methoxy-3-( 6-methoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3- yl)benzoic Acid
Figure imgf000118_0002
A sample of 3-iodo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (20 mg, 0.056 mmol, see Example 10, Step 1 ) was dissolved in DMF (0.47 ml) and was treated with K2CO3 (39 mg, 0.28 mmol), water (0.094 ml), and 3-borono-4- methoxybenzoic acid (33 mg, 0.17 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (6.7 mg, 8.5 pmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 90 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide the title compound (13.6 mg, 0.036 mmol, 64% yield). LCMS calculated for Ci9Hi8N504(M+H)+: m/z = 380.1; found: 380.2.
Step 2. 4-Methoxy-3-( 6-methoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3-yl)- N-methylbenzamide
A sample of 4-methoxy-3-(6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- 6]pyridazin-3-yl)benzoic acid (13.6 mg, 0.036 mmol) was dissolved in DMF (0.36 ml) and treated with Hiinig's base (15.7 mΐ, 0.090 mmol) and HATU (21 mg, 0.054 mmol). The solution was stirred at 22 °C for 15 minutes. At this point, methylamine (269 mΐ, 0.538 mmol, 2.0 M in THF) was added and the mixture was stirred at 60 °C. After 15 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide the title compound (9.1 mg, 0.023 mmol, 65% yield). LCMS calculated for C20H21N6O3 (M+H)+: m/z = 393.2; found: 393.1.
Example 13.
4-Cyano-3-(6-methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-/V- methylbenzamide
Figure imgf000119_0001
A sample of 3-iodo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (40 mg, 0.11 mmol, see Example 10, Step 1 ) was dissolved in DMF (1 ml) and was treated with K2CO3 (47 mg, 0.34 mmol), water (0.047 ml), and 3-borono-4- methoxybenzoic acid (33 mg, 0.17 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (3.3 mg, 4.2 pmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 90 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, and filtered over a SiliaPrep Thiol cartridge. The solid precipitate was dissolved in
DCM and EtOAc, and the organic filtrate was concentrated in vacuo. The crude material was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to give the title compound (16.5 mg, 0.041 mmol, 36% yield). LCMS calculated for C21H19N6O3 (M+H)+: m/z = 403.2; found: 403.3. Step 2. 4-Cyano-3-( 6-methoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3- yl)benzoic acid
Figure imgf000120_0001
A sample of ethyl 4-cyano-3-(6-methoxy-7-(l-methyl-li/-pyrazol-4-yl)imidazo[l,2- Z>]pyridazin-3-yl)benzoate (16.5 mg, 0.041 mmol) was dissolved in THF (3.4 ml) and water (0.68 ml) and stirred at 22 °C. This solution was treated with lithium hydroxide (25 mg, 1.0 mmol) and stirred at 50 °C. After 30 mins, LCMS showed complete consumption of the starting material. The solution was cooled to room temperature, concentrated in vacuo , treated with pH 4 aqueous buffer, and filtered to afford the solid title compound (16.8 mg, 0.045 mmol, mass was over theoretical yield, so quantitative yield was assumed). The crude material was used without further purification. LCMS calculated for C19H15N6O3 (M+H)+: m/z = 375.1; found: 375.1.
Step 3. 4-Cyano-3-( 6-methoxy- 7-( l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3-yl)-N- methylbenzamide
A sample of 4-cyano-3-(6-methoxy-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- 6]pyridazin-3-yl)benzoic acid (16.7 mg, 0.045 mmol) was dissolved in DMF (0.45 ml) and treated with Hiinig's base (19.5 mΐ, 0.112 mmol) and HATU (25 mg, 0.067 mmol). The solution was stirred at 22 °C for 15 minutes. At this point, methylamine (335 mΐ, 0.67 mmol, 2.0 M in THF) was added and the mixture was stirred at 60 °C. After 15 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide the title compound (3.3 mg, 8.5 pmol, 19% yield). LCMS calculated for C20H18N7O2 (M+H)+: m/z = 388.2; found: 388.1. Example 14.
4-Fluoro-3-(6-methoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-/V-
(2,2,2-trifluoroethyl)benzamide
Figure imgf000121_0001
Step 1. 4-Fluoro-3-( 6-methoxy- 7-(l -methyl-lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3- yl)benzoic acid
Figure imgf000121_0002
A sample of 3-iodo-6-methoxy-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (20 mg, 0.056 mmol, see Example 10, Step 1 ) was dissolved in DMF (0.47 ml) and was treated with K2CO3 (39 mg, 0.28 mmol), water (0.094 ml), and 3-borono-4- fluorobenzoic acid (31 mg, 0.17 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Palladium XPhos G2 (6.7 mg, 8.5 pmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 90 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide the title compound (7.6 mg, 0.021 mmol, 37% yield). LCMS calculated for C18H15FN5O3 (M+H)+: m/z = 368.1; found: 368.2.
Step 2. 4-Fluoro-3-( 6-methoxy- 7-(l -methyl-lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3-yl)- N-(2, 2, 2-trifluoroethyl)benzamide
A sample of 4-fluoro-3-(6-methoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2- 6]pyridazin-3-yl)benzoic acid (8 mg, 0.021 mmol) was dissolved in DMF (0.21 ml) and treated with Hiinig's base (9.0 mΐ, 0.052 mmol) and HATU (12 mg, 0.031 mmol). The solution was stirred at 22 °C for 15 minutes. At this point, 2,2,2-trifluoroethan-l -amine (24 mΐ, 0.31 mmol) was added and the mixture was stirred at 60 °C. After 15 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide the title compound (9.1 mg, 0.023 mmol, 65% yield). LCMS calculated for C20H17F4N6O2 (M+H)+: m/z = 449.1; found: 449.1.
Example 15.
/V-Methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-(oxetan-3-yloxy)imidazo[l,2-6]pyridazin-3- yl)nicotinamide
Figure imgf000122_0001
Step 1. 3,8-Dibromo-6-chloroimidazo[l,2-b]pyridazine
Figure imgf000122_0002
A sample of 8-bromo-6-chloroimidazo[l,2-/>]pyridazine (10.6 g, 45.8 mmol) was dissolved in DMF (114 ml) and treated with NBS (10.6 g, 59.5 mmol). The solution was stirred at 60 °C. After 2 hours, LCMS indicated complete consumption of the starting material. The reaction was poured into ice water (800 mL) and stirred for an hour at room temperature. The mixture was filtered under vacuum and the residue was dried with continued air flow to provide 3,8-dibromo-6-chloroimidazo[l,2-/>]pyridazine (14.8 g, 47.5 mmol, mass was over theoretical yield, so quantitative yield was assumed). The crude material was used without further purification. LCMS calculated for CeTLBnCllNh (M+H)+: m/z = 311.8, 309.8, 313.8; found: 311.8, 309.8, 313.8.
Step 2. 3-Bromo-6-chloroimidazo[l,2-b]pyridazin-8-amine
Figure imgf000122_0003
A solid sample of 3,8-dibromo-6-chloroimidazo[l,2-/>]pyridazine (14.8 g, 47.5 mmol) was placed in a 350 mL heavy -walled pressure vessel with a stir bar. This sample was treated with ammonium hydroxide (111 ml, 2850 mmol), the chamber was sealed, and the heterogeneous mixture was warmed to 120 °C. After 4 hours, the reaction was cooled to room temperature, carefully opened, and an LCMS aliquot indicated complete consumption of the starting material. The mixture was poured into 800 mL of ice water and stirred for an hour at room temperature. The mixture was filtered under vacuum and the residue was dried with continued air flow to provide 3-bromo-6-chloroimidazo[l,2-/>]pyridazin-8-amine (9.5 g, 38 mmol, 81% yield). The crude material was used without further purification. LCMS calculated for C6H5BrClN4 (M+H)+: m/z = 246.9, 248.9; found: 246.9, 248.9.
Step 3. 3-Bromo-6-chloro- 7 -iodoimidazo [ 1, 2-b ]pyridazin-8-amine
Figure imgf000123_0001
A sample of 3-bromo-6-chloroimidazo[l,2-/>]pyridazin-8-amine (6.8 g, 28 mmol) was dissolved in DMF (69 ml) and treated with /V-iodosuccinimide (10.5 g, 46.7 mmol). The solution was stirred at 60 °C. After 2 hours, LCMS indicated complete consumption of the starting material. The reaction was poured into ice water (500 mL) and stirred for an hour at room temperature. The mixture was filtered under vacuum and the residue was dried with continued air flow to provide 3-bromo-6-chloro-7-iodoimidazo[l,2-/>]pyridazin-8-amine (11.6 g, 31.1 mmol, mass was over theoretical yield, so quantitative yield was assumed). The crude material was used without further purification. LCMS calculated for CeLLBrClIbL (M+H)+: m/z = 372.8, 374.8; found: 372.8, 374.8.
Step 4. 3-Bromo-6-chloro-7 -iodoimidazo [ 1 ,2-b]pyridazine
Figure imgf000123_0002
A sample of 3-bromo-6-chloro-7-iodoimidazo[l,2-Z>]pyridazin-8-amine (10.3 g, 27.5 mmol) was placed in a 350 mL heavy -walled pressure vessel and dissolved in THF (83 ml). The sample was treated with salicylic acid (0.76 g, 5.5 mmol) and /cvV-butyl nitrite (36.3 ml, 275 mmol) and the vessel was sealed. The reaction was warmed to 70 °C. After 2 hours, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature and concentrated in vacuo. The concentrate was dissolved in EtOAc and adsorbed onto silica, and concentrated in vacuo again. The sample was then purified by flash chromatography in 0-50% EtO Ac/hexanes to provide 3-bromo-6-chloro-7-iodoimidazo[l,2- 6]pyridazine (7.95 g, 22.2 mmol, 81% yield). LCMS calculated for C6EEBrClIN3 (M+H)+: m/z = 357.8, 359.8; found: 357.8, 359.8.
Step 5. 3-Bromo-6-chloro- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazine
Figure imgf000124_0001
A sample of 3-bromo-6-chloro-7-iodoimidazo[l,2-/>]pyridazine (1.4 g, 3.9 mmol) was dissolved in dioxane (16 ml) and was treated with K2CO3 (1.08 g, 7.81 mmol), water (3.3 ml), and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-liT-pyrazole (0.853 g, 4.10 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (0.451 g, 0.391 mmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 16 hours, LCMS indicated -85% conversion. The solution was cooled to room temperature and quenched with aqueous NH4CI, and extracted with EtOAc, then 25% /.s -propanol in chloroform. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide 3-bromo-6-chloro-7-iodoimidazo[l,2-/>]pyridazine (7.95 g, 22.2 mmol, 81% yield). LCMS calculated for CioHsBrCINs (M+H)+: m/z = 312.0, 314.0; found: 311.8, 313.8.
Step 6. 3-Bromo- 7-(l -methyl-lH-pyrazol-4-yl)-6-(oxetan-3-yloxy)imidazo[ 1, 2-b ]pyridazine
Figure imgf000124_0002
A sample of 3 -bromo-6-chloro-7-( 1 -methyl- li7-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazine (60 mg, 0.19 mmol) was dissolved in DMF (5 ml) and was treated with cesium carbonate (190 mg, 0.58 mmol) and oxetan-3-ol (71 mg, 0.96 mmol). This solution was stirred at 90 °C. After 1 hour, LCMS indicated near-complete conversion. The reaction mixture was used directly in Step 7. LCMS calculated for CisHisBrNsCh (M+H)+: m/z = 350.0, 352.0; found: 350.0, 352.0.
Step 7. N-Methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-(oxetan-3-yloxy)imidazo[l,2- b]pyridazin-3-yl)nicotinamide
An aliquot of 3-bromo-7-( 1 -methyl - l//-pyrazol-4-yl)-6-(oxetan-3-yloxy)i mi dazo[ l ,2- Z>]pyridazine (12 mg, 0.033 mmol) in DMF (1 ml) was treated with K2CO3 (9 mg, 0.07 mmol), and water (0.2 ml). This solution was treated with A-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)nicotinamide (43 mg, 0.17 mmol). Palladium XPhos G2 (2.6 mg, 3.3 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 25 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide the title compound (8.5 mg, 0.020 mmol, 62% yield). LCMS calculated for C20H20N7O3 (M+H)+: m/z = 406.2; found: 406.3.
Example 16.
(A)-3,4-Difluoro-A-methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-((l-methylpyrrolidin-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000125_0001
Step 1. (S)-3-Bromo- 7-( l -methyl- lH-pyrazol-4-yl)-6-( ( l -methylpyrrolidin-3- yl)oxy)imidazo[ 1, 2-b ]pyridazine
Figure imgf000125_0002
A sample of 3 -bromo-6-chloro-7-( 1 -methyl- li7-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazine (15 mg, 0.048 mmol, see Example 15, Step 5) was dissolved in DMF (0.8 ml) and was treated with cesium carbonate (47 mg, 0.14 mmol) and (ri)-l-methylpyrrolidin-3-ol (24 mΐ, 0.24 mmol). This solution was stirred at 90 °C. After 3 hours, LCMS indicated complete consumption of the starting material. The crude reaction mixture was used directly in Step 2. LCMS calculated for CisHisBrNeO (M+H)+: m/z = 377.1, 379.1; found: 377.1, 379.1. Step 2. (S)-3,4-Difluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-((l-methylpyrrolidin-3- yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)benzamide
The crude solution of (ri)-3-bromo-7-(l-methyl-li7-pyrazol-4-yl)-6-((l- methylpyrrolidin-3-yl)oxy)imidazo[l,2-/]pyridazine (< 0.048 mmol, from Step 1 ) in DMF (0.8 ml) was treated with 3,4-difluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzamide (67 mg, 0.23 mmol, see Intermediate A) as a solution in DMF (0.94 ml). Water (0.38 ml) was added, followed by Pd XPhos G2 (5.3 mg, 6.8 pmol), the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide the title compound (0.8 mg, 1.7 pmol, 4% yield). LCMS calculated for C23H24F2N7O2 (M+H)+: m/z = 468.2; found: 468.3.
Example 17.
(A)-3,4-Difluoro-A-methyl-5-(7-(l-methyl-l/ -pyrazol-4-yl)-6-(pyrrolidin-3- yloxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000126_0001
Step 1. tert-Butyl (S)-3-((3-bromo-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-6- yl)oxy)pyrrolidine-l-carboxylate
Figure imgf000126_0002
A sample of 3 -bromo-6-chloro-7-( 1 -methyl- li7-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazine (15 mg, 0.048 mmol, see Example 15, Step 5) was dissolved in DMF (0.8 ml) and was treated with cesium carbonate (47 mg, 0.14 mmol) and /cvV-butyl fV)-3-hydroxypyrrolidine-l - carboxylate (45 mg, 0.24 mmol). This solution was stirred at 90 °C. After 3 hours, LCMS indicated complete consumption of the starting material. The crude reaction mixture was used directly in Step 2. LCMS calculated for CiiLhrBrNeCh (M+H)+: m/z = 463.1, 465.1; found: 463.1, 465.1.
Step 2. (S)-3, 4-Difluoro-N-methyl-5-(7-( 1 -methyl-lH-pyrazol-4-yl)-6-(pyrrolidin-3- yloxy)imidazo[ 1, 2-b ]pyridazin-3-yl)benzamide
The crude solution of /cvV-butyl fV)-3-((3-bromo-7-(l -methyl-l//-pyrazol-4- yl)imidazo[l,2-/)]pyridazin-6-yl)oxy)pyrrolidine-l -carboxylate (< 0.048 mmol, from Step 1 ) in DMF (0.8 ml) was treated with 3,4-difluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzamide (67 mg, 0.23 mmol, see Intermediate A) as a solution in DMF (0.94 ml). Water (0.38 ml) was added, followed by Pd XPhos G2 (5.3 mg, 6.8 pmol), the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with DCM, and filtered through a SiliaPrep Thiol cartridge.
The filtrate was treated with trifluoroacetic acid (1 mL), and stirred for an hour at 22 °C. After 1 hour, LCMS indicated consumption of the intermediate. The solution was concentrated in vacuo. The concentrate was dissolved in MeCN and water, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro-Af-methyl-5-(7-( l -methyl -l//-pyrazol -4- yl)-6-(pyrrolidin-3-yloxy)imidazo[l,2-/)]pyridazin-3-yl)benzamide (1.3 mg, 2.9 pmol, 8% yield). LCMS calculated for C22H22F2N7O2 (M+H)+: m/z = 454.2; found: 454.3.
Example 18.
(A)-3,4-Difluoro-A-methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-((2-oxopyrrolidin-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000127_0001
Step 1. (S)-3-( (3-Bromo- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-6- yl)oxy)pyrrolidin-2-one
Figure imgf000128_0001
A sample of 3 -bromo-6-chloro-7-( 1 -methyl- li7-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazine (15 mg, 0.048 mmol, see Example 15, Step 5) was dissolved in DMF (0.8 ml) and was treated with cesium carbonate (47 mg, 0.14 mmol) and fV)-3-hydroxypyrrolidin-2-one (24 mg, 0.24 mmol). This solution was stirred at 90 °C. After 45 mins, LCMS indicated complete consumption of the starting material. The crude reaction mixture was used directly in Step 2. LCMS calculated for CirH^BrNeCh (M+H)+: m/z = 377.0, 379.0; found: 377.2, 379.2.
Step 2. (S)-3, 4-Difluoro-N-methyl-5-(7-( 1 -methyl- lH-pyrazol-4-yl)-6-( (2-oxopyrrolidin-3- yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)benzamide
The crude solution of (ri)-3-((3-bromo-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- />]pyridazin-6-yl)oxy)pyrrolidin-2-one (< 0.048 mmol, from Step 1 ) in DMF (0.8 ml) was treated with 3,4-difluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (67 mg, 0.23 mmol, see Intermediate A) as a solution in DMF (0.94 ml). Water (0.38 ml) was added, followed by Pd XPhos G2 (5.3 mg, 6.8 pmol), the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro- /V-methyl-5-(7-(l-methyl-li7-pyrazol-4-yl)-6-((2-oxopyrrolidin-3-yl)oxy)imidazo[l,2- />]pyridazin-3-yl)benzamide (1.8 mg, 3.9 pmol, 9% yield). ¾ NMK (600 MHz, DMSO- is) d 8.90 (d, J = 7.4 Hz, 1 H), 8.59 (q, J = 5.6 Hz, 1H), 8.50 (s, 1H), 8.42 (s, 1H), 8.26 (s, 2H), 8.13 (d, J = 3.9 Hz, 1H), 7.91 (m, 1H), 5.55 (t, J = 10.1 Hz, 1H), 3.91 (s, 3H), 3.33 (m, 2H), 2.90 (m, 1H), 2.82 (d, J = 5.3 Hz, 3H), 2.14 (m, 1H). LCMS calculated for C22H20F2N7O3 (M+H)+: m/z = 468.2; found: 468.3. Example 19.
(»y)-3,4-Difluoro-/V-methyl-5-(7-(l-methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)amino)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000129_0001
Step 1. 3-Bromo-6, 7-dichloroimidazo[l,2-b]pyridazin-8-amine
Figure imgf000129_0002
A sample of 3-bromo-6-chloroimidazo[l,2-/>]pyridazin-8-amine (10.1 g, 40.8 mmol, see Example 15, Step 2) was dissolved in DMF (102 ml) and treated with NCS (5.99 g, 44.9 mmol). The solution was stirred at 60 °C. After 2 hours, LCMS indicated complete consumption of the starting material. The reaction was poured into ice water (600 mL) and stirred for an hour at room temperature. The mixture was filtered under vacuum and the residue was dried with continued air flow to provide 3-bromo-6,7-dichloroimidazo[l,2-Z>]pyridazin-8- amine (10.9 g, 38.7 mmol, 95% yield). The crude material was used without further purification. LCMS calculated for C6H4BrCl2N4 (M+H)+: m/z = 280.9, 282.9, 284.9; found: 280.8, 282.8, 284.8.
Step 2. 3-Bromo-6, 7-dichloroimidazo[l,2-b]pyridazine
Figure imgf000129_0003
A sample of 3-bromo-6,7-dichloroimidazo[l,2-Z>]pyridazin-8-amine (10.9 g, 38.7 mmol) was placed in a 350 mL heavy-walled pressure vessel and dissolved in THF (117 ml). The sample was treated with salicylic acid (1.07 g, 7.73 mmol) and /ert-butyl nitrite (51.1 ml, 387 mmol) and the vessel was sealed. The reaction was warmed to 70 °C. After 2 hours, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature and concentrated in vacuo. The concentrate was dissolved in EtOAc, adsorbed onto silica, and concentrated in vacuo again. The sample was then purified by flash chromatography in 0-50% EtOAc/hexanes to provide 3-bromo-6,7-dichloroimidazo[l,2- 6]pyridazine (8.08 g, 30.3 mmol, 78% yield). LCMS calculated for CeEEBrChNr (M+H)+: m/z = 265.9, 267.9, 269.9; found: 265.8, 267.8, 269.8.
Step 3. (S)-3-Bromo-7-chloro-N-(tetrahydrofuran-3-yl)imidazo[ l,2-b]pyridazin-6-amine
Figure imgf000130_0001
A sample of 3-bromo-6,7-dichloroimidazo[l,2-/>]pyridazine (89 mg, 0.33 mmol) was dissolved in A-methyl-2-pyrrolidinone (0.8 ml) and was treated with Hiinig's base (87 mΐ, 0.50 mmol) and (ri)-tetrahydrofuran-3 -amine (144 mΐ, 1.67 mmol). This solution was stirred at 120 °C. After 6 hours, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NELCl, and the mixture was extracted with EtOAc. The combined organic fractions were dried over MgS04, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography in 0-100% EtOAc/DCM to provide fV)-3-bromo-7-chloro-A-(tetrahydrofuran-3-yl)imidazo[ l ,2- Z>]pyridazin-6-amine (88 mg, 0.28 mmol, 83% yield). LCMS calculated for CioHiiBrCINrO (M+H)+: m/z = 317.0, 319.0; found: 316.9, 318.9.
Step 4. (S)-3-(7 -Chloro-6-( ( tetrahydrofuran-3-yl)amino)imidazo[ 1, 2-b ]pyridazin-3-yl)-4, 5- difluoro-N-methylbenzamide
Figure imgf000130_0002
A sample of (ri)-3-bromo-7-chloro-/V-(tetrahydrofuran-3-yl)imidazo[l,2-Z>]pyridazin- 6-amine (40 mg, 0.13 mmol) was dissolved in dioxane (1.2 ml) and was treated with K2CO3 (35 mg, 0.25 mmol), water (0.12 ml), and 3,4-difluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzamide (52 mg, 0.18 mmol, see Intermediate A). This solution was degassed with bubbling nitrogen for 5 minutes. [1,1'- Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (15 mg, 0.019 mmol) was added, the vial was capped, and the solution was stirred at 80 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc, then DCM. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)amino)i mi dazo[l ,2- Z>]pyridazin-3-yl)-4,5-difluoro-/V-methylbenzamide (9 mg, 0.02 mmol, 18% yield). LCMS calculated for C18H17CIF2N5O2 (M+H)+: m/z = 408.1; found: 408.1.
Step 5. (S)-3, 4-Difluoro-N-methyl-5-(7-( 1 -methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)amino)imidazo[ 1, 2-b ]pyridazin-3-yl)benzamide
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)amino)imidazo[l,2-Z>]pyridazin- 3-yl)-4,5-difluoro-/V-methylbenzamide (9 mg, 0.02 mmol) was dissolved in DMF (0.25 ml) and water (0.05 ml). This solution was treated with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-17T-pyrazole (14 mg, 0.066 mmol) and K2CO3 (9 mg, 0.07 mmol). Pd XPhos G2 (2.6 mg, 3.3 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 45 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro-Af-methyl-5-(7- (1 -methyl- li7-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)amino)imidazo[l,2-/>]pyridazin-3- yl)benzamide (3.4 mg, 7.5 pmol, 34% yield). LCMS calculated for C22H22F2Nv02(M+H)+: m/z = 454.2; found: 453.9.
Example 20.
3,4-Difluoro-5-(6-(2-methoxyethoxy)-7-(l-methyl-Li/-pyrazol-4-yl)imidazo[l,2-
6]pyridazin-3-yl)-A-methylbenzamide
Figure imgf000131_0001
Step 1. 3-Bromo- 7-chloro-6-(2-methoxyethoxy)imidazo[ 1, 2-b ]pyridazine
Figure imgf000132_0001
A sample of 3-bromo-6,7-dichloroimidazo[l,2-/>]pyridazine (100 mg, 0.375 mmol, see Example 19, Step 2) was dissolved in Af-methyl -2-pyrrol idinone (1 ml) and was treated with cesium carbonate (305 mg, 0.937 mmol) and 2-methoxyethan-l-ol (74 mΐ, 0.94 mmol). This solution was stirred at 90 °C. After 45 mins, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NEECl, and the mixture was extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography in 0-100% EtOAc/hexanes to provide 3-bromo-7-chloro-6-(2- m ethoxy ethoxy)imidazo[l,2-Z>]pyridazine (60 mg, 0.20 mmol, 52% yield). LCMS calculated for CiHioBrClNsCE (M+H)+: m/z = 306.0, 308.0; found: 305.9, 307.9.
Step 2. 3-(7-Chloro-6-(2-methoxyethoxy)imidazo[ 1, 2-b ]pyridazin-3-yl)-4, 5-difluoro-N- methylbenzamide
Figure imgf000132_0002
A sample of 3-bromo-7-chloro-6-(2-methoxyethoxy)imidazo[l,2-Z>]pyridazine (60 mg, 0.20 mmol) was dissolved in dioxane (1.8 ml) and was treated with K2CO3 (81 mg, 0.59 mmol), water (0.18 ml), and 3,4-difluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzamide (64 mg, 0.22 mmol, see Intermediate A). This solution was degassed with bubbling nitrogen for 5 minutes. [l,r-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (16 mg, 0.020 mmol) was added, the vial was capped, and the solution was stirred at 80 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NEECl, and extracted with EtOAc. The combined organic fractions were dried over MgS04, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM to provide 3-(7-chloro-6-(2-methoxyethoxy)imidazo[l,2-Z>]pyridazin-3-yl)-4,5- difluoro-A-methylbenzamide (31 mg, 0.078 mmol, 40% yield). LCMS calculated for C17H16CIF2N4O3 (M+H)+: m/z = 397.1; found: 397.1.
Step 3. 3, 4-Difluoro-5-( 6-(2-methoxyethoxy)-7-( 1 -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2- b]pyridazin-3-yl)-N-methylbenzamide
A sample of 3-(7-chloro-6-(2-methoxyethoxy)imidazo[l,2-/>]pyridazin-3-yl)-4,5- difluoro-A-methylbenzamide (15 mg, 0.038 mmol) was dissolved in DMF (0.42 ml) and water (0.084 ml). This solution was treated with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lF/-pyrazole (16 mg, 0.076 mmol) and K2CO3 (16 mg, 0.11 mmol). Pd XPhos G2 (4.5 mg, 5.7 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 45 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide 3,4-difluoro-5-(6-(2- m ethoxy ethoxy)-7-(l -methyl- 17T-pyrazol-4-yl)imidazo[l, 2-Z>]pyridazin-3-yl)-/V- methylbenzamide (3.2 mg, 7.2 pmol, 19% yield). LCMS calculated for C21H21F2N6O3 (M+H)+: m/z = 443.2; found: 443.1.
Example 21.
(A)-3,4-Difluoro-A-methyl-5-(7-(6-methylpyridin-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000133_0001
Step 1. (S)-3-Bromo- 7-chloro-6-( ( tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2-b ]pyridazine
Figure imgf000133_0002
A sample of 3-bromo-6,7-dichloroimidazo[l,2-Z>]pyridazine (600 mg, 2.25 mmol, see Example 19, Step 2) was dissolved in A-methyl -2-pyrrol idi none (5.62 ml) and was treated with cesium carbonate (1010 mg, 3.37 mmol) and fV)-tetrahydrofuran-3-ol (540 mΐ, 6.7 mmol). This solution was stirred at 90 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NEECl, and the mixture was extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography in 0-50% EtOAc/hexanes to provide fV)-3-bromo-7-chloro-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazine (410 mg, 1.29 mmol, 57% yield). LCMS calculated for CioHioBrCINsCE (M+H)+: m/z = 318.0, 320.0; found: 317.9, 319.9.
Step 2. (S)-3-(7-Chloro-6-( ( tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)-4, 5- difluoro-N-methylbenzamide
Figure imgf000134_0001
A sample of fV)-3-bromo-7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[ l ,2- Zijpyridazine (325 mg, 1.02 mmol) was dissolved in dioxane (9.3 ml) and was treated with K2CO3 (282 mg, 2.04 mmol), water (0.93 ml), and 3,4-difluoro-A-methyl-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (424 mg, 1.43 mmol, see Intermediate A). This solution was degassed with bubbling nitrogen for 5 minutes. [1,1'- Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (125 mg, 0.153 mmol) was added, the vial was capped, and the solution was stirred at 80 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NEECl, and extracted with EtOAc. The combined organic fractions were dried over MgS04, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM to provide fV)-3-(7- chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-4,5-difluoro-/V- methylbenzamide (443 mg, 1.08 mmol, mass was over theoretical yield, so quantitative yield was assumed). LCMS calculated for C18H16CIF2N4O3 (M+H)+: m/z = 409.1; found: 409.1.
Step 3. (S)-3, 4-Difluoro-N-methyl-5-(7-( 6-methylpyridin-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)benzamide
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (30 mg, 0.073 mmol) was dissolved in DMF (0.41 ml) and water (0.16 ml). This solution was treated with (6-m ethylpyri din-3 -yl)boronic acid (30 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol). Pd XPhos G2 (8.7 mg, 0.011 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro-Af-methyl-5-(7-(6-methylpyridin-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (2.5 mg, 5.4 pmol, 7% yield). LCMS calculated for C24H22F2N5O3 (M+H)+: m/z = 466.2; found: 466.1.
Example 22.
(A)-3-(7-(5,6-Dihydro-4//-pyrrolo[l,2-6]pyrazol-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-4,5-difluoro-/V-methylbenzamide
Figure imgf000135_0001
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (30 mg, 0.073 mmol, see Example 21, Step 2) was dissolved in DMF (0.41 ml) and water (0.16 ml). This solution was treated with 3-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-5,6-dihydro-4//-pyrrolo[ l ,2-/i]pyrazole (52 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol). Pd XPhos G2 (8.7 mg, 0.011 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (X)-3-(7-(5,6-dihydro-4i7-pyrrolo[l,2-Z>]pyrazol-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-4,5-difluoro-/V-methylbenzamide (2.9 mg, 6.0 pmol, 8% yield). LCMS calculated for C24H23F2N6Ch(M+H)+: m/z = 481.2; found: 481.0. Example 23.
(A)-3,4-Difluoro-A-methyl-5-(7-(l-(oxetan-3-yl)-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000136_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (30 mg, 0.073 mmol, see Example 21, Step 2) was dissolved in DMF (0.41 ml) and water (0.16 ml). This solution was treated with l-(oxetan-3- yl)-4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)- l//-pyrazole (55 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol). Pd XPhos G2 (8.7 mg, 0.011 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro-A-methyl-5-(7-( l -(oxetan-3-yl)- l//-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (3.6 mg, 7.3 pmol, 10% yield). LCMS calculated for C24H23F2N6O4 (M+H)+: m/z = 497.2; found: 497.0.
Example 24.
(A)-3,4-Difluoro-5-(7-(l-isopropyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-A-methylbenzamide
Figure imgf000136_0002
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (30 mg, 0.073 mmol, see Example 21, Step 2) was dissolved in DMF (0.41 ml) and water (0.16 ml). This solution was treated with 1-isopropyl- 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-liT-pyrazole (52 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol). Pd XPhos G2 (8.7 mg, 0.011 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method, then pH = 10 method) to provide fV)-3,4-difluoro-5-(7-(l -isopropyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran- 3-yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)-/V-methylbenzamide (1.3 mg, 2.7 pmol, 4% yield). LCMS calculated for C24H25F2N6O3 (M+H)+: m/z = 483.2; found: 483.1.
Example 25.
(A)-3-(7-(l-Cyclobutyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- 6]pyridazin-3-yl)-4,5-difluoro-A-methylbenzamide
Figure imgf000137_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[l ,2-/)]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (30 mg, 0.073 mmol, see Example 21, Step 2) was dissolved in DMF (0.41 ml) and water (0.16 ml). This solution was treated with 1 -cyclobutyl- 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-liT-pyrazole (55 mg, 0.22 mmol) and K2CO3 (30 mg, 0.22 mmol). Pd XPhos G2 (8.7 mg, 0.011 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (S)-3- (7-(l-cyclobutyl-li7-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (13.1 mg, 0.026 mmol, 36% yield). LCMS calculated for C25H25F2N6O3 (M+H)+: m/z = 495.2; found: 494.9. Example 26.
(A)-3-(7-(l-(2-Cyanopropan-2-yl)-Li/-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-5-(difluoromethyl)-4-fluoro-A-methylbenzamide
Figure imgf000138_0001
Step 1. (S)-3-(7-Chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo [ 1 ,2-b]pyridazin-3-yl)-5- ( difluoromethyl) -4-fluoro-N-methyl benzamide
Figure imgf000138_0002
A sample of fV)-3-bromo-7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2- Z]pyridazine (650 mg, 2.04 mmol, see Example 21, Step 1 ) was dissolved in dioxane (19 ml) and was treated with K2CO3 (564 mg, 4.08 mmol), water (1.9 ml), and 3-(difluoromethyl)-4- fluoro-/V-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (940 mg, 2.86 mmol, see Intermediate C). This solution was degassed with bubbling nitrogen for 5 minutes. [l,l'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (250 mg, 0.31 mmol) was added, the vial was capped, and the solution was stirred at 80 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM to provide fV)-3-(7- chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-5-(difluoromethyl)-4- fluoro-ZV-methylbenzamide (900 mg, 2.04 mmol, 100% yield). LCMS calculated for C19H17CIF3N4O3 (M+H)+: m/z = 441.1; found: 441.1.
Step 2. (S)-3-(7-(l-(2-Cyanopropan-2-yl)-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)-5-(difluoromethyl)-4-fluoro-N-methylbenzamide A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[l ,2-/ ]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 2-methyl-2-(4-(4, 4,5,5- tetramethyl- 1 ,3,2-dioxaborolan-2-yl)- l//-pyrazol- 1 -yl)propanenitrile (27 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (S)-3- (7-( 1 -(2-cyanopropan-2-yl)- l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[ l ,2- Z>]pyridazin-3-yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (6.5 mg, 0.012 mmol, 35% yield).. LCMS calculated for C26H25F3N7O3 (M+H)+: m/z 540.2; found: 539.9.
Example 27.
(A)-3-(Difluoromethyl)-4-fluoro-A-methyl-5-(7-(pyrazolo[l,5-a]pyridin-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000139_0001
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 3- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazolo[l,5-a]pyridine (25 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (S)- 3- (difluoromethyl)-4-fluoro-/V-methyl-5-(7-(pyrazolo[l,5-a]pyridin-3-yl)-6-((tetrahydrofuran- 3-yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)benzamide (5.7 mg, 11 pmol, 32% yield). LCMS calculated for C26H22F3N6O3 (M+H)+: m/z = 523.2; found: 522.9. Example 28.
(A)-3-(Difluoromethyl)-4-fluoro-A-methyl-5-(6-((tetrahydrofuran-3-yl)oxy)-7-(4, 5,6,7- tetrahydropyrazolo[l,5-fl]pyrazin-3-yl)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000140_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3 -yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with tert- butyl 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-6,7-dihydropyrazolo[l,5-a]pyrazine- 5(4iT)-carboxylate (36 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins,
LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with DCM, and filtered through a SiliaPrep Thiol cartridge.
The filtrate was treated with trifluoroacetic acid (1 mL), and stirred for an hour at 22 °C. After 1 hour, LCMS indicated consumption of the intermediate. The solution was concentrated in vacuo. The concentrate was dissolved in MeCN and water, filtered, and purified by HPLC (pH = 2 method) to provide fV)-3-(difluoromethyl)-4-fluoro-Af-methyl-5-(6- ((tetrahydrofuran-3-yl)oxy)-7-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)imidazo[l,2- Z>]pyridazin-3-yl)benzamide (6.4 mg, 0.012 mmol, 36% yield). LCMS calculated for C25H25F3N7O3 (M+H)+: m/z = 528.2; found: 527.9.
Example 29.
(»y)-3-(Difluoromethyl)-4-fluoro-/V-methyl-5-(7-(l-(pyridin-3-ylmethyl)-l//-pyrazol-4- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000141_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3 -yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 3- ((4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)- l//-pyrazol- 1 -yl)methyl)pyridine (29 mg, 0.10 mmol) and K2C03 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(difluoromethyl)-4-fluoro-A-methyl-5-(7-( l -(pyridin-3- yl methyl )-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[l ,2-/)]pyridazin-3- yl)benzamide (5.3 mg, 9.4 pmol, 28% yield). LCMS calculated for C28H25F3N7O3 (M+H)+: m/z = 564.2; found: 563.9.
Example 30.
(X)-3-(Difluoromethyl)-4-fluoro-A-methyl-5-(7-(l-(2-morpholinoethyl)-Li/-pyrazol-4-yl)- 6-((tetrahydr ofuran-3-yl)oxy)imidazo [1,2 -b] pyr idazin-3-yl)benzamide
Figure imgf000141_0002
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 4- (2-(4-(4,4,5,5-tetramethyi- 1 ,3,2-dioxaborolan-2-yl)- l//-pyrazol-l -yl)ethyl)morpholine (31 mg, 0.10 mmol) and K2C03 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(difluoromethyl)-4-fluoro-A-methyl-5-(7-( l -(2- morphol i noethyl )- l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[l ,2-/)]pyridazin-3- yl)benzamide (7.9 mg, 0.013 mmol, 40% yield). LCMS calculated for C28H31F3N7O4 (M+H)+: m/z = 586.2; found: 585.9.
Example 31.
(A)-3-(7-(3-Cyano-4-methylphenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-
6]pyridazin-3-yl)-5-(difluoromethyl)-4-fluoro-A-methylbenzamide
Figure imgf000142_0001
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 2- methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzonitrile (25 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide {S)~ 3- (7-(3-cyano-4-methylphenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-0]pyridazin-3-yl)-5- (difluoromethyl)-4-fluoro-A-methylbenzamide (4.4 mg, 8.4 pmol, 25% yield). LCMS calculated for C27H23F3N5O3 (M+H)+: m/z = 522.2; found: 522.1.
Example 32. (A)-3-(Difluoromethyl)-4-fluoro-A-methyl-5-(7-(6-(pyrrolidin-l-yl)pyridin-3-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000143_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 2- (pyrrolidin-l-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (28 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(difluoromethyl)-4-fluoro-Af-methyl-5-(7-(6-(pyrrolidin-l -yl)pyridin-3-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (2.5 mg, 4.5 pmol, 13% yield). LCMS calculated for C28H28F3N6O3 (M+H)+: m/z = 553.2; found: 552.9.
Example 33.
(A)-3-(Difluoromethyl)-4-fluoro-A-methyl-5-(7-(6-(2-oxopyrrolidin-l-yl)pyridin-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000144_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3 -yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 1- (5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrrolidin-2-one (29 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(difluoromethyl)-4-fluoro-Af-methyl-5-(7-(6-(2-oxopyrrolidin-l -yl)pyridin-3- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (1.7 mg, 3.0 pmol, 9% yield). LCMS calculated for CisHieFsNeCL (M+H)+: m/z = 567.2; found: 566.9.
Example 34.
3-(Difluoromethyl)-4-fluoro-5-(7-(l-((lr,4A)-4-hydroxycyclohexyl)-l//-pyrazol-4-yl)-6-
(((A)-tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-A-methylbenzamide
Figure imgf000144_0002
A sample of (ri)-3-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (30 mg, 0.068 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.8 ml) and water (0.15 ml). This solution was treated with 1- ((lr,4r)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lF/-pyrazole (83 mg, 0.20 mmol) and K2CO3 (28 mg, 0.20 mmol). Pd XPhos G2 (8 mg, 10 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material.
The solution was cooled to room temperature, diluted with EtOAc, filtered through a SiliaPrep Thiol cartridge, and the filtrate was concentrated in vacuo. The concentrate was dissolved in dioxane (1.5 mL) and treated with HC1 in dioxane (4N, 1.5 mL). The solution was stirred at room temperature for 48 hours, at which point LCMS indicated consumption of the intermediate. The solution was concentrated in vacuo , and the concentrate was diluted with MeCN and water, filtered, and purified by HPLC (pH = 2 method) to provide 3- (difluoromethyl)-4-fluoro-5-(7-(l -(( l/,4A)-4-hydroxycyclohexyl)- l//-pyrazol-4-yl)-6-((fV)- tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-/V-methylbenzamide (4.6 mg, 8.1 pmol, 12% yield). LCMS calculated for C28H30F3N6O4 (M+H)+: m/z = 571.2; found: 571.1.
Example 35.
(A)-3-(Difluoromethyl)-4-fluoro-5-(7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-A-methylbenzamide
Figure imgf000145_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/ ]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 2- (5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-ol (27 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide C.V)-3-(difluorom ethyl )-4-fluoro-5-(7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l ,2-/>]pyridazin-3-yl)-/V-methylbenzamide (4.6 mg, 8.5 pmol, 25% yield). LCMS calculated for C27H27F3N5O4 (M+H)+: m/z = 542.2; found: 542.2. Example 36.
(A)-3-(Difluoromethyl)-4-fluoro-5-(7-(3-fluoro-4-(methylcarbamoyl)phenyl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-/V-methylbenzamide
Figure imgf000146_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (15 mg, 0.034 mmol, see Example 26, Step 1 ) was dissolved in DMF (0.4 ml) and water (0.08 ml). This solution was treated with 2- fluoro-/V-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (29 mg, 0.10 mmol) and K2CO3 (14 mg, 0.10 mmol). Pd XPhos G2 (4 mg, 5 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3 -(difl uoromethyl )-4-fluoro-5-(7-(3-fluoro-4-(methyl carbarn oyl)phenyl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-/V-methylbenzamide (4.9 mg, 8.8 pmol, 26% yield). LCMS calculated for C27H24F4N5O4 (M+H)+: m/z = 558.2; found: 557.9.
Example 37.
(»y)-3-(Dimethylamino)-4-fluoro-/V-methyl-5-(7-(l-methyl-l//-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000147_0001
Step 1. (S)-3-Bromo-7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- b]pyridazim
Figure imgf000147_0002
A sample of 3 -bromo-6-chloro-7-( 1 -methyl- li7-pyrazol-4-yl)imidazo[ 1 ,2-/>]pyridazine (218 mg, 0.697 mmol, see Example 15, Step 5) was dissolved in dioxane (8.7 ml) and was treated with cesium carbonate (682 mg, 2.09 mmol) and fV)-tetrahydrofuran-3-ol (846 mΐ, 10.5 mmol). This solution was stirred at 110 °C. After 16 hours, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NEECl, and the mixture was extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide fV)-3-bromo-7-(l -methyl -l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-Z>]pyridazine (188 mg, 0.516 mmol, 74% yield). LCMS calculated for Ci4Hi5BrN502 (M+H)+: m/z = 364.0, 366.0; found: 364.2, 366.2. Step 2. (S)-3-Chloro-4-fluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran- 3-yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl) benzamide
Figure imgf000148_0001
A sample of (A)-3-bromo-7-( l -methyl - l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazine (200 mg, 0.55 mmol) was dissolved in dioxane (6.1 ml) and was treated with K2CO3 (228 mg, 1.65 mmol), water (1.22 ml), and 3 -chi oro-4-fl uoro- A - methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (224 mg, 0.714 mmol, see Intermediate D). This solution was degassed with bubbling nitrogen for 5 minutes. [1,T- Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (67 mg, 0.082 mmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide (A)-3-chloro-4-fluoro-A-methyl-5-(7-(l -methyl-l//-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (92 mg, 0.20 mmol, 36% yield). LCMS calculated for C22H21CIFN6O3 (M+H)+: m/z = 471.1; found: 471.1.
Step 3. (S)-3-(Dimethylamino)-4-fluoro-N-methyl-5-(7-( 1 -methyl-lH-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide
A sample of (A)-3-chloro-4-fluoro-A-methyl-5-(7-(l -methyl- l//-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (15 mg, 0.032 mmol) was dissolved in dioxane (0.6 ml) and treated with sodium /cvV-but oxide (15 mg, 0.16 mmol) and dimethylamine (80 mΐ, 0.16 mmol, 2M in THF). The solution was degassed with bubbling nitrogen for 5 minutes. Pd XPhos G2 (2.5 mg, 3.2 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 2 hours, LCMS indicated 50% conversion, and that conversion had stalled. The solution was cooled to room temperature, quenched with acetic acid, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide ( A)-3 -(di methyl ami no)-4-fluoro-A-methyl-5-(7-( l - methyl- li7-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-/>]pyridazin-3- yl)benzamide (1.4 mg, 2.9 pmol, 9% yield). LCMS calculated for C24H27FN7O3 (M+H)+: m/z = 480.2; found: 480.2. Example 38.
(A)-3-Cyclopropyl-4-fluoro-A-methyl-5-(7-(l-methyl-l//-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000149_0001
A sample of (A)-3-chloro-4-fluoro-A-methyl-5-(7-(l -methyl -l//-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)benzamide (15 mg, 0.032 mmol, see Example 37, Step 2) was dissolved in dioxane (0.6 ml) and water (0.1 ml). This solution was treated with potassium cyclopropyltrifluoroborate (24 mg, 0.16 mmol) and K2CO3 (13 mg, 0.10 mmol). Pd XPhos G2 (2.5 mg, 3.2 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 2 hours, LCMS indicated 60% conversion, and that conversion had stalled. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (S)-3- cyclopropyl-4-fluoro-Af-methyl-5-(7-(l -methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)benzamide (0.7 mg, 2 pmol, 5% yield). LCMS calculated for C25H26FN6O3 (M+H)+: m/z = 477.2; found: 477.1.
Example 39.
(A)-3-(2-Fluoro-3-methyl-5-(l-methyl-l//-l,2,3-triazol-4-yl)phenyl)-7-(l-methyl-Li/- pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazine
Figure imgf000149_0002
Step 1. (S)-3-(5-Chloro-2-fluoro-3-methylphenyl)-7-(l-methyl-lH-pyrazol-4-yl)-6-
Figure imgf000150_0001
A sample of fV)-3-bromo-7-( l -methyl - l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazine (200 mg, 0.55 mmol, see Example 37, Step 1 ) was dissolved in dioxane (6.1 ml) and was treated with K2CO3 (228 mg, 1.65 mmol), water (1.22 ml), and 2- (5-chloro-2-fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (193 mg, 0.714 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. [I,G- Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (67 mg, 0.082 mmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide fV)-3-(5-chloro-2-fluoro-3-methylphenyl)-7-( l -methyl- l//-pyrazol-4- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazine (113 mg, 0.26 mmol, 48% yield). LCMS calculated for C21H20CIFN5O2 (M+H)+: m/z = 428.1; found: 428.2.
Step 2. (S)-3-( 2-Fluoro-3-methyl-5-( 1 -methyl- IH-l, 2, 3-triazol-4-yl)phenyl)~ 7-(l -methyl- 1H- pyrazol-4-yl)-6-( ( tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2-b ]pyridazine
A sample of (ri)-3-(5-chloro-2-fluoro-3-methylphenyl)-7-(l-methyl-liT-pyrazol-4-yl)- 6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazine (15 mg, 0.035 mmol) was dissolved in DMF (0.6 ml) and treated with K2CO3 (15 mg, 0.11 mmol) and l-methyl-4-(4,4,5,5- tetramethyl-1, 3, 2-dioxaborolan-2-yl)-liT-l, 2, 3-triazole (37 mg, 0.18 mmol) and water (0.12 ml). The solution was degassed with bubbling nitrogen for 5 minutes. Pd XPhos G2 (2.8 mg, 3.5 pmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 45 mins, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(2-fluoro-3-methyl-5-( l -methyl- 1//- 1 ,2,3-triazol-4-yl)phenyl)-7-(l -methyl -l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-Z>]pyridazine (2.6 mg, 5.5 pmol, 16% yield). LCMS calculated for C24H24FN8O2 (M+H)+: m/z = 475.2; found: 475.2.
Example 40.
(A)-4-Fluoro-3-(hydroxymethyl)-A-methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000151_0001
Step 1. (S)-4-Fluoro-N-methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofoiran-3- yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)-5-vinylbenzamide
Figure imgf000151_0002
A sample of (ri)-3-chloro-4-fluoro-/V-methyl-5-(7-(l-methyl-li7-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)benzamide (81 mg, 0.17 mmol, see Example 37, Step 2) was dissolved in dioxane (2.9 ml) and was treated with K2CO3 (71 mg, 0.52 mmol), water (0.57 ml), and 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (146 mΐ, 0.86 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Pd XPhos G2 (14 mg, 0.017 mmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 2 hours, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo to provide fV)-4-fl uoro-A-m ethyl -3 -(7-( l -methyl - 1 //-py razol -4-y 1 )-6-((tetrahy drofuran-3 - yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-5-vinylbenzamide (83 mg, 0.18 mmol, mass was over theoretical yield, so quantitative yield was assumed). The product was used without further purification. LCMS calculated for C24H24FN6O3 (M+H)+: m/z = 463.2; found: 463.4.
Step 2. (S)-4-Fluoro-3-formyl-N-methyl-5-(7-( l -methyl- lH-pyrazol-4-yl) -6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide
Figure imgf000152_0001
A sample of (ri)-4-fluoro-/V-methyl-3-(7-(l-methyl-li7-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-5-vinylbenzamide (72 mg, 0.16 mmol) was dissolved in acetone (3.9 ml) and water (3.9 ml). The solution was treated with potassium osmate dihydrate (3.4 mg, 9.3 pmol), NMO (1 mg, 9 pmol), and sodium periodate (100 mg, 0.47 mmol). The mixture was stirred at 22 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was concentrated in vacuo (approximately 50% of volume), and the concentrate was diluted with EtOAc, and then washed with water. The aqueous layer was extracted again with 25% /.vo-propanol in chloroform. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo to provide (S)- 4-fluoro-3 -formyl -A-methyl-5-(7-(l -methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)benzamide (52 mg, 0.11 mmol, 72% yield). The crude material was used without further purification. LCMS calculated for C23H22FN6O4 (M+H)+: m/z = 465.2; found: 465.4.
Step 3. (S)-4-Fluoro-3-(hydroxymethyl)-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide
A crude sample of (A)-4-fluoro-3 -formyl -A-methyl-5-(7-(l -methyl-l//-pyrazol-4-yl)- 6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (41 mg, 0.088 mmol) was dissolved in methanol (3 ml). This solution was treated with NaBFL (17 mg, 0.44 mmol), added in three portions over 10 minutes. The solution was stirred at 22 °C. After 30 minutes, LCMS indicated complete consumption of the starting material. The solution was diluted with MeOH and water, filtered, and purified by HPLC (pH = 2 method) to provide (A)-4-fluoro-3- (hydroxymethyl )-A-methyl-5-(7-( l -methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)benzamide (3 mg, 6 pmol, 7% yield). LCMS calculated for C23H24FN6O4 (M+H)+: m/z = 467.2; found: 467.2.
Example 41.
(A)-3-(Difluoromethyl)-4-fluoro-A-methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000153_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-5-(difluoromethyl)-4-fluoro-/V-methylbenzamide (50 mg, 0.11 mmol, see Example 26, Step 1 ) was dissolved in DMF (1.3 ml) and water (0.25 ml). This solution was treated with 1- methyl-4-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2-yl)- l//-pyrazole (71 mg, 0.34 mmol) and K2CO3 (47 mg, 0.34 mmol). Pd XPhos G2 (13 mg, 0.017 mmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(difluoromethyl)-4-fluoro-A-methyl-5-(7-( l -methyl- l//-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (12.3 mg, 0.025 mmol, 22% yield). ¾ NMR (600 MHz, DMSO-de) d 9.02 (d, J = 5.5 Hz, 1 H), 8.70 (q, J = 5.6 Hz, 1H), 8.47 (s, 1H), 8.29 (s, 1H), 8.18 (s, 1H), 8.15 (d, J = 5.4 Hz, 1H), 8.12 (s, 1H), 7.38 (t, J = 65 Hz, 1H), 5.60 (m, 1H), 4.08 (d, J = 13.0 Hz, 1H), 4.01 (dd, J = 13.0, 5.6 Hz, 1H), 3.96 (m, 1H), 3.93 (s, 3H), 3.81 (dt, J = 5.9, 9.8 Hz, 1H), 2.82 (d, J = 5.4 Hz, 3H), 2.35 (m, 2H). LCMS calculated for C23H22F3N6O3 (M+H)+: m/z = 487.2; found: 487.1. Example 42.
(A)-4-Fluoro-A,3-dimethyl-5-(7-(l-methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000154_0001
A sample of (A)-3-bromo-7-( l -methyl - l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazine (34 mg, 0.093 mmol, see Example 37, Step 1 ) was dissolved in DMF (1.6 ml) and water (0.3 ml). This solution was treated with 4-fluoro-A(3 -dimethyl -5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (82 mg, 0.28 mmol, see Intermediate B) and K2CO3 (39 mg, 0.28 mmol). Pd XPhos G2 (11 mg, 0.014 mmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (A)-4-fluoro-Af,3-dimethyl-5-(7-( l -methyl- l//-pyrazol-4- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (1.3 mg, 2.9 pmol, 3% yield). ¾NMR (600 MHz, DMSO-de) d 8.65 (d, J = 8.0 Hz, 1H), 8.47 (q, J = 5.5 Hz, 1H),
8.44 (s, 1H), 8.28 (s, 1H), 8.17 (s, 1H), 8.07 (br, 1H), 7.83 (d, J = 6.8 Hz, 1H), 5.57 (m, 1H), 4.08 (d, J = 13.0 Hz, 1H), 4.01 (dd, J = 13.0, 5.7 Hz, 1H), 3.95 (m, 1H), 3.93 (s, 3H), 3.81 (dt, J not measured [large water peak would render measurement imprecise], 1H), 2.80 (d, J = 5.3 Hz, 3H), 2.38 (s, 3H), 2.33 (m, 2H). LCMS calculated for C23H24FN6O3 (M+H)+: m/z = 451.2; found: 451.2.
Example 43.
(X)-3,4-Difluoro-A-methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000155_0001
A sample of fV)-3-bromo-7-( l -methyl- l//-pyrazol-4-yl )-6-((tetrahydrofuran-3 - yl)oxy)imidazo[l,2-/>]pyridazine (34 mg, 0.093 mmol, see Example 37, Step 1 ) was dissolved in DMF (1.6 ml) and water (0.3 ml). This solution was treated with 3,4-difluoro-A-methyl-5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide (83 mg, 0.28 mmol), see Intermediate A) and K2CO3 (39 mg, 0.28 mmol). Pd XPhos G2 (11 mg, 0.014 mmol) was added, the vial was capped, and the solution was stirred at 85 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (A)-3,4-difluoro-Af-methyl-5-(7-( l -methyl- l//-pyrazol-4- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (1.7 mg, 3.7 pmol, 4% yield). ¾NMR (600 MHz, DMSO-de) d 8.76 (d, J = 5.9 Hz, 1H), 8.60 (q, J = 4.7 Hz, 1H),
8.46 (s, 1H), 8.28 (s, 1H), 8.17 (s, 1H), 8.12 (s, 1H), 7.91 (m, 1H), 5.61 (m, 1H), 4.08 (d, J = 10.7 Hz, 1H), 4.04 (dd, J = 10.8, 4.6 Hz, 1H), 3.95 (m, 1H), 3.93 (s, 3H), 3.82 (dt, J = 4.9, 8.2 Hz, 1H), 2.81 (d, J = 4.5 Hz, 3H), 2.38 (m, 1H), 2.32 (m, 1H). LCMS calculated for C22H21F2N6O3 (M+H)+: m/z = 455.2; found: 455.4.
Example 44.
(A)-3-(Cyanomethyl)-4-fluoro-A-methyl-5-(7-(l-methyl-Li/-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000156_0001
A sample of (A)-3-bromo-7-(l -methyl -l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazine (17 mg, 0.047 mmol, see Example 37, Step 1 ) was dissolved in DMF (1 ml) and water (0.4 ml). This solution was treated with 3-(cyanomethyl)-4-fluoro- A-methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)benzamide (74 mg, 0.23 mmol, see Intermediate E) as a solution in additional DMF (1 ml) and K2CO3 (19 mg, 0.14 mmol). Pd XPhos G2 (5.5 mg, 7.0 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (A)-3-(cyanomethyl)-4-fluoro-A- m ethyl -5-(7-(l -methyl -l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[l ,2- Z>]pyridazin-3-yl)benzamide (1.8 mg, 3.8 pmol, 8% yield). LCMS calculated for C24H23FN7O3 (M+H)+: m/z = 476.2; found: 476.3.
Example 45.
(A)-4-Fluoro-/V-methyl-3-(7-(l-methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-5-(pyrrolidin-l-ylmethyl)benzamide
Figure imgf000156_0002
A sample of (A)-3-bromo-7-(l -methyl -l//-pyrazol-4-yl )-6-((tetrahydrofuran-3 - yl)oxy)imidazo[l,2-/>]pyridazine (20 mg, 0.055 mmol, see Example 37, Step 1 ) was dissolved in DMF (0.75 ml) and water (0.3 ml). This solution was treated with crude 4- fl uoro-A-methyl -3 -(pyrrol idin-1 -ylmethyl)-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)benzamide (~99 mg, -0.275 mmol, see Intermediate F) as a solution in additional DMF (0.7 ml) and K2CO3 (19 mg, 0.14 mmol). Pd XPhos G2 (6.5 mg, 8.2 pmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 30 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method, then pH = 10 method) to provide fV)-4-fl uoro-A-methyl -3 -(7-(l -methyl-1//- pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-5-(pyrrolidin-l- ylmethyl)benzamide (4.7 mg, 9.0 pmol, 16% yield). LCMS calculated for C27H31FN7O3 (M+H)+: m/z = 520.3; found: 520.2.
Example 46.
(A)-3-(2,3-Difluorophenyl)-7-(l-isopropyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazine
Figure imgf000157_0001
Step 1. (S)-7-Chloro-3-(2, 3-difluorophenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2- b]pyridazine
Figure imgf000157_0002
A sample of (A)-3-bromo-7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2- Z>]pyridazine (50 mg, 0.16 mmol, see Example 21, Step 1 ) was dissolved in dioxane (1.4 ml) and was treated with K2CO3 (43 mg, 0.31 mmol), water (0.14 ml), and (2,3- difluorophenyl)boronic acid (35 mg, 0.22 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. [l,r-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (19 mg, 0.024 mmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 1 hour, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NTBCl, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo to provide C.V)-7-chl oro-3 -(2,3 -di fluorophenyl )-6-((tetrahydrofuran -3- yl)oxy)imidazo[l,2-/>]pyridazine (59 mg, 0.17 mmol, mass was over theoretical yield, so quantitative yield was assumed). The product was used without further purification. LCMS calculated for C16H13CIF2N3O2 (M+H)+: m/z = 352.1; found: 352.1.
Step 2. (S)-3-( 2, 3-Difluorophenyl)- 7-(l -isopropyl-lH-pyrazol-4-yl)-6-( ( tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b ]pyridazine
A sample of C.V)-7-chl oro-3-(2, 3 -di fluorophenyl )-6-((tetrahydrofuran-3 - yl)oxy)imidazo[l,2-/>]pyridazine (30 mg, 0.085 mmol) was dissolved in DMF (0.95 ml) and water (0.19 ml). This solution was treated with (1 -isopropyl- lF/-pyrazol-4-yl)boronic acid (39 mg, 0.26 mmol) and K2CO3 (35 mg, 0.26 mmol). Pd XPhos G2 (10 mg, 0.013 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(2,3-difluorophenyl)-7-( l -isopropyl- l//-pyrazol-4- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazine (12 mg, 0.028 mmol, 33% yield). LCMS calculated for C22H22F2N5O2 (M+H)+: m/z 426.2; found: 426.2.
Example 47.
(A)-3-(3-Ethoxyphenyl)-7-(l-methyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazine
Figure imgf000158_0001
Step 1. (S)-7-Chloro-3-(3-ethoxyphenyl)-6-((tetrahydrofoiran-3-yl)oxy)imidazo [ 1 ,2- b]pyridazine
Figure imgf000159_0001
A sample of fV)-3-bromo-7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2- Z)]pyridazine (40 mg, 0.13 mmol, see Example 21, Step 1 ) was dissolved in dioxane (1.1 ml) and was treated with K2CO3 (52 mg, 0.38 mmol), water (0.11 ml), and (3- ethoxyphenyl)boronic acid (23 mg, 0.14 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. [l,l'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (10 mg, 0.013 mmol) was added, the vial was capped, and the solution was stirred at 80 °C. After 45 mins, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography in 0-100% EtOAc/DCM to provide fV)-7-chloro-3-(3-ethoxyphenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazine (36 mg, 0.100 mmol, 80% yield). LCMS calculated for C18H19CIN3O3 (M+H)+: m/z = 360.1; found: 360.1.
Step 2. (S)-3-( 3-Ethoxyphenyl)- 7-( l -methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b ]pyridazine
A sample of fV)-7-chloro-3-(3-ethoxyphenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazine (18 mg, 0.050 mmol) was dissolved in DMF (0.56 ml) and water (0.11 ml). This solution was treated with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-17T-pyrazole (21 mg, 0.10 mmol) and KzCCb (21 mg, 0.15 mmol). Pd XPhos G2 (6 mg, 8 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3-(3-ethoxyphenyl)-7-( l - methyl- li7-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-/>]pyridazine (7.8 mg, 0.019 mmol, 39% yield). LCMS calculated for C22H24N5O3 (M+H)+: m/z 406.2; found: 406.2. Example 48.
(*V)-l-(4-(3-(2',4'-Difluoro-[l,l'-biphenyl]-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-7-yl)-l -pyrazol-l-yl)-2-methylpropan-2-ol
Figure imgf000160_0001
Step 1. l-(4-(3-Bromo-6-chloroimidazo[ l,2-b]pyridazin-7-yl)-lH-pyrazol-l-yl)-2- methylpropan-2-ol
Figure imgf000160_0002
A sample of 3-bromo-6-chloro-7-iodoimidazo[l,2-/>]pyridazine (210 mg, 0.59 mmol, see Example 15, Step 4) was dissolved in dioxane (2.4 ml) and was treated with K2CO3 (162 mg, 1.17 mmol), water (0.5 ml), and 2-methyl-l-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-li7-pyrazol-l-yl)propan-2-ol (220 mg, 0.82 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (135 mg, 0.12 mmol) was added, the vial was capped, and the solution was stirred at 120 °C. After 2 hours, LCMS indicated complete conversion to the product. The solution was cooled to room temperature, quenched with aqueous NH4CI, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM to provide l-(4-(3-bromo-6- chloroimidazo[l,2-Z>]pyridazin-7-yl)-liT-pyrazol-l-yl)-2-methylpropan-2-ol (130 mg, 0.35 mmol, 59% yield). LCMS calculated for CnHuBrClNsO (M+H)+: m/z = 370.0, 372.0; found: 370.0, 372.0. Step 2. (S)-l-( 4-(3-Bromo-6-( ( tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2-b ]pyridazin- 7-yl)-lH- pyrazol-l-yl)-2-methylpropan-2-ol
Figure imgf000161_0001
A sample of l-(4-(3-bromo-6-chloroimidazo[l,2-0]pyridazin-7-yl)-li/-pyrazol-l-yl)- 2-methylpropan-2-ol (130 mg, 0.35 mmol) was dissolved in A-methyl-2-pyrrolidinone (0.9 ml) and was treated with cesium carbonate (340 mg, 1.04 mmol) and fV)-tetrahydrofuran-3-ol (83 mΐ, 1.0 mmol). This solution was stirred at 90 °C. After 90 mins, LCMS indicated complete consumption of the starting material. The reaction mixture was used directly in Step 3. LCMS calculated for CnHziBrNsOs (M+H)+: m/z = 422.1, 424.1; found: 422.1, 424.1.
Step 3. (S)-l-(4-(3-(3-Chlorophenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin- 7-yl)-lH-pyrazol-l-yl)-2-methylpropan-2-ol
Figure imgf000161_0002
A solution of (5)-l-(4-(3-bromo-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- Z>]pyridazin-7-yl)-liT-pyrazol-l-yl)-2-methylpropan-2-ol (<0.35 mmol) in NMP (and containing cesium carbonate and (ri)-tetrahy drofuran-3 -ol , from Step 2) was diluted with DMF (2.9 ml) and water (0.6 ml). This solution was treated with (3-chlorophenyl)boronic acid (60 mg, 0.38 mmol). The solution was then degassed with bubbling nitrogen for 5 minutes. [l,T-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (28 mg, 0.035 mmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 30 mins, LCMS indicated complete consumption of the starting material. The solution was cooled to room temperature, quenched with aqueous NLLCl, and extracted with EtOAc. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtOAc/DCM, then 0-10% MeOH/DCM to provide fV)-l -(4-(3-(3-chlorophenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-/>]pyridazin-7-yl)-li7-pyrazol-l-yl)-2-methylpropan-2-ol (83 mg, 0.18 mmol, 53% yield). LCMS calculated for C23H25CIN5O3 (M+H)+: m/z = 454.2; found: 454.2.
Step 4. (S)-l-(4-(3-(2 \4'-Difluoro-[ 1, 1 '-biphenyl]-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b Jpyridazin- 7-yl)-lH-pyrazol-l-yl)-2-methylpropan-2-ol
A sample of fV)- l -(4-(3-(3-chlorophenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[ l ,2- />]pyridazin-7-yl)-li7-pyrazol-l-yl)-2-methylpropan-2-ol (20 mg, 0.044 mmol) was dissolved in DMF (0.5 ml) and water (0.1 ml). This solution was treated with (2,4-difluorophenyl)boronic acid (21 mg, 0.13 mmol) and K2CO3 (18 mg, 0.13 mmol). Pd XPhos G2 (5 mg, 7 pmol) was added, the vial was capped, and the solution was stirred at 110 °C. After 15 mins, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide (ri)-l-(4-(3-(2',4'-difhioro-[l,r-biphenyl]-3-yl)-6- ((tetrahydrofuran-3 -yl)oxy)imidazo[ 1 ,2-Z>]pyridazin-7-yl)- l//-pyrazol- 1 -yl)-2-methylpropan- 2-ol (4.7 mg, 8.8 pmol, 20% yield). LCMS calculated for C29H28F2N5O3 (M+H)+: m/z = 532.2; found: 532.2.
Example 49.
5-(6-ethoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-A- methylnicotinamide
Figure imgf000162_0001
Step 1. 3-Bromo-6-ethoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazine
Figure imgf000162_0002
To a solution of 3-bromo-6-chloro-7-(l-methyl-liT-pyrazol-4-yl)imidazo[l,2- Z>]pyridazine (10 mg, 0.03 mmol, see Example 15, Step 5) in DMF (1 ml) was added ethanol (0.1 mL, 2.7 mmol), followed by sodium hydride (3.8 mg, 0.16 mmol) at room temperature, and the reaction mixture was heated to 90 °C for 1 h. The reaction mixture was carefully quenched by the dropwise addition of water, partitioned between water and EtOAc, and the layers were separated. The organic layer was washed with brine, dried over MgSCri, filtered, and concentrated. The product was used without purification. LCMS calculated for Ci2Hi3BrN50 (M+H)+: m/z = 322.0; found: 322.1.
Step 2. 5-( 6-Ethoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3-yl)-N- methylnicotinamide
A mixture of 3-bromo-6-ethoxy-7-( l-methyl- l//-pyrazol-4-yl)imidazo[ l ,2- Z>]pyridazine (8 mg, 0.03 mmol), /V-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)nicotinamide (9.8 mg, 0.04 mmol), [l,r-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (1.0 mg, 1.2 pmol), and sodium carbonate (7.9 mg, 0.07 mmol) in dioxane (1.5 ml) and water (0.5 ml) was sparged with nitrogen and heated to 90 °C for 2 h. The reaction was diluted with MeOH and filtered through a SiliaPrep Thiol cartridge. The product was purified by prep HPLC (pH = 2 method). ¾ NMR (600 MHz, DMSO- is) d 9.47 (d, J= 2.2 Hz, 1H), 9.02 (t, 7= 2.1 Hz, 1H), 8.99 (d, 7= 2.1 Hz, 1H), 8.76 (q, J= 4.6 Hz, 1H), 8.47 (s, 1H), 8.45 (s, 1H), 8.38 (s, 1H), 8.22 (s, 1H), 4.61 (q, J= 7.0 Hz, 2H), 3.94 (s, 3H), 2.86 (d, J= 4.5 Hz, 3H), 1.56 (t, J= 7.1 Hz, 3H). LCMS calculated for C19H20N7O2 (M+H)+: m/z = 378.2; found: 378.3.
Example 50.
5-(6-(2,2-Difluoroethoxy)-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-A- methylnicotinamide
Figure imgf000163_0001
This compound was synthesized by a procedure analogous to that reported for Example 49, utilizing 1,1-difluoroethanol instead of ethanol in Step 1. LCMS calculated for C19H18F2N7O2 (M+H)+: m/z = 414.2; found: 414.2. Example 51.
5-(6-Isopropoxy-7-(l-methyl-l//-pyrazol-4-yl)imidazo[l,2-6]pyridazin-3-yl)-/V- methylnicotinamide
Figure imgf000164_0001
Step 1. 3-Bromo-6-isopr opoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-b]pyridazine
Figure imgf000164_0002
To a solution of 3-bromo-6-chloro-7-(l-methyl-li7-pyrazol-4-yl)imidazo[l,2- 6]pyridazine (10 mg, 0.03 mmol, see Example 15, Step 5) in DMF (1 ml) was added propan- 2-ol (50 pL, 0.66 mmol), followed by cesium carbonate (10 mg, 0.03 mmol) at room temperature. The reaction mixture was heated to 90 °C for 1 h. The reaction mixture was cooled to room temperature and used directly for the next step. LCMS calculated for CnHisBrNsO (M+H)+: m/z = 336.0; found: 336.1.
Step 2. 5-( 6-Isopropoxy- 7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ]pyridazin-3-yl)-N- methylnicotinamide
A mixture of 3-bromo-6-isopropoxy-7-(l -methyl -l//-pyrazol-4-yl)i mi dazo[l ,2- Z>]pyridazine (8 mg, 0.02 mmol), /V-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)nicotinamide (9.4 mg, 0.04 mmol), [l,r-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (0.9 mg, 1.2 pmol), and sodium carbonate (7.6 mg, 0.07 mmol) in DMF (1 ml) and water (0.5 ml) was sparged with nitrogen and heated to 90 °C for 2 h. The reaction was diluted with MeOH and filtered through a SiliaPrep Thiol cartridge. The product was purified by prep HPLC (pH = 10 method). LCMS calculated for C20H22N7O2 (M+H)+: m/z = 392.2; found: 392.2. Examples 52 - 66.
The examples in the following table were synthesized by a procedure analogous to that described in Example 51, utilizing the appropriate alcohol (or amine) in Step 1 and the appropriate boronate or boronic acid in Step 2.
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0003
Example 67.
Methyl (A)-(4-(3-(5-(Methylcarbamoyl)pyridin-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-7-yl)phenyl)carbamate
Figure imgf000168_0001
Step 1. (S)-5-(7-Chloro-6-( ( tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2-b ]pyridazin-3-yl)-N- methylnicotinamide
Figure imgf000168_0002
A sample of fV)-3-bromo-7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2- Z]pyridazine (149 mg, 0.468 mmol, see Example 21, Step 1 ) was dissolved in dioxane (8.9 ml) and was treated with CS2CO3 (457 mg, 1.40 mmol), water (1.5 ml), and /V-methyl-5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)nicotinamide (147 mg, 0.56 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. [1,T- Bis(diphenylphosphino)ferrocene]palladium(II) dichloride, complex with DCM (19.0 mg, 0.023 mmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with EtOAc, filtered through a SiliaPrep Thiol cartridge, and concentrated in vacuo to provide fV)-5-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[ l ,2- Z>]pyridazin-3-yl)-/V-methylnicotinamide (171 mg, 0.46 mmol, 98% yield). The product was used without further purification. LCMS calculated for C17H17CIN5O3 (M+H)+: m/z = 374.1; found: 374.1.
Step 2. Methyl (S)-(4-(3-(5-(Methylcarbamoyl)pyridin-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b Jpyridazin- 7 -yl)phenyl) carbamate
A sample of fV)-5-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[ l ,2-/ ]pyridazin-3- yl)-/V-methylnicotinamide (21.4 mg, 0.057 mmol) was dissolved in dioxane (1.9 ml) and water (0.95 ml). This solution was treated with (4-((methoxycarbonyl)amino)phenyl)boronic acid (11.0 mg, 0.057 mmol) and CS2CO3 (56.0 mg, 0.172 mmol). Pd XPhos G2 (4.50 mg, 5.73 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 2 h, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide methyl fV)-(4-(3-(5-(methylcarbamoyl)pyridin-3-yl)-6-((tetrahydrofuran- 3-yl)oxy)imidazo[l,2-/>]pyridazin-7-yl)phenyl)carbamate (11.5 mg, 0.024 mmol, 41% yield). LCMS calculated for C25H25N6O5 (M+H)+: m/z = 489.2; found: 489.0.
Example 68.
(A)-A-Methyl-5-(7-(4-(4-methylpiperazin-l-yl)phenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)nicotinamide
Figure imgf000169_0001
A sample of (ri)-5-(7-chloro-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3- yl)-/V-methylnicotinamide (19.6 mg, 0.052 mmol, see Example 67, Step 1 ) was dissolved in dioxane (1.75 ml) and water (0.9 ml). This solution was treated with (4-(4-methylpiperazin-l- yl)phenyl)boronic acid (12.0 mg, 0.052 mmol) and CS2CO3 (51.0 mg, 0.16 mmol). Pd XPhos G2 (4.1 mg, 5.2 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-A-methyl-5-(7-(4-(4-methylpiperazin-l - yl)phenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)nicotinamide (14.4 mg, 0.028 mmol, 53% yield). LCMS calculated for C28H32Nv03(M+H)+: m/z = 514.3; found: 514.1.
Example 69.
3-(7-(l-(l,l-Dioxidotetrahydrothiophen-3-yl)-l//-pyrazol-4-yl)-6-(((A)-tetrahydrofuran-
3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-4,5-difluoro-/V-methylbenzamide
Figure imgf000170_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (19.2 mg, 0.047 mmol, see Example 21, Step 2) was dissolved in dioxane (1.6 ml) and water (0.8 ml). This solution was treated with 3-(4-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-l//-pyrazol- l -yl)tetrahydrothiophene 1,1 -dioxide (15.0 mg, 0.047 mmol) and CS2CO3 (46.0 mg, 0.14 mmol). Pd XPhos G2 (3.7 mg, 4.7 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide 3-(7-( l-( 1 , 1 -dioxidotetrahydrothiophen-3-yl)- l//-pyrazol-4-yl)-6-((fV)- tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-4,5-difluoro-/V-methylbenzamide
(4.8 mg, 0.009 mmol, 18% yield). LCMS calculated for C25H25F2N6O5S (M+H)+: m/z = 559.2; found: 559.0. Example 70.
(A)-3,4-Difluoro-A-methyl-5-(7-(l-(pyridin-2-yl)-l//-pyrazol-4-yl)-6-((tetrahydrofuran-
3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000171_0001
A sample of fV)-3 -(7-chi oro-6-((tetrahydrofuran-3-yi)oxy)i mi dazo[l ,2-/)]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (19.2 mg, 0.047 mmol, see Example 21, Step 2) was dissolved in dioxane (1.6 ml) and water (0.8 ml). This solution was treated with 2-(4-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-l//-pyrazol- l -yl (pyridine (13.0 mg, 0.05 mmol) and CS2CO3 (46.0 mg, 0.14 mmol). Pd XPhos G2 (3.7 mg, 4.7 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 2 hours, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4- difluoro-A-methyl-5-(7-(l -(pyridin-2-yl)-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (1.5 mg, 0.003 mmol, 6.2% yield). LCMS calculated for C26H22F2N7O3 (M+H)+: m/z = 518.2; found: 518.0.
Example 71.
(A)-3,4-Difluoro-A-methyl-5-(7-(l-(l-methylpiperidin-4-yl)-Li/-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000171_0002
Step 1. (S)-3, 4-Difluoro-N-methyl-5-(7-( 1 -(piperidin-4-yl)-lH-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide
Figure imgf000172_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i i dazo[ l ,2-/ ]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (61.2 mg, 0.150 mmol, see Example 21, Step 2) was dissolved in dioxane (5 ml) and water (2.50 ml). This solution was treated with fe/7-butyl 4-(4- (4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)- l//-pyrazol- 1 -yl (piperidine-! -carboxyl ate (0.056 g, 0.150 mmol) and CS2CO3 (146.0 mg, 0.449 mmol). Pd XPhos G2 (12.0 mg, 15.0 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 2 hours, LCMS indicated consumption of the starting material.
The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and the filtrate was concentrated in vacuo. The concentrate was dissolved in DCM (7.5 mL) and treated with HC1 in dioxane (4N, 10 mL). The solution was stirred at room temperature for 20 minutes, at which point LCMS indicated consumption of the intermediate. The solvent was removed by filtration and the crude product was triturated with EtOAc (three times) to provide fV)-3,4-difluoro-Af-methyl-5-(7-( l -(piperidin-4-yl)- 1 //- pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (82 mg, 0.156 mmol, mass was over theoretical yield, so quantitative yield was assumed). LCMS calculated for C26H28F2N7O3 (M+H)+: m/z = 524.2; found: 524.3.
Step 2. (S)-3, 4-Difluoro-N-methyl-5-(7-( l-(l -methylpiperidin-4-yl)-lH-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide
A sample of (ri)-3,4-difluoro-/V-methyl-5-(7-(l-(piperidin-4-yl)-li7-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (26.2 mg, 0.050 mmol) was dissolved in MeOH (4.0 ml). This solution was treated with formaldehyde in water (37 wt. %, 126 pL, 1.69 mmol) followed by sodium cyanoborohydride (10.0 mg, 0.159 mmol). The vial was capped and the solution was stirred at room temperature. After 2 hours, LCMS indicated consumption of the starting material. The reaction mixture was filtered, then purified by HPLC (pH = 2 method) to provide (ri)-3,4-difluoro-/V-methyl-5-(7-(l-(l-methylpiperidin- 4-yl)-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2-/)]pyridazin-3- yl)benzamide (4.7 mg, 0.009 mmol, 18% yield). LCMS calculated for C27H30F2N7O3 (M+H)+: m/z = 538.2; found: 538.4. Example 72.
(A)-3,4-Difluoro-A-methyl-5-(7-(pyridin-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- b ] pyridazin-3-yl)benzamide
Figure imgf000173_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (20.4 mg, 0.050 mmol, see Example 21, Step 2) was dissolved in dioxane (1.7 ml) and water (0.8 ml). This solution was treated with pyridin-4- ylboronic acid (6.13 mg, 0.050 mmol) and CS2CO3 (49.0 mg, 0.150 mmol). Pd XPhos G2 (3.9 mg, 5.0 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 1 hour, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro-A-methyl-5-(7-(pyridin-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (4.5 mg, 0.010 mmol, 20% yield). LCMS calculated for C23H20F2N5O3 (M+H)+: m/z = 452.2; found: 452.3.
Example 73.
(A)-4-(4-(3-(2,3-Difluoro-5-(methylcarbamoyl)phenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-7-yl)-Li/-pyrazol-l-yl)-AyV-dimethylpiperidine-l- carboxamide
Figure imgf000174_0001
A sample of (S)-3,4-difluoro-iV-methyl-5-(7-(l-(piperidin-4-yl)-li7-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[ 1 ,2-/)]pyridazin-3-yl)benzamide (22.0 mg, 0.042 mmol, see Example 71, Step 1 ) was dissolved in MeCN (1.9 ml). This solution was treated with Hiinig's base (37.0 mΐ, 0.21 mmol) followed by dimethylcarbamoyl chloride (7.7 mΐ, 0.08 mmol). The vial was capped and the solution was stirred at room temperature. After 2 hours, LCMS indicated consumption of the starting material. The reaction mixture was diluted with MeCN, then purified by HPLC (pH = 2 method) to provide fV)-4-(4-(3-(2,3-difluoro-5- (methyl carbamoyl )phenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2-A]pyridazin-7-yl)- 1 //- pyrazol-l-yl)-/V,/V-dimethylpiperidine-l -carboxamide (1.2 mg, 0.002 mmol, 4.8% yield). LCMS calculated for C29H33F2N8O4 (M+H)+: m/z = 595.3; found: 595.1.
Example 74.
(A)-3-(7-(l-(l-Acetylpiperidin-4-yl)-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-4,5-difluoro-A-methylbenzamide
Figure imgf000174_0002
A sample of (,S)-3,4-difluoro-/V-methyl-5-(7-(l-(piperidin-4-yl)-li7-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (22.0 mg, 0.042 mmol, see Example 71, Step 1 ) was dissolved in MeCN (1.9 ml). This solution was treated with Hiinig's base (37.0 mΐ, 0.210 mmol) followed by acetyl chloride (6.0 mΐ, 0.08 mmol). The vial was capped and the solution was stirred at room temperature. After 2 hours, LCMS indicated consumption of the starting material. The reaction mixture was diluted with MeCN, then purified by HPLC (pH = 2 method) to provide f V)-3 -(7-( 1 -( 1 -acetyl pi peri di n-4-y 1 )- 1 //-py razol - 4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-/>]pyridazin-3-yl)-4,5-difluoro-/V- methylbenzamide (3.7 mg, 0.007 mmol, 16% yield). LCMS calculated for C28H30F2N7O4 (M+H)+: m/z = 566.2; found: 566.1.
Example 75.
(A)-3,4-Difluoro-/V-methyl-5-(7-(l-(2-(2-oxopyrrolidin-l-yl)ethyl)-Li/-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)benzamide
Figure imgf000175_0001
A sample of fV)-3 -(7-chl oro-6-((tetrahydrofuran-3-yl)oxy)i mi dazo[ l ,2-/)]pyridazin-3- yl)-4,5-difluoro-/V-methylbenzamide (20.4 mg, 0.050 mmol, see Example 21, Step 2) was dissolved in dioxane (1.7 ml) and water (0.8 ml). This solution was treated with l-(2-(4- (4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)-l//-pyrazol-l -yl)ethyl)pyrrolidin-2-one (15.0 mg, 0.050 mmol) and CS2CO3 (49.0 mg, 0.150 mmol). Pd XPhos G2 (3.9 mg, 5.0 pmol) was added, the vial was capped, and the solution was stirred at 100 °C. After 90 minutes, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeOH, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-3,4-difluoro-A-methyl-5-(7-(l -(2-(2-oxopyrrolidin-l -yl )ethyl )- 1 //- pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)benzamide (5.6 mg, 0.010 mmol, 20% yield). LCMS calculated for C27H28F2N7O4 (M+H)+: m/z = 552.2; found: 552.1. Example 76.
(A)-3-(7-(l-(l-(AyV-Dimethylsulfamoyl)piperidin-4-yl)-Li/-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-6]pyridazin-3-yl)-4,5-difluoro-/V- methylbenzamide
Figure imgf000176_0001
A sample of (S)-3,4-difluoro-iV-methyl-5-(7-(l-(piperidin-4-yl)-li7-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l ,2-/)]pyridazin-3-yl)benzamide (22.0 mg, 0.042 mmol, see Example 71, Step 1 ) was dissolved in MeCN (1.9 ml). This solution was treated with Hiinig's base (37.0 mΐ, 0.210 mmol) followed by dimethyl sulfamoyl chloride (9.0 mΐ, 0.08 mmol). The vial was capped and the solution was stirred at room temperature. After 2 hours, LCMS indicated consumption of the starting material. The reaction mixture was diluted with MeCN, then purified by HPLC (pH = 2 method) to provide fV)-3-(7-(l -(1 -(N,N- dimethylsulfamoyl)piperidin-4-yl)-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)-4,5-difluoro-/V-methylbenzamide (2.1 mg, 0.003 mmol, 7.9% yield). LCMS calculated for C28H33F2N8O5S (M+H)+: m/z = 631.2; found: 631.1.
Example 77.
(A)-6-(7-(l-Isopropyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-
6]pyridazin-3-yl)isoindolin-l-one
Figure imgf000176_0002
Step 1. 3-Bromo-6-chloro- 7-(l -isopropyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b ] pyridazine
Figure imgf000177_0001
A sample of 3-bromo-6-chloro-7-iodoimidazo[l,2-/>]pyridazine (135 mg, 0.38 mmol, see Example 15, Step 4) was dissolved in dioxane (1.6 ml) and was treated with K2CO3 (104 mg, 0.78 mmol), water (0.3 ml), and l-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)-liT-pyrazole (125 mg, 0.53 mmol). This solution was degassed with bubbling nitrogen for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (44 mg, 0.038 mmol) was added, the vial was capped, and the solution was stirred at 120 °C. After 1.5 hours, LCMS indicated complete conversion to the product. The solution was cooled to room temperature and quenched with aqueous NLLCl, and extracted with EtOAc, then 25% /.s -propanol in chloroform. The combined organic fractions were dried over MgSCri, filtered, and concentrated in vacuo. The crude sample was purified by flash chromatography in 0-100% EtO Ac/hexanes to provide 3-bromo-6-chloro-7-( l -isopropyl- l//-pyrazol-4-yl)imidazo[ l ,2- b] pyridazine (98 mg, 0.29 mmol, 76% yield). LCMS calculated for Ci2Hi2BrClN5 (M+H)+: m/z = 340.0, 342.0; found: 340.0, 342.0.
Step 2. (S)-3-Bromo- 7-(l -isopropyl-lH-pyrazol-4-yl)-6-( ( tetrahydrofuran-3- yl)oxy)imidazo[ 1, 2-b ] pyridazine
Figure imgf000177_0002
A sample of 3-bromo-6-chloro-7-(l-isopropyl-lH-pyrazol-4-yl)imidazo[l,2- bjpyridazine (98 mg, 0.29 mmol) was dissolved in DMF (1.5 ml) and was treated with cesium carbonate (190 mg, 0.58 mmol) and fV)-tetrahydrofuran-3-ol (69 mΐ, 0.86 mmol). This solution was stirred at 90 °C. After 45 minutes, LCMS indicated near-complete conversion to fV)-3-bromo-7-(l-isopropyl-l//-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l ,2- Z>]pyridazine. The reaction mixture was used directly in Step 3. LCMS calculated for Ci6Hi9BrN502 (M+H)+: m/z = 392.1, 394.1; found: 392.1, 394.1. Step 3. (S)-6-(7-(l-Isopropyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[ 1, 2- b]pyridazin-3-yl)isoindolin-l-one
An aliquot of fV)-3-bromo-7-(l -isopropyl - l//-pyrazol-4-yl )-6-((tetrahydrofuran-3 - yl)oxy)imidazo[l,2-/>]pyridazine (27 mg, 0.069 mmol, from Step 2) in DMF (0.6 ml, and containing residual cesium carbonate) was treated with 6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)isoindolin-l-one (36 mg, 0.14 mmol) and water (0.15 ml). [1,1’- Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (6 mg, 7 pmol) was added, the vial was capped, and the solution was stirred at 90 °C. After 30 minutes, LCMS indicated consumption of the starting material. The solution was cooled to room temperature, diluted with MeCN and water, filtered through a SiliaPrep Thiol cartridge, and purified by HPLC (pH = 2 method) to provide fV)-6-(7-( l -isopropyl- l//-pyrazol-4-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-Z>]pyridazin-3-yl)isoindolin-l-one (13.5 mg, 0.030 mmol, 44% yield). LCMS calculated for C24H25N6O3 (M+H)+: m/z = 445.2; found: 445.2.
Example A: FGFR Enzymatic Assay
The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET measurements to detect product formation. Inhibitors were serially diluted in DMSO and a volume of 0.2 pL was transferred to the wells of a 384-well plate. A 5 pL/well volume of enzyme isoforms of FGFR (-1, -2, -3 wild-type and mutant isoforms, -4) including phosphorylated and un- phosphorylated proteins diluted in assay buffer (50 mM HEPES, 10 mM MgCh, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated with inhibitor for 5 to 15 minutes at ambient temperature. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate. The reaction was initiated by the addition of a 5 pL/well volume containing both biotinylated EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP in assay buffer. The 10 pL/well reaction concentration of the peptide substrate was 500 nM whereas the ATP concentration was maintained near or below the ATP Km. The ATP Km values were pre-determined in a separate series of experiments. The reaction plate was incubated at 25 °C for 1 hr and the reactions were ended with the addition of 5 pL/well of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 45 mM EDTA, 600 nM staurosporin, with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin). The plate was allowed to equilibrate for ~10 minutes at ambient temperature before scanning on a PheraStar plate reader (BMG Labtech) instrument. Either GraphPad prism or XLfit was used to analyze the data. The IC50 values were derived by fitting the data to a four parameter logistic equation producing a sigmoidal dose- response curve with a variable Hill coefficient. Prism equation: Y=Bottom + (Top- Bottom)/(l+10A((LogIC5o-X)*Hill slope)); XLfit equation: Y = (A+((B-A)/(1+((X/C)AD)))) where X is the logarithm of inhibitor concentration and Y is the response. Compounds having an IC50 of 1 mM or less are considered active.
Table 1 provides IC50 data for compounds of the disclosure assayed in the FGFR Enzymatic Assay after dilution in assay buffer, added to the plate and pre-incubated for 4 hours. The symbol: “+” indicates an IC50 less than 10 nM; “++” indicates an IC50 greater than or equal to 10 nM but less than 100 nM;
Figure imgf000179_0001
indicates an IC50 greater than or equal to
100 nM but less than 400 nM; and “++-H-” indicates an IC50 greater than or equal to 400 nM.
The data in Table 1 was measured in wild-type un-phosphorylated FGFR1, FGFR2, FGFR3 and FGFR4 protein.
Figure imgf000179_0002
Figure imgf000179_0003
Figure imgf000180_0001
Figure imgf000181_0001
Example B: Luminescent Viability Assay
RT112 cells are purchased from ATCC (Manassas, VA) and maintained in RPMI,
10% FBS (Gibco/Life Technologies). To measure the effect of test compounds on the viability of cells, the cells are plated with RPMI 10 % FBS (5xl03 cells/well/in 50 pL) into black 96-well Greiner polystyrene in the presence or absence of 50ul of a concentration range of test compounds. After 3 days, lOOul of CellTiter-Glo Reagent (Promega) is added. Luminescence is read with a TopCount (PerkinElmer). ICso determination is performed by fitting the curve of percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
Example C: pFGFR2 and pFGFRl,3 Functional Cell HTRF Assay
To measure phosphorylated Fibroblast Growth Factor Receptor 2 (FGFR2), KATOIII cells (Human Gastric Carcinoma) are purchased from ATCC and maintained in Iscove’s with 20% FBS (Gibco/Life Technologies). For the pFGFR2 assay, KATOIII cells are plated overnight in 5% FBS and Iscove’s medium at 5xl04 cells/well into Corning 96-well flat- bottom tissue culture treated plates. The next morning, 50 mΐ of fresh media with 0.5% FBS is incubated in the presence or absence of a concentration range of test compounds also at 50ul, for 1 hour at 37°C, 5% C02. Cell are washed with PBS, lysed with Cell Signaling Lysis Buffer with standard Protease inhibitors for 45 min at room temperature. 4 mΐ total of Cis Bio Anti Phospho-YAP d2 and Cis Bio Anti Phospho-YAP Cryptate together are added to the lysate and mixed well (following directions of the kit). 16 mΐ is then transferred to 384 well Greiner white plates and stored at 4°C overnight in the dark. Plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. ICso determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
To measure phosphorylated Fibroblast Growth Factor Receptor 3 (FGFR3), in house stable cell lines BAF3-TEL-FGFR1 or BAF3-TEL-FGFR3 are maintained in RPMI with 10% FBS and lug/ml puromycin (Gibco/Life Technologies). For the assay, 12nl of BAF3- TEL-FGFR1 or BAF3-TEL-FGFR3 cells in serum free and puromycin free RPMI media at 1 x 106 cell/ml are added to 384 Greiner white plate already containing 20nl dots of compounds at a concentration range. The plates are gently shaken (100 rpm) for 2 minutes at room temperature to mix well and incubate for 2 hours in a single layer at 37°C, 5% C02. 4 pl/well of 1/25 dilution of lysis buffer #3 (Cis Bio) is added with standard Protease inhibitors and shaken at 200 rpm at room temperature for 20 minutes. 4 mΐ total of the Cis Bio Tb-pFGFR Ab (10ng) and d2-FGFR3 (lng) together are added to the lysate and mixed well. The plates are sealed and incubated at room temperature overnight in the dark. The plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. ICso determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
Example D: pFGFR3 Functional Whole Blood HTRF Assay
To measure phosphorylated Fibroblast Growth Factor Receptor 3 (FGFR3) in a whole blood assay, in house stable cell lines BAF3-TEL-FGFR3 are maintained in RPMI with 10% FBS and 1 pg/ml puromycin (Gibco/Life Technologies). For the assay, lOOul BAF3-TEL- FGFR3 cells in 10% FBS and puromycin free RPMI media at 5 x 104 cell/well are added to fibronectin coated 96 well tissue culture plate (5ug/ml) overnight at 37°C, 5% C02. The next day, serum is separated from the top of the blood by a low speed spin, 1200, RPM, and heat inactivated by incubating at 56°C for 15 minutes. 30 mΐ of the cooled serum is added to a 96 well plate pre dotted with 70nM dots of compounds at a concentration range. Cell plates are washed gently with media, all the blood/compound mixture is added to the plates, and the plates are incubated for 2 hours at 37°C, 5% C02. Blood from the plate is gently washed twice by adding media to the side of the wells and then dumping media from the plate, and allowing the plate to briefly sit on a paper towel to drain. 70 mΐ/well of lx of lysis buffer #1 (Cis Bio) are added with standard Protease inhibitors, and are shaken at 400 rpm at room temperature for 30 minutes. Following lysis, the plate is spun down for 5 minutes and 16 uL of lysate is transferred into a 384-well small volume plate. 4 mΐ total of the Cis Bio Tb- pFGFR Ab (10ng) and d2-FGFR3 (lng) together are added to the lysate and mixed well. The plates are sealed and incubated at room temperature overnight in the dark. Plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. ICso determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software. Example E: KATOIII Whole Blood pFGFR2a ELISA Assay
To measure tyrosine-phosphorylated Fibroblast Growth Factor Receptor 2 alpha (FGFR2a) in KATO III spiked whole blood assay, KATO III cells are purchased from ATCC and maintained in Iscove’s medium with 20% FBS (Gibco/Life Technologies). To measure the inhibition of FGFR2a activity of test compounds, the cells are resuspended with Iscove’s, 0.2 % FBS at 5xl06 cells/ml. 50 μL of the cells are then spiked into a 96-deep well 2 ml polypropylene assay block (Costar,) in the presence or absence of a concentration range of test compounds and 300ul human heparinized whole blood (Biological Specialty Corp, Colmar PA). After 4 hours incubation in 37°C, the red cells are lysed using Qiagen EL buffer and the cell lysates are resuspended in lysis buffer (Cell Signaling) containing standard protease inhibitor cocktail (Calbiochem/EMD,) and PMSF (Sigma) for 30 minutes ice. The lysates are transferred to a standard V bottom propylene tissue culture plate and frozen overnight at -80°C. Samples are tested an in an R & D Systems DuoSet IC Human Phospho- FGF R2a ELISA and the plate is measured using a SpectraMax M5 microplate set to 450 nm with a wavelength correction of 540. ICso determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

What is claimed is:
1. A compound of Formula I:
Figure imgf000184_0001
I or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from ORal, SRal, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(0)NRclRdl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each independently selected from H, D, halo, CN, Ci-6 alkyl, ORa8 and NRcXRdx; wherein the Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50;
A is N or CRa;
RA is selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, halo, CN, N02, ORa, SRa, C(0)Rb, C(0)NRcRd, C(0)ORa, OC(0)Rb, OC(0)NRcRd, NRcRd, NRcC(0)Rb, NRcC(0)ORa, NRcC(0)NRcRd, NRcS(0)Rb, NRcS(0)2Rb, NRcS(0)2NRcRd, S(0)Rb, S(0)NRcRd, S(0)2Rb and S(0)2NRcRd; wherein said Ci-e alkyl, C2-e alkenyl and C2-e alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R6;
R6 is selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, halo,
CN, NO2, ORa12, SRa12, C(0)Rb12, C(0)NRcl2Rd12, C(0)0Ra12, 0C(0)Rb12, 0C(0)NRcl2Rd12, NRcl2Rd12, NRcl2C(0)Rb12, NRcl2C(0)0Ra12, NRcl2C(0)NRcl2Rd12, NRcl2S(0)Rb12, NRcl2S(0)2Rb12, NRcl2S(0)2NRcl2Rd12, S(0)Rb12, S(0)NRcl2Rd12, S(0)2Rb12 and S(0)2NRcl2Rd12; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)0Ra3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)0Ra3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each R11 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)0Ra5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NORa2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl- Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on the R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)RM, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each R22 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)0Ra6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, C(=NRe9)Rb9, C(=NORa9)Rb9, C(=NRe9)NRc9Rd9, NRc9C(=NRe9)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-C 1-3 alkylene, 5-10 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, NRcl0C(O)ORal°, NRcl0S(O)Rbl°, NRcl0S(O)2Rbl°, NRcl0S(O)2NRcl0Rdl°, S(0)Rbl°, S(O)NRcl0Rdl°, S(0)2Rbl°, and S(O)2NRcl0Rdl°; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each R52 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORa11, SRa11, C(0)Rbu, C(0)NRcllRdu, C(0)0Ra11, NRcllRdu, NRcllC(0)Rbu, NRcllC(0)0Ra11, NRcllS(0)Rbu, NRcllS(0)2Rbu, NRcllS(0)2NRcllRdu, S(0)Rbu, S(0)NRcllRdu, S(0)2Rbu, and S(0)2NRcllRdu; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-C 1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra, Rc, and Rd is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R6; each Rb is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R6; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 4-10 membered heterocycloalkyl-Ci-3 alkylene is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Re2 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R11; each Rb3 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R22; each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each Ra5, Rc5 and Rd5 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rb5 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra6, Rc6 and Rd6 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rc6 and Rd6 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rb6 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra8, Rc8 and Rd8 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Re9 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R52; each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each Ral1, Rcl1 and Rdu is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rcl1 and Rdu attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rbu is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ral2, Rcl2, and Rdl2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2- 6 alkynyl, and Ci-6haloalkyl,; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rbl2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; and each Rg is independently selected from D, OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Ci-2 alkylene, Ci-6 alkoxy, Ci-6haloalkoxy, C1-3 alkoxy-Ci-3 alkyl, C1-3 alkoxy-Ci-3 alkoxy, HO-C1-3 alkoxy, HO- Ci-3 alkyl, cyano-Ci-3 alkyl, H2N-C1-3 alkyl, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, Ci-6 alkylthio, Ci-6 alkylsulfmyl, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci-6 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci-6 alkoxycarbonylamino, Ci-6 alkylcarbonyloxy, aminocarbonyloxy, Ci-6 alkylaminocarbonyloxy, di(Ci-6 alkyl)aminocarbonyloxy, Ci-6 alkylsulfonylamino, aminosulfonyl, Ci-6 alkylaminosulfonyl, di(Ci-6 alkyl)aminosulfonyl, aminosulfonylamino, Ci-6 alkylaminosulfonylamino, di(Ci-6 alkyl)aminosulfonylamino, aminocarbonylamino, Ci-6 alkylaminocarbonylamino, and di(Ci-6 alkyl)aminocarbonylamino; provided that a compound of Formula I is other than
3-(2-benzofuranyl)-6-[3-(methylsulfonyl)propoxy]-7-phenyl-imidazo[l,2-b]pyridazine; 2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]propanoic acid;
2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]-propanoic acid, ethyl ester;
4-[6-( 1 -cyanoethoxy)-7-( 1 -methyl- lH-pyrazol-4-yl)imidazo[ 1 ,2-a]pyri din-3 -yl]-N- cyclopropyl-2-(difluoromethoxy)-6-methoxy-benzamide;
N-cyclopropyl-2-(difluoromethoxy)-6-methoxy-4-[7-(l-methyl-lH-pyrazol-4-yl)-6-
(phenylmethoxy)imidazo[l,2-a]pyridin-3-yl]-benzamide;
2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]-acetic acid; and
2-[[3-[4-[(cyclopropylamino)carbonyl]-3-(difluoromethoxy)-5-methoxyphenyl]-7-(l-methyl- lH-pyrazol-4-yl)imidazo[l,2-a]pyridin-6-yl]oxy]-acetic acid, ethyl ester.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is N.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from ORal and NRclRdl.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1 is ORal.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein each Ral is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, and C6-10 aryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, and C6-10 aryl-Ci-3 alkylene, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10.
6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein Ral is selected from methyl, ethy, isopropyl, cyclobutyl, benzyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, oxetanyl, oxopyrrolidinyl, azetidinyl, and tetrahydropyranyl; wherein methyl, ethy, isopropyl, cyclobutyl, benzyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, oxetanyl, oxopyrrolidinyl, azetidinyl, and tetrahydropyranyl are each optionally substituted with with 1 or 2 substituents independently selected from R10 .
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, and NRc3C(0)Rb3.
8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each R10 is independently selected from Ci-6 alkyl, C6-10 aryl, CN, ORa3, C(0)Rb3, and NRc3Rd3.
9. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each R10 is independently selected from methyl, methoxy, methylcarbonyl, CN, phenyl, and amino.
10. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein Ral is selected from methyl, ethy, isopropyl, 3-cyanocyclobutyl, benzyl, phenyl, methoxyethyl, dimethylaminoethyl, tetrahydrofuran-3-yl, pyrrolidin-3-yl, 1- methylpyrrolidin-3-yl, oxetan-3-yl, 2-oxopyrrolidin-3-yl, l-methyl-2-oxopyrrolidin-3-yl, 1- acetylazeti din-3 -yl, and tetrahydo-2H-pyran-4-yl.
11. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein Ral is methyl.
12. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein Ral is tetrahydrofuranyl.
13. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1 is NRclRdl.
14. The compound of any one of claims 1-3 and 13, or a pharmaceutically acceptable salt thereof, wherein each Rcl and Rdl is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, and 4-10 membered heterocycloalkyl; wherein said Ci-6 alkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10.
15. The compound of any one of claims 1-3 and 13, or a pharmaceutically acceptable salt thereof, wherein one of Rcl and Rdl is H and the other is methyl or tetrahydrofuranyl.
16. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from methoxy, ethoxy, isopropoxy, 3-cyanocyclobutoxy, benzyloxy, phenoxy, 2-methoxyethoxy, (dimethylamino)ethoxy, (tetrahydrofuran-3-yl)oxy, pyrrolidin-3-yloxy, (l-methylpyrrolidin-3-yl)oxy, oxetan-3-yloxy, 2-oxopyrrolidin-3-yloxy, (l-methyl-2-oxopyrrolidin-3-yl)oxy, (l-acetylazetidin-3-yl)oxy, (tetrahydo-2H-pyran-4- yl)oxy, (tetrahydrofuran-3-yl)amino, and methylamino.
17. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R1 is methoxy.
18. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R1 is (tetrahydrofuran-3-yl)oxy.
19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5- 10 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R20.
20. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R2 is phenyl, pyrazolyl, pyridinyl, or pyrazolopyridinyl; and wherein phenyl, pyrazolyl, pyridyl, and pyrazolopyridinyl are each optionally substituted with 1 or 2 substituents independently selected from R20.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R21; or any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1 or 2 substituents independently selected from R21.
22. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein each R20 is independently selected from Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, halo, CN, C(0)NRc2Rd2, and NRc2C(0)0Ra2; wherein the 4-6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-Ci-3 alkylene, and phenyl-Ci-3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R21.
23. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21.
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)0Ra4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)0Ra4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R22.
25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein each R21 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, CN, ORa4, C(0)Rb4, C(0)NRc4Rd4, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group.
26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R21is CN, pyridinyl, morpholinyl, hydroxy, methyl, N,N- dimethylaminocarbonyl, acetyl, oxopyrrolidinyl, or /V,/V-dimethylsulfamoyl.
27. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R20 is methyl, isopropyl, propanyl, cyclobutyl, oxetanyl, cyanopropanyl, pyridinylmethyl, morpholinoethyl, CN, pyrrolidinyl, oxopyrrolidinyl, hydroxylcyclohexyl, hydroxypropanyl, fluoro, methylcarbamoyl, methylhydroxypropanyl, methoxycarbonylamino, methylpiperazinyl, dioxidotetrahydrothiophenyl, pyridinyl, methylpiperidinyl, (N,N-dimethylaminocarbonyl)piperidinyl, acetylpiperidinyl, oxopyrrolidinylethyl, or (/V,/V-dimethylsulfamoyl)piperidinyl; or any two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused cyclopentyl ring or a fused piperidinyl.
28. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R2 is 1 -methyl- l /-pyrazol-4-yl, 6-methylpyri din-3 -yl, 5,6-dihydro-4//- pyrrolo[l,2-6]pyrazol-3-yl, 1 -(oxetan-3 -yl )- l//-py razol -4-yl, 1 -i sopropyl - 1 //-py razol -4-y 1 , 1- cyclobutyl- l /-pyrazol-4-yl, 1 -(2-cyanopropan-2-yl)- 1 //-py razol -4-yl, (pyrazolo[ 1,5- a]pyri din-3 -yl), 1 -(pyri din-3-yl methyl )- l//-pyrazol-4-yl, 1 -(2-morphol i noethyl )- l//-pyrazol- 4-yl, 3-cyano-4-methylphenyl, 6-(pyrrolidin-l-yl)pyri din-3 -yl, 6-(2-oxopyrrolidin-l- yl)pyridin-3-yl, ( 1 /,45')-4-hy droxy cy cl ohexy 1 - 1 //-py razol -4-yl , 6-(2-hydroxypropan-2- yl)pyridin-3-yl, 3-fluoro-4-(methylcarbamoyl)phenyl, l-(2-methyl-2-hydroxypropanyl)-lH- pyrazol-4-yl, 4-(methoxycarbonylamino)phenyl, 4-(4-methylpiperazin-l-yl)phenyl, 1-(1,1- dioxidotetrahydrothiophen-3 -yl)- lH-pyrazol-4-yl, 1 -(pyri din-2 -yl)- l//-py razol -4-yl, 1 -(1 - m ethy 1 pi peri din-4-yl)-l//-py razol -4-yl, pyridin-4-yl, 1-((N,N- dimethylaminocarbonyl)piperidin-4-yl)-lH-pyrazol-4-yl, l-(acetylpiperidin-4-yl)-lH- pyrazol-4-yl, 1 -(2-(2-oxopyrrolidin-l -yl)ethyl)-l//-py razol -4-yl, or l-(l-(N,N- dimethylsulfamoyl)piperidin-4-yl)-li/-pyrazol-4-yl.
29. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R2 is l-methyl-lH-pyrazol-4-yl.
30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are both H.
31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5- 10 membered heteroaryl has at least one ring -forming carbon atom and 1, 2, 3, or 4 ring forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R50.
32. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein R5 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R50.
33. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein R5 is pyridinyl, quinolinyl, indazolyl, or benzoisoxazolyl; and wherein pyridinyl, quinolinyl, indazolyl, benzoisoxazolyl, and isoindolinonyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R50.
34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R51; or any two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, or 6-membered heterocycloalkyl ring; wherein each fused 4-, 5-, or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R51.
35. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein each R50 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl -C 1-3 alkylene, halo, D, CN, ORa9, C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl-Ci-3 alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R51.
36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, and Ci-6 haloalkyl.
37. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein any two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, or 6-membered heterocycloalkyl ring; wherein each fused 4-, 5-, or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, or 6-membered heterocycloalkyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R51.
38. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein each R50 is independently selected from methyl, propanyl, cyclopropyl, morpholinyl, phenyl, triazolyl, pyrrolidinylmethyl, pyrazolyl, fluoro, methoxy, ethyoxy, CN, methylaminocarbonyl, methylcarbonylamino, dimethylamino, (2,2,2- trifluoroethyljami nocarbonyl, difluoromethyl, and methylaminosulfonyl; wherein said methyl, propanyl, cyclopropyl, morpholinyl, phenyl, triazolyl, pyrrolidinylmethyl, pyrazolyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R51; or any two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused oxopyrrolidinyl; and wherein the fused oxopyrrolidinyl ring is optionally substituted with 1, 2 or 3 substituents independently selected from R51.
39. The compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, wherein each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, and ORal°.
40. The compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, wherein each R51 is independently selected from Ci-6 alkyl, 4-6 membered heterocycloalkyl, halo, D, CN, and ORal°.
41. The compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, wherein each R51 is independently selected from methyl, pyrrolidinyl, fluoro, CN, or hydroxy.
42. The compound of any one of claims 1, 5-12, 14-16, and 19-41, wherein the compound is a compound of Formula Ila or Formula lib:
Figure imgf000202_0001
or a pharmaceutically acceptable salt thereof.
43. The compound of any one of claims 1, 5-12, 14-16, 19-29, and 31-41, wherein the compound is a compound of Formula Ilia or Formula Illb:
Figure imgf000202_0002
or a pharmaceutically acceptable salt thereof.
44. The compound of any one of claims 1, 7-9, 19-29, and 31-41, wherein the compound is a compound of Formula IVa, Formula IVb, or Formula IVc:
Figure imgf000202_0003
or a pharmaceutically acceptable salt thereof.
45. The compound of any one of claims 1, 5-12, 21-27, and 31-41, wherein the compound is a compound of Formula Va, Formula Vb, or Formula Vc:
Figure imgf000203_0001
or a pharmaceutically acceptable salt thereof.
46. The compound of any one of claims 1, 5-12, 19-29, and 34-41, wherein the compound is a compound of Formula Via or Formula VIb:
Figure imgf000203_0002
or a pharmaceutically acceptable salt thereof.
47. The compound of any one of claims 1, 5-12, 19-29, and 34-41, wherein the compound is a compound of Formula Vila or Formula Vllb:
Figure imgf000203_0003
or a pharmaceutically acceptable salt thereof.
48. The compound of claim 1, wherein:
R1 is selected from ORal, SRal, 0C(0)Rbl, 0C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)0Ral, NRclC(0)NRclRdl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each independently selected from H, D, halo, CN, Ci-6 alkyl, ORa8 and NRcXRdx; wherein the Ci-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50;
Ais N; each R10 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)0Ra3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, and S(0)2NRc3Rd3; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each R11 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)0Ra5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R20 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa2, SR32, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NORa2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl- Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRc4S(0)RM, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R22; each R22 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-Ci-3 alkylene, halo, D, CN, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)0Ra6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each R50 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-Ci-3 alkylene, halo, D, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, C(=NRe9)Rb9, C(=NORa9)Rb9, C(=NRe9)NRc9Rd9, NRc9C(=NRe9)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused C3-6 cycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7- membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- io aryl-Ci-3 alkylene, 5-10 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORal°, SRal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, NRcl0C(O)ORal°, NRcl0S(O)Rbl°, NRcl0S(O)2Rbl°, NRcl0S(O)2NRcl0Rdl°, S(0)Rbl°, S(O)NRcl0Rdl°, S(0)2Rbl°, and S(O)2NRcl0Rdl°; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each R52 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, 5-6 membered heteroaryl-C 1-3 alkylene, halo, D, CN, ORa11, SRa11, C(0)Rbu, C(0)NRcllRdu, C(0)ORa11, NRcllRdu, NRcllC(0)Rbu, NRcllC(0)ORa11, NRcllS(0)Rbu, NRcllS(0)2Rbu, NRcllS(0)2NRcllRdu, S(0)Rbu, S(0)NRcllRdu, S(0)2Rbu, and S(0)2NRcllRdu; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-C 1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 4-10 membered heterocycloalkyl-C 1-3 alkylene is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6- 10 aryl -C 1-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Re2 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R11; each Rb3 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-C 1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R22; each Rb4 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22; each Ra5, Rc5 and Rd5 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and Ci-6haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rb5 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra6, Rc6 and Rd6 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rc6 and Rd6 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rb6 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra8, Rc8 and Rd8 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 memberedheterocycloalkyl-Ci-3 alkylene, C6- 10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl, C2- 6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-Ci-3 alkylene, 4-10 membered heterocycloalkyl-Ci-3 alkylene, C6-10 aryl-Ci-3 alkylene, and 5-10 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Re9 is independently selected from H, CN, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkylthio, Ci-6 alkylsulfonyl, Ci-6 alkylcarbonyl, Ci-6 alkylaminosulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, aminosulfonyl, Ci-6 alkylaminosulfonyl and di(Ci-6 alkyl)aminosulfonyl; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl -C1-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl-Ci-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R52; each Rbl° is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene; wherein said Ci-6 alkyl C2-6 alkenyl, C2- 6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6cycloalkyl-Ci-3 alkylene, 4-7 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci-3 alkylene, and 5-6 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R52; each Ral1, Rcl1 and Rdu is independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C 1-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or any Rcl1 and Rdu attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rbu is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; and each Rg is independently selected from D, OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Ci-2 alkylene, Ci-6 alkoxy, Ci-6haloalkoxy, C1-3 alkoxy-Ci-3 alkyl, C1-3 alkoxy-Ci-3 alkoxy, HO-C1-3 alkoxy, HO- Ci-3 alkyl, cyano-Ci-3 alkyl, H2N-C1-3 alkyl, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, Ci-6 alkylthio, Ci-6 alkylsulfmyl, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci-6 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci-6 alkoxycarbonylamino, Ci-6 alkylcarbonyloxy, aminocarbonyloxy, Ci-6 alkylaminocarbonyloxy, di(Ci-6 alkyl)aminocarbonyloxy, Ci-6 alkylsulfonylamino, aminosulfonyl, Ci-6 alkylaminosulfonyl, di(Ci-6 alkyl)aminosulfonyl, aminosulfonylamino, Ci-6 alkylaminosulfonylamino, di(Ci-6 alkyl)aminosulfonylamino, aminocarbonylamino, Ci-6 alkylaminocarbonylamino, and di(Ci-6 alkyl)aminocarbonylamino.
49. The compound of claim 1, wherein:
R1 is selected from ORal, and NRclRdl;
R2 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R20;
R3 and R4 are each H;
R5 is selected from C6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R50;
Ais N; each R10 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)0Ra3, NRc3Rd3, and NRc3C(0)Rb3; each R20 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, 0C(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)0Ra2, NRc2C(0)NRc2Rd2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein the 4-10 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized to form N-oxide or sulfonyl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or two adjacent R20 substituents on R2 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring,; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each R21 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)0Ra4, NRC4S(0)2Rm, NRc4S(0)2NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; each R50 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-io aryl, 5-10 membered heteroaryl, halo, D, CN, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, 0C(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)0Ra9, NRc9C(0)NRc9Rd9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)2Rb9, and S(0)2NRc9Rd9; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6- 10 aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or two adjacent R50 substituents on the R5 ring, taken together with the atoms to which they are attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 4-, 5-,
6- or 7-membered heterocycloalkyl ring is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each R51 is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, 5-10 membered heteroaryl, halo, D, CN, ORal°, C(0)Rbl°, C(O)NRcl0Rdl°, C(0)ORal°, NRcl0Rdl°, NRcl0C(O)Rbl°, and S(0)2Rbl°; each Ral, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3- 10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; or any Rcl and Rdl attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10; each Rbl is independently selected from Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10; each R32, Rc2 and Rd2 is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5- 10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21; each Rb2 is independently selected from Ci-6 alkyl, Ci-6haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; each Ra3, Rc3 and Rd3 is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb3 is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; each Ra4, Rc4 and Rd4 is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; each Rb4 is independently selected from Ci-6 alkyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; each Ra9, Rc9 and Rd9 is independently selected from H, Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-io aryl, and 5- 10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; or any Rc9 and Rd9 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, 3 or 4 substituents independently selected from R51; each Rb9 is independently selected from Ci-6 alkyl, C 1-6 haloalkyl, C3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl; wherein said Ci-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-ioaryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R51; each Ral°, Rcl° and Rdl° is independently selected from H, Ci-6 alkyl, Ci-6haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; or any Rcl° and Rdl° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and each Rbl° is independently selected from Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl.
50. The compound of claim 1, wherein the compound is selected from:
3-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[ l,2-a]pyri dine-3-yl)-N- methy lb enzami de,
3-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1, 2-b]pyridazin-3-yl)-N- methy lb enzami de,
6-Methoxy-7-(l-methyl-lH-pyrazol-4-yl)-3-(5-methylpyridin-3-yl)imidazo[l,2- bjpyridazine,
5-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3-yl)-N- methylnicotinamide,
6-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3-yl)quinol one,
4-(3-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l, 2-b]pyridazin-3- yl)phenyl)morpholine,
2-(3-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l, 2-b]pyridazin-3- yl)phenyl)acetonitrile,
3-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3-yl)-N- methylbenzenesulfonamide,
2-(3-(6-Methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l, 2-b]pyridazin-3- yl)phenyl)propan-2-ol,
N-(3-(6-Methoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)phenyl)acetamide,
2,,4’-Difluoro-5-(6-methoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin- 3 -yl)-N-methyl-[ 1 , -biphenyl]-3 -carboxamide,
4-Methoxy-3-(6-methoxy-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)-N-methylbenzamide, 4-Cyano-3-(6-methoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3-yl)- N -methy lb enzami de,
4-Fluoro-3-(6-methoxy-7-(l -methyl- lH-pyrazol -4-yl)imidazo[l, 2-b]pyridazin-3-yl)- N-(2,2,2-trifluoroethyl)benzamide,
N-Methyl-5-(7-(l -methyl- lH-pyrazol-4-yl)-6-(oxetan-3-yloxy)imidazo[ 1,2- b]pyridazin-3-yl)nicotinamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l -methyl- lH-pyrazol-4-yl)-6-((l-methylpyrrc>lidin-
3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l -methyl- lH-pyrazol-4-yl)-6-(pyrrolidin-3- yloxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l -methyl- lH-pyrazol-4-yl)-6-((2-oxopyrrc>lidin-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)amino)imidazo[l,2-b]pyridazin-3-yl)benzamide,
3,4-Difluoro-5-(6-(2-methoxyethoxy)-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2- b]pyridazin-3-yl)-N-methylbenzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(6-methylpyridin-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(7-(5,6-Dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-4,5-difluoro-N-methylbenzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l-(oxetan-3-yl)-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-5-(7-(l-isopropyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-N-methylbenzamide,
(S)-3-(7-(l-Cyclobutyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- b]pyridazin-3-yl)-4,5-difluoro-N-methylbenzamide,
(S)-3-(7-(l-(2-Cyanopropan-2-yl)-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-5-(difluoromethyl)-4-fluoro-N-methylbenzamide,
(S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(7-(pyrazolo[l,5-a]pyridin-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(6-((tetrahydrofuran-3-yl)oxy)-7-
(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(7-(l-(pyridin-3-ylmethyl)-lH-pyrazol-
4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide, (S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(7-(l-(2-morpholinoethyl)-lH-pyrazol-
4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(7-(3-Cyano-4-methylphenyl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- b]pyridazin-3-yl)-5-(difluoromethyl)-4-fluoro-N-methylbenzamide,
(S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(7-(6-(pyrrolidin-l-yl)pyridin-3-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(7-(6-(2-oxopynOlidin-l-yl)pyridin-3- yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
3-(Difluoromethyl)-4-fluoro-5-(7-(l -((lr,4S)-4-hy droxy cyclohexyl)- lH-pyrazol-4- yl)-6-(((S)-tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-N-methylbenzamide, (S)-3-(Difluoromethyl)-4-fluoro-5-(7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-6- ((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-N-methylbenzamide,
(S)-3-(Difluoromethyl)-4-fluoro-5-(7-(3-fluoro-4-(methylcarbamoyl)phenyl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-N-methylbenzamide,
(S)-3-(Dimethylamino)-4-fluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-Cyclopropyl-4-fluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(2 -Fluoro-3-methyl-5-(l -methyl- IFF 1,2, 3-triazol-4-yl)phenyl)-7-(l -methyl- 1F1- pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazine,
(S)-4-Fluoro-3-(hydroxymethyl)-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(Difluoromethyl)-4-fluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-4-Fluoro-N,3-dimethyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(Cyanomethyl)-4-fluoro-N-methyl-5-(7-(l-methyl-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-4-Fluoro-N-methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1 ,2-b]pyridazin-3 -yl)-5-(pyrrolidin- 1 -ylmethyl)benzamide,
(S)-3 -(2, 3 -Difluorophenyl)-7-( 1 -i sopropyl- 1 H-pyrazol-4-yl)-6-((tetrahy drofuran-3 - yl)oxy)imidazo[ 1 ,2-b]pyridazine, (S)-3-(3-Ethoxyphenyl)-7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1 ,2-b]pyridazine,
(S)-l-(4-(3-(2',4'-Difluoro-[l,r-biphenyl]-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1 ,2-b]pyridazin-7-yl)- lH-pyrazol- 1 -yl)-2-methylpropan-2-ol,
5-(6-ethoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3-yl)-N- methylnicotinamide,
5-(6-(2,2-Difluoroethoxy)-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)-N-methylnicotinamide,
5-(6-Isopropoxy-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3-yl)-N- methylnicotinamide,
N-Methyl-5-(7-(l -methyl- lH-pyrazol-4-yl)-6-phenoxyimidazo[l, 2-b]pyridazin-3- yl)nicotinamide,
5-(6-(Benzyloxy)-7-(l -methyl- lH-pyrazol-4-yl)imidazo[l, 2-b]pyridazin-3-yl)-N- methylnicotinamide,
5-(6-(2-(Dimethylamino)ethoxy)-7-(l -methyl- lH-pyrazol-4-yl)imidazo[ 1,2- b]pyridazin-3-yl)-N-methylnicotinamide,
N-Methyl-5-(7-(l -methyl- lH-pyrazol-4-yl)-6-(methylamino)imidazo[l,2-b]pyridazin- 3-yl)nicotinamide,
3-(6-(3-Cyanocyclobutoxy)-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2-b]pyridazin-3- yl)-N-methylbenzamide,
N-Methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
N-Methyl-3-(7-(l -methyl- lH-pyrazol-4-yl)-6-(oxetan-3-yloxy)imidazo[ 1,2- b]pyridazin-3-yl)benzamide,
3-(6-((l-Acetylazetidin-3-yl)oxy)-7-(l-methyl-lH-pyrazol-4-yl)imidazo[l,2- b]pyridazin-3-yl)-N-methylbenzamide,
N-Methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((l-methyl-2-oxopyrrolidin-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
3 -(3 -( 1 H-Pyrazol- 1 -yl)phenyl)-7-( 1 -methyl- 1 H-pyrazol-4-yl)-6-(oxetan-3 - yloxy)imidazo[l,2-b]pyridazine,
N-Methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydro-2H-pyran-4- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-N-Methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide, (R)-N-Methyl-3-(7-(l-methyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
3-(l -Methyl-lH-indazol-6-yl)-7-(l -methyl- lH-pyrazol-4-yl)-6-((tetrahy drofuran-3- yl)oxy)imidazo[ 1 ,2-b]pyridazine,
5-(7-(l -Methyl- lH-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[ 1 ,2- b]pyridazin-3-yl)benzo[d]isoxazole,
Methyl (S)-(4-(3-(5-(Methylcarbamoyl)pyridin-3-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-7-yl)phenyl)carbamate,
(S)-N-Methyl-5-(7-(4-(4-methylpiperazin-l-yl)phenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)nicotinamide,
3-(7-(l-(l,l-Dioxidotetrahydrothiophen-3-yl)-lH-pyrazol-4-yl)-6-(((S)- tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-4,5-difluoro-N-methylbenzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l-(pyridin-2-yl)-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)-6-
((tetrahydrofuran-3-yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(pyridin-4-yl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-4-(4-(3-(2,3-Difluoro-5-(methylcarbamoyl)phenyl)-6-((tetrahydrofuran-3- yl)oxy)imidazo[ 1 ,2-b]pyridazin-7-yl)- lH-pyrazol- 1 -yl)-N,N-dimethylpiperidine- 1 - carboxamide,
(S)-3 -(7-( 1 -( 1 - Acetylpiperidin-4-yl)- 1 H-pyrazol-4-yl)-6-((tetrahy drofuran-3 - yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-4,5-difluoro-N-methylbenzamide,
(S)-3,4-Difluoro-N-methyl-5-(7-(l-(2-(2-oxopyrrolidin-l-yl)ethyl)-lH-pyrazol-4-yl)- 6-((tetrahy drofuran-3 -yl)oxy)imidazo[l,2-b]pyridazin-3-yl)benzamide,
(S)-3-(7-(l-(l-(N,N-Dimethylsulfamoyl)piperidin-4-yl)-lH-pyrazol-4-yl)-6- ((tetrahy drofuran-3 -yl)oxy)imidazo[l,2-b]pyridazin-3-yl)-4,5-difluoro-N-methylbenzamide, and
(S)-6-(7-(l-Isopropyl-lH-pyrazol-4-yl)-6-((tetrahydrofuran-3-yl)oxy)imidazo[l,2- b]pyridazin-3 -yl)isoindolin- 1 -one, or a pharmaceutically acceptable salt thereof.
51. A pharmaceutical composition comprising a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
52. A method of inhibiting an FGFR3 enzyme comprising contacting said enzyme with a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51.
53. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51.
54. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51, in combination with another therapy or therapeutic agent.
55. The method of claim 53 or 54, wherein said cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin’s or non-Hodgkin’s lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.
56. The method of claim 53 or 54 wherein said cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.
57. A method for treating a skeletal or chondrocyte disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-50 or a pharmaceutically acceptable salt thereof, or a composition of claim 51.
58. The method of claim 57 wherein said skeletal or chondrocyte disorder is selected from achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.
PCT/US2021/013438 2020-01-15 2021-01-14 Bicyclic heterocycles as fgfr inhibitors Ceased WO2021146424A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961538P 2020-01-15 2020-01-15
US62/961,538 2020-01-15

Publications (1)

Publication Number Publication Date
WO2021146424A1 true WO2021146424A1 (en) 2021-07-22

Family

ID=74759442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/013438 Ceased WO2021146424A1 (en) 2020-01-15 2021-01-14 Bicyclic heterocycles as fgfr inhibitors

Country Status (2)

Country Link
US (1) US12012409B2 (en)
WO (1) WO2021146424A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125503C2 (en) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Substituted tricyclic compounds as fgfr inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
PE20210919A1 (en) 2018-05-04 2021-05-19 Incyte Corp SALTS FROM A FGFR INHIBITOR
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (en) 2019-12-04 2025-08-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
PE20221504A1 (en) 2019-12-04 2022-09-30 Incyte Corp DERIVATIVES OF AN FGFR INHIBITOR
CA3176337A1 (en) * 2020-04-21 2021-10-28 Peter King Rna-binding protein multimerization inhibitors and methods of use thereof
TW202304459A (en) 2021-04-12 2023-02-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (en) 2021-06-09 2023-04-01 美商英塞特公司 Tricyclic heterocycles as fgfr inhibitors
WO2025199359A1 (en) * 2024-03-21 2025-09-25 The Translational Genomics Research Institute Methods of modulating cdk7 and flt3 using fused bicyclic compounds

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2008078091A1 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
WO2008078100A2 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2009050183A2 (en) * 2007-10-17 2009-04-23 Novartis Ag Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
WO2009150240A1 (en) * 2008-06-13 2009-12-17 Astex Therapeutics Limited Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
WO2010119285A1 (en) * 2009-04-15 2010-10-21 Astex Therapeutics Limited Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013041634A1 (en) * 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2014011900A2 (en) * 2012-07-11 2014-01-16 Blueprint Medicines Inhibitors of the fibroblast growth factor receptor
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170362253A1 (en) 2016-06-20 2017-12-21 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Family Cites Families (786)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280853C (en)
US850370A (en) 1906-06-05 1907-04-16 William L Hynes Water-automobile.
DE2156720A1 (en) 1971-11-16 1973-05-24 Bayer Ag Pyrimido(4,5-d) pyrimidines - prepd from polychloroalkylimino acid chloride and 4-amino uracils, are starting materials for plant
US3894021A (en) 1974-01-28 1975-07-08 Squibb & Sons Inc Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS522706Y2 (en) 1974-07-31 1977-01-21
US4347348A (en) 1978-06-05 1982-08-31 Chernikhov Alexei Y Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (en) 1978-06-13 1980-01-11 Chernikhov Alexei Heat-stable heterocyclic polymer prepn. - by reacting polyfunctional nitrile with polyfunctional isocyanate opt. contg. silicon, halogen, nitrogen, phosphorus and/or boron atoms
CH635828A5 (en) 1978-08-30 1983-04-29 Ciba Geigy Ag N-SUBSTITUTED IMIDES AND BISIMIDS.
CH641470A5 (en) 1978-08-30 1984-02-29 Ciba Geigy Ag SILANES CONTAINING IMID GROUPS.
US4339267A (en) 1980-01-18 1982-07-13 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4405519A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Di-Acetylene-terminated polyimide derivatives
US4405786A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4402878A (en) 1980-10-22 1983-09-06 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4460773A (en) 1982-02-05 1984-07-17 Lion Corporation 1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
DE3432983A1 (en) 1983-09-07 1985-04-18 Lion Corp., Tokio/Tokyo 1,5-disubstituted 1H-pyrazolo[3,4-b]pyrazine derivatives and antitumour agents which contain them
JPS62273979A (en) 1986-05-21 1987-11-28 Lion Corp 1,5-substituted-1H-pyrazolo[3,4-b]pyrazine derivatives and antitumor agents containing the compounds
JPS6310630A (en) 1986-06-23 1988-01-18 Teijin Ltd Production of aromatic polyamide-imide ether
JPS6317882A (en) 1986-07-09 1988-01-25 Lion Corp 5-substituted-1H-pyrazolo[3,4-b]pyrazine derivatives and antitumor agents containing the compounds
JPS6336665U (en) 1986-08-27 1988-03-09
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en) 1987-09-21 1989-10-17 Pennwalt Corporation Dianhydride coupled polymer stabilizers
DE3814549A1 (en) 1987-10-30 1989-05-18 Bayer Ag N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
JPH029895A (en) 1988-06-28 1990-01-12 Lion Corp Nucleoside analog compound and antitumor agent
US5159054A (en) 1989-05-16 1992-10-27 The United States Of America As Represented By The Secretary Of The Navy Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (en) 1989-07-17 1999-01-13 三井化学株式会社 Novel diphenols having imide ring and process for producing the same
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
DE3937633A1 (en) 1989-11-11 1991-05-16 Bayer Ag HETEROCYCLIC COMPOUNDS AND THEIR USE AS PIGMENTS AND DYES
US5342723A (en) 1989-12-28 1994-08-30 Hoechst Aktiengesellschaft Biscationic acid amide and acid imide derivatives as charge controllers
DE59007528D1 (en) 1989-12-28 1994-11-24 Hoechst Ag BISCATIONIC ACID AMID AND IMID DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
JP2883670B2 (en) 1990-03-23 1999-04-19 三井化学株式会社 Novel bisphenol having imide ring and method for producing the same
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
JPH06501257A (en) 1990-10-03 1994-02-10 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション Epoxy resin based on diaminobisimide compounds
JPH04158084A (en) 1990-10-22 1992-06-01 Fuji Photo Film Co Ltd Recording material
JPH04179576A (en) 1990-11-14 1992-06-26 Fuji Photo Film Co Ltd Recording material
JPH04328121A (en) 1991-04-26 1992-11-17 Sumitomo Bakelite Co Ltd Epoxy resin composition for sealing semiconductor
WO1992022552A1 (en) 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
DE4119767A1 (en) 1991-06-15 1992-12-17 Dresden Arzneimittel Prepn. of (pyrimid-2-yl-thio- or seleno-) acetic acid derivs. - by reacting the corresp. chloro:alkanoyl-amino cpd. with a rhodanide and water or an alcohol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (en) 1992-05-18 2002-04-30 鐘淵化学工業株式会社 Hydrosilyl group-containing imide compound
JP3232123B2 (en) 1992-05-20 2001-11-26 鐘淵化学工業株式会社 Curable composition
WO1993024488A1 (en) 1992-05-28 1993-12-09 Commonwealth Scientific And Industrial Research Organisation Bismaleimide compounds
CA2150566A1 (en) 1992-12-07 1994-06-23 Jonathan Howard Hodgkin Bisnadimides
JPH08506189A (en) 1993-01-11 1996-07-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Polycyclic aromatic compounds with nonlinear optical properties
AU4293193A (en) 1993-04-28 1994-11-21 Du Pont Merck Pharmaceutical Company, The Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
NZ276885A (en) 1993-11-30 1999-08-30 Searle & Co Substituted pyrazolyl-benzenesulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5480887A (en) 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
CA2182090A1 (en) 1994-02-02 1995-08-10 William Joseph Hornback Hiv protease inhibitors and intermediates
ES2146782T3 (en) 1994-11-14 2000-08-16 Warner Lambert Co 6-ARYL-PIRIDO (2,3-D) PIRIMIDINAS AND NAFTIRIDINAS FOR THE INHIBITION OF THE CELL PROLIFERATION INDUCED BY THE PROTEIN TIROSINA QUINASA.
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (en) 1996-01-11 1997-07-22 Mitsui Toatsu Chem Inc Crystallization accelerator
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
ATE232863T1 (en) 1996-08-06 2003-03-15 Pfizer 6,6- OR 6,7-BICYCLIC DERIVATIVES CONTAINING SUBSTITUTED PYRIDO OR PYRIMIDO GROUPS
JP2000516611A (en) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー 2-Phenylbenzimidazole derivatives as MCP-1 antagonists
JP3669783B2 (en) 1996-08-21 2005-07-13 三井化学株式会社 Organic electroluminescence device
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
JP2001507349A (en) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
ES2301194T3 (en) 1997-02-05 2008-06-16 Warner-Lambert Company Llc PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION.
CA2285263C (en) 1997-04-11 2009-03-10 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
JP2002500675A (en) 1997-05-28 2002-01-08 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド Quinolines and quinoxaline compounds that inhibit platelet-derived growth factor and / or p56 trkosine kinase
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
EP0994892A1 (en) 1997-08-11 2000-04-26 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1999009030A1 (en) 1997-08-20 1999-02-25 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JPH11171865A (en) 1997-12-04 1999-06-29 Yoshitomi Pharmaceut Ind Ltd Fused heterocyclic compound
CA2316944A1 (en) 1998-02-20 1999-08-26 Mitsuru Shiraishi Aminoguanidinehydrazone derivative, production and use thereof
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
EE200000706A (en) 1998-05-26 2002-06-17 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cell proliferation
US20040044012A1 (en) 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP2002517486A (en) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド inhibitors of p38
JP4516690B2 (en) 1998-08-11 2010-08-04 ノバルティス アーゲー Isoquinoline derivatives having angiogenesis inhibitory activity
JP2000123973A (en) 1998-10-09 2000-04-28 Canon Inc Organic light emitting device
EP1123295B1 (en) 1998-10-23 2004-09-29 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19912638A1 (en) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarboxamide substituted sulfonamides
DE19920790A1 (en) 1999-05-06 2000-11-09 Bayer Ag Bis-sulfonamides with anti-HCMV activity
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
JP4041624B2 (en) 1999-07-21 2008-01-30 三井化学株式会社 Organic electroluminescence device
SI1225874T1 (en) 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Antiviral solid dispersions
DE19946289A1 (en) 1999-09-28 2001-03-29 Basf Ag Benzodiazepine derivatives, their production and use
CZ20021744A3 (en) 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles substituted with heteroalkylamino group functioning as P38 protein kinase inhibitors
EP1226144B1 (en) 1999-10-21 2006-12-27 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CA2396579A1 (en) 1999-12-29 2001-07-05 Wyeth Tricyclic protein kinase inhibitors
KR20020067701A (en) 2000-01-24 2002-08-23 워너-램버트 캄파니 3-aminoquinazolin-2,4-dione antibacterial agents
HUP0203803A3 (en) 2000-01-27 2004-09-28 Warner Lambert Co Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
US7041675B2 (en) 2000-02-01 2006-05-09 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as PARP inhibitors
DK1257550T3 (en) 2000-02-04 2006-03-27 Portola Pharm Inc The platelet ADP receptor inhibitor
AU2001231710A1 (en) 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE300303T1 (en) 2000-03-06 2005-08-15 Astrazeneca Ab USE OF QUINAZOLINE DERIVATIVES AS INHIBITORS OF ANGIOGENesis
JP2001265031A (en) 2000-03-15 2001-09-28 Fuji Xerox Co Ltd Electrophotographic photoreceptor, process cartridge and electrophotographic device
DE10012549A1 (en) 2000-03-15 2001-09-20 Bayer Ag New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections
AR028385A1 (en) 2000-04-28 2003-05-07 Acadia Pharm Inc MUSCARINIC AGONISTS
WO2001085722A1 (en) 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
CN1439008A (en) 2000-06-23 2003-08-27 布里斯托尔-迈尔斯斯奎布药品公司 1-(heteroaryl-henyl)-condensed pyrazol derivatives as factor XA inhibitors
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
EP1325006A2 (en) 2000-08-07 2003-07-09 Neurogen Corporation Heterocyclic compounds as ligands of the gaba a? receptor
PT1309593E (en) 2000-08-14 2006-08-31 Ortho Mcneil Pharm Inc SUBSTITUTED PYRAZOLES
ATE413878T1 (en) 2000-09-06 2008-11-15 Ortho Mcneil Pharm Inc METHOD OF FIGHTING ALLERGIES BY USING SUBSTITUTED PYRAZOLES
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (en) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd Heat developable color image recording material
WO2002083648A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compound
DE60227794D1 (en) 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd NITROGENIC COMPOUND WITH CONDENSED RING AND PYRAZOLYL GROUP AS A SUBSTITUENT AND MEDICAL COMPOSITION THEREOF
AR033295A1 (en) 2001-04-30 2003-12-10 Glaxo Group Ltd PIRIMIDINE BICYCLE COMPOUNDS, PROCESS FOR OBTAINING, USE OF THE SAME FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AND SUCH PHARMACEUTICAL COMPOSITION
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
BR0210028A (en) 2001-06-19 2004-06-22 Warner Lambert Co Antibacterial agents
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
IL160139A0 (en) 2001-08-07 2004-06-20 Banyu Pharma Co Ltd Spiro compounds
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
DK1441737T3 (en) 2001-10-30 2006-11-13 Novartis Ag Staurosporin derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
RU2308455C2 (en) 2001-11-07 2007-10-20 Ф.Хоффманн-Ля Рош Аг Aminopyrimidines and pyridines
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en) 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
PL218692B1 (en) 2002-01-22 2015-01-30 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
ATE395911T1 (en) 2002-03-05 2008-06-15 Merck Frosst Canada Ltd CATHEPSIN-CYSTEIN PROTEASE INHIBITORS
US6815519B2 (en) 2002-03-22 2004-11-09 Chung-Shan Institute Of Science & Technology Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
JP2006503802A (en) 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー Imidazo condensation compounds
NZ548796A (en) 2002-05-15 2008-01-31 Janssen Pharmaceutica Nv N-substituted trycyclic 3-aminopyrazoles as PDFG receptor inhibitors
JP4499342B2 (en) 2002-05-16 2010-07-07 株式会社カネカ Method for producing nitrogen-containing organic compound containing SiH group
CA2486966A1 (en) 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
AR037647A1 (en) 2002-05-29 2004-12-01 Novartis Ag USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
RS51752B (en) 2002-07-29 2011-12-31 Rigel Pharmaceuticals METHODS OF TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS
JP4252534B2 (en) 2002-08-06 2009-04-08 エフ．ホフマン−ラ ロシュ アーゲー 6-Alkoxy-pyrido-pyrimidines as p-38 MAP kinase inhibitors
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
AR042052A1 (en) 2002-11-15 2005-06-08 Vertex Pharma USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
EP1565475B1 (en) 2002-11-18 2009-04-08 F. Hoffmann-La Roche Ag Diazinopyrimidines and their use as protein kinase inhibitors
BR0316680A (en) 2002-11-28 2005-10-18 Schering Ag Chk, pdk and akt inhibitor pyrimidines, their production and use as pharmaceutical agents
AU2003298034B2 (en) 2002-12-06 2011-04-21 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
JP4666256B2 (en) 2002-12-10 2011-04-06 小野薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
BR0316880A (en) 2002-12-23 2005-10-25 Wyeth Corp Pd-1 Antibodies and Uses
JP2004203749A (en) 2002-12-24 2004-07-22 Kanegafuchi Chem Ind Co Ltd METHOD FOR PRODUCING NITROGEN-CONTAINING ORGANIC COMPOUND CONTAINING SiH GROUP
JP2006516561A (en) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 2-Aminopyridine substituted heterocycles as inhibitors of cell proliferation
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
KR20050122220A (en) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 Dipeptidyl peptidase inhibitors
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
KR20050111636A (en) 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 Pyrimido compounds
CN100372851C (en) 2003-05-05 2008-03-05 弗·哈夫曼-拉罗切有限公司 Fused pyrimidine derivatives with CRF activity
JP2004346145A (en) 2003-05-21 2004-12-09 Teijin Ltd Imide composition, resin composition comprising the same and its manufacturing method
US7625909B2 (en) 2003-05-23 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinazolinone compounds
WO2004108139A2 (en) 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
US20060270849A1 (en) 2003-06-18 2006-11-30 Shigeyoshi Nishino Process for producing pyrimidin-4-one compound
JP2005015395A (en) 2003-06-26 2005-01-20 Japan Science & Technology Agency A novel pyrimidopyrimidine nucleoside and its structural analogs
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
CN1860118A (en) 2003-07-29 2006-11-08 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US20070185007A1 (en) 2003-09-19 2007-08-09 Haolun Jin Aza-quinolinol phosphonate integrase inhibitor compounds
PE20050952A1 (en) 2003-09-24 2005-12-19 Novartis Ag DERIVATIVES OF ISOQUINOLINE AS INHIBITORS OF B-RAF
DE602004032276D1 (en) 2003-10-01 2011-05-26 Xention Ltd Tetrahydro-naphthalene and urea derivatives
CN1863774B (en) 2003-10-08 2010-12-15 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused aryl and heteroaryl derivatives and methods of use
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005047289A1 (en) 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
KR100703068B1 (en) 2003-12-30 2007-04-05 에스케이케미칼주식회사 Pyridine derivatives and preparation method thereof, and pharmaceutical composition
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
MXPA06008257A (en) 2004-01-23 2006-08-31 Amgen Inc Vanilloid receptor ligands and their use in treatments.
UA86952C2 (en) 2004-01-23 2009-06-10 Янссен Фармацевтика Н.В. Quinoline derivatives and use thereof as mycobacterial inhibitors
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
DK1713806T3 (en) 2004-02-14 2013-08-05 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
BRPI0508036A (en) 2004-02-27 2007-07-17 Hoffmann La Roche fused pyrazole derivatives
BRPI0508220A (en) 2004-02-27 2007-07-17 Hoffmann La Roche fused heteroaryl pyrazole derivatives
US20080004263A1 (en) 2004-03-04 2008-01-03 Santora Vincent J Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
US20070197510A1 (en) 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
KR100861434B1 (en) 2004-03-29 2008-10-02 미쓰이 가가쿠 가부시키가이샤 Novel compound and organic electronic device using such compound
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (en) 2004-05-10 2005-11-17 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoreceptor given by using the compound, and electrophotographic device
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
PE20060426A1 (en) 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
RU2401265C2 (en) 2004-06-10 2010-10-10 Айрм Ллк Compounds and compositions as protein kinase inhibitors
PL1761528T3 (en) 2004-06-11 2008-05-30 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2006028027A (en) 2004-07-12 2006-02-02 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoconductor using the compound and electrohptographic apparatus
AU2005278959A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
DE602005013248D1 (en) 2004-08-31 2009-04-23 Hoffmann La Roche AMID DERIVATIVES OF 3-PHENYLDIHYDROPYRIMIDOÄ4,5-DÜPYRIMIDINONES, THEIR PREPARATION AND USE AS PHARMACEUTICAL AGENTS
MX2007002089A (en) 2004-08-31 2007-03-29 Hoffmann La Roche Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents.
DE102004042667A1 (en) 2004-09-01 2006-03-30 Ewald Dörken Ag Multilayered building wall
CN1980970B (en) 2004-09-10 2010-05-26 宇部兴产株式会社 Modified polyimide resin and curable resin composition
WO2007053135A1 (en) 2004-09-14 2007-05-10 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (en) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
WO2006050162A2 (en) 2004-10-28 2006-05-11 Phenomix Corporation Imidazole derivatives
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006052712A1 (en) 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor
CN101103016A (en) 2004-11-18 2008-01-09 因塞特公司 11-beta hydroxysteroid dehydrogenase type 1 inhibitors and methods of use thereof
CN101098872B (en) 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 Pyrrolopyrazines and pyrazolopyrazines useful as protein kinase inhibitors
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JP5111113B2 (en) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Pyridopyrimidinone, dihydropyrimidopyrimidinone and pteridinone useful as Raf kinase inhibitors
WO2006074293A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
DE102005008310A1 (en) 2005-02-17 2006-08-24 Schering Ag Use of CDKII inhibitors for fertility control
RU2007132865A (en) 2005-03-01 2009-03-10 Пфайзер Лимитед (GB) APPLICATION OF PDE7 INHIBITORS FOR TREATMENT OF NEUROPATHIC PAIN
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
JP2006284843A (en) 2005-03-31 2006-10-19 Mitsui Chemicals Inc Electrophotographic photoreceptor using tetracarboxylic acid derivative and electrophotographing device
US20060223993A1 (en) 2005-04-01 2006-10-05 Connor Daniel M Colorant compounds, intermediates, and compositions
JP2006316054A (en) 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd High conductance calcium-sensitive K channel opener
KR100781704B1 (en) 2005-04-20 2007-12-03 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
MX2007013595A (en) 2005-05-04 2008-01-24 Renovis Inc Fused heterocyclic compounds, and compositions and uses thereof.
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006247757B2 (en) 2005-05-13 2009-08-27 Irm, Llc Compounds and compositions as protein kinase inhibitors
WO2006135821A2 (en) 2005-06-09 2006-12-21 Achille Carlisle Tisdelle Vehicular head and neck safety system and method
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
WO2007013964A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
ES2351939T3 (en) 2005-08-09 2011-02-14 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES.
KR20080035698A (en) 2005-08-16 2008-04-23 아이알엠 엘엘씨 Compounds and Compositions as Protein Kinase Inhibitors
AU2006283935A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Fused pyrazole as p38 MAP kinase inhibitors
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
ES2338590T3 (en) 2005-09-06 2010-05-10 Glaxosmithkline Llc REGIONAL ELEMENT PROCEDURE FOR THE PREPARATION OF BENZOIMIDAZOLTIOFENOS.
AU2006289838B2 (en) 2005-09-15 2011-08-18 Aska Pharmaceutical Co., Ltd. Heterocyclic compound, and production process and use thereof
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
CA2623026A1 (en) 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
DE102005048072A1 (en) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazoles as fungicides
JP5480503B2 (en) 2005-10-07 2014-04-23 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
EP2364974A1 (en) 2005-10-07 2011-09-14 Exelixis, Inc. N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors
WO2007061554A2 (en) 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
EP1943231A1 (en) 2005-10-26 2008-07-16 Boehringer Ingelheim International Gmbh (hetero)aryl compounds with mch antagonistic activity and medicaments comprising these compounds
MX362412B (en) 2005-11-01 2019-01-15 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases.
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007056023A2 (en) 2005-11-02 2007-05-18 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
JP5116687B2 (en) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
DK1954274T3 (en) 2005-11-10 2011-01-31 Chemocentryx Inc Substituted quinolones and methods of use
BRPI0618354B8 (en) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd compound and its use, pharmaceutical composition, preventive or medicine
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2007058392A1 (en) 2005-11-21 2007-05-24 Japan Tobacco Inc. Heterocyclic compound and medicinal application thereof
PE20070855A1 (en) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
BRPI0619146A2 (en) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp Substituted 4-amino-pyrroltriazine derivatives useful in the treatment of disorders and hyperproliferative diseases associated with angiogenesis
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2007066189A2 (en) 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
UY30118A1 (en) 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDE COMPUTER
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
JP2009528989A (en) 2006-02-17 2009-08-13 ファイザー・リミテッド 3-Deazapurine derivatives as TLR7 modulators
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0709699A2 (en) 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inhibition of alpha synuclein toxicity
AU2007234717B2 (en) 2006-04-06 2012-04-19 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
WO2007120097A1 (en) 2006-04-13 2007-10-25 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
JP2009535393A (en) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク Substituted 2-amino fused heterocyclic compounds
JP5241704B2 (en) 2006-05-11 2013-07-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
BRPI0711628A2 (en) 2006-05-15 2011-12-06 Irm Llc compound, pharmaceutical composition, use and process for preparing the compound
WO2007143600A2 (en) 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
DE102006027156A1 (en) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
JP2009541480A (en) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ Pyrimidine derivatives useful in the treatment of cancer
US20090281115A1 (en) 2006-06-30 2009-11-12 Board of Regents, The University of Texas System, a Texas University Inhibitors of c-kit and uses thereof
US8258129B2 (en) 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
JP2010500994A (en) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Methods of using PI3K and MEK modulators
DE102006041382A1 (en) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl sulfoximides as protein kinase inhibitors
BRPI0719123A2 (en) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc SERINA-TREONINE PROTEIN KINASE AND PARP MODULATORS
JP5600004B2 (en) 2006-09-05 2014-10-01 エモリー ユニバーシティー Tyrosine kinase inhibitors for the prevention or treatment of infection
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
JP5372759B2 (en) 2006-09-21 2013-12-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, pharmaceuticals containing the compounds and methods of use and preparation thereof
EP2069341B1 (en) 2006-09-22 2010-12-29 Glaxo Group Limited Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors
WO2008037459A1 (en) 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
AR063420A1 (en) 2006-10-30 2009-01-28 Glaxo Group Ltd DERIVATIVES OF 2-CIANO-4-PIRIMIDINIL SUBSTITUTED, PROCESS OF PREPARATION OF THE SAME, MEDICINES THAT CONTAIN THEM AND ITS USE FOR THE TREATMENT OF THE MALARIA.
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
US8148361B2 (en) 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
WO2008063583A1 (en) 2006-11-17 2008-05-29 Polyera Corporation Acene-based organic semiconductor materials and methods of preparing and using the same
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (en) 2006-11-20 2008-05-23 에스케이케미칼주식회사 Pharmaceutical composition having a hepatitis treatment and prevention or hepatoprotective effect comprising a pyridine compound
JP2010513278A (en) 2006-12-13 2010-04-30 シェーリング コーポレイション Method for treating cancer using IGF1R inhibitor
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP2010514689A (en) 2006-12-22 2010-05-06 ノバルティス アーゲー Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
FR2911140B1 (en) 2007-01-05 2009-02-20 Sanofi Aventis Sa NOVEL 2-ANILINO 4-HETEROARYL PYRIMIDES DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR AS INHIBITORS OF IKK
EP2104676A2 (en) 2007-01-08 2009-09-30 Polyera Corporation Methods for preparing arene-bis(dicarboximide)-based semiconducting materials and related intermediates for preparing same
CN101007778A (en) 2007-01-10 2007-08-01 复旦大学 Chain-prolonged type fluorenyl bimaleimide and its preparation method
JP5287253B2 (en) 2007-01-12 2013-09-11 アステラス製薬株式会社 Condensed pyridine compound
PL2114980T3 (en) 2007-01-12 2012-11-30 Biocryst Pharm Inc Antiviral nucleoside analogs
FR2911604B1 (en) 2007-01-19 2009-04-17 Sanofi Aventis Sa N- (HETEROARYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP5358962B2 (en) 2007-02-06 2013-12-04 住友化学株式会社 Composition and light-emitting device using the composition
JP2008198769A (en) 2007-02-13 2008-08-28 Nippon Steel Chem Co Ltd Organic electroluminescent device
CA2678492A1 (en) 2007-03-06 2008-09-12 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
MX2009009540A (en) 2007-03-07 2009-09-16 Alantos Pharm Holding Metalloprotease inhibitors containing a heterocyclic moiety.
CN104030990B (en) 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 Phenyl amino pyrimidine compounds and application thereof
JP5191497B2 (en) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド S1P receptor modulating compounds and uses thereof
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US7919498B2 (en) 2007-03-23 2011-04-05 Amgen Inc. Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
KR20080091948A (en) 2007-04-10 2008-10-15 에스케이케미칼주식회사 Pharmaceutical composition for the prevention and treatment of ischemic diseases containing lactam type pyridine compound
US20100112211A1 (en) 2007-04-12 2010-05-06 Advanced Technology Materials, Inc. Zirconium, hafnium, titanium, and silicon precursors for ald/cvd
MX2009011359A (en) 2007-04-20 2009-11-05 Schering Corp Pyrimidinone derivatives and methods of use thereof.
EP1985612A1 (en) 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc Quinoxaline derivatives as p13 kinase inhibitors
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
WO2008153852A1 (en) 2007-06-07 2008-12-18 Merck & Co., Inc. Tricyclic anilide heterocyclic cgrp receptor antagonists
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8436004B2 (en) 2007-06-15 2013-05-07 Msd K.K. Bicycloaniline derivative
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
ES2375425T3 (en) 2007-07-26 2012-02-29 Novartis Ag ORGANIC COMPOUNDS.
EP2018859A1 (en) 2007-07-26 2009-01-28 Bayer Schering Pharma Aktiengesellschaft Arylmethylene substituted N-acyl-beta-amino alcohols
EP2020404A1 (en) 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
CA2698511C (en) 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en) 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
KR101660989B1 (en) 2007-10-01 2016-09-28 아이오니스 파마수티컬즈, 인코포레이티드 Antisense modulation of fibroblast growth factor receptor 4 expression
WO2009044788A1 (en) 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. Benzoxazinone derivative
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en) 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
CN101821243B (en) 2007-10-11 2013-05-08 中国科学院上海药物研究所 A class of pyrimidine-substituted phenylpropionic acid derivatives and their use as PPAR agonists
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009047993A1 (en) 2007-10-13 2009-04-16 Konica Minolta Holdings, Inc. Organic electroluminescent device, display device and illuminating device
WO2009052145A1 (en) 2007-10-16 2009-04-23 Wyeth Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) NEW THIAZOLE-, TRIAZOLE- OR OXADIAZOLE-CONTAINING TETRACYCLIC COMPOUNDS
KR20100089090A (en) 2007-10-25 2010-08-11 아스트라제네카 아베 Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CA2707046A1 (en) 2007-11-28 2009-06-11 Nathanael S. Gray Small molecule myristate inhibitors of bcr-abl and methods of use
JP2011505407A (en) 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Diaminopyridine for treating diseases characterized by excessive or abnormal cell proliferation
MX2010006457A (en) 2007-12-19 2010-07-05 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors.
CN101970441A (en) 2007-12-21 2011-02-09 惠氏有限责任公司 Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
JP2011507910A (en) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター Methods for changing the lifetime of eukaryotes
US8153827B2 (en) 2007-12-27 2012-04-10 Purdue Research Foundation Reagents for biomolecular labeling, detection and quantification employing Raman spectroscopy
FR2926297B1 (en) 2008-01-10 2013-03-08 Centre Nat Rech Scient INHIBITORY CHEMICAL MOLECULES IN THE SPLICE MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICE ANOMALIES.
JP5584626B2 (en) 2008-01-24 2014-09-03 アンドレイ・アレクサンドロビッチ・イワシェンコ 2-alkylamino-3- (arylsulfonyl) -cycloalkyl [e or d] pyrazolo [1,5-a] pyrimidine-serotonin 5-HT6 receptor antagonists, methods of preparation and use thereof
EA017818B1 (en) 2008-01-24 2013-03-29 Андрей Александрович ИВАЩЕНКО SUBSTITUTED CYCLOALCANO[e OR d]PYRAZOLO[1,5-a]PYRIMIDINES - ANTAGONISTS OF SEROTONIN 5-HTRECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
EA201001205A1 (en) 2008-01-24 2011-04-29 Юсб Фарма, С.А. COMPOUNDS CONTAINING CYCLOBUTOXY GROUP
AU2009206368B2 (en) 2008-01-25 2014-12-11 Vtv Therapeutics Llc Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
CA2711759A1 (en) 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
EP2257541B1 (en) 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
CA2716330A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
JP5451646B2 (en) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
JP5530422B2 (en) 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド Gem-disubstituted and spirocyclic aminopyridine / pyrimidines as cell cycle inhibitors
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Aminocyclohexyl derivative
WO2009125809A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Piperidine derivatives
JPWO2009128520A1 (en) 2008-04-18 2011-08-04 塩野義製薬株式会社 Heterocyclic compounds having PI3K inhibitory activity
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
SG190592A1 (en) 2008-04-29 2013-06-28 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
EP2280969A1 (en) 2008-04-29 2011-02-09 F. Hoffmann-La Roche AG Pyrimidinyl pyridone inhibitors of jnk.
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
KR101257158B1 (en) 2008-05-23 2013-04-23 노파르티스 아게 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2288671B1 (en) 2008-06-10 2012-08-15 Basf Se Novel transition metal complex and use thereof in organic light-emitting diodes - iii
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
EA201100030A1 (en) 2008-06-19 2011-08-30 Астразенека Аб PYRAZOL COMPOUNDS 436
WO2009157423A1 (en) 2008-06-24 2009-12-30 財団法人乙卯研究所 Oxazolidinone derivative having fused ring
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
ES2552681T3 (en) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag New phenyl-imidazopyridines and pyridazines
AU2009270983A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as GPCR modulators
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
AR072906A1 (en) 2008-08-06 2010-09-29 Novartis Ag MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL
JP2011530596A (en) 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Halofuginone analogs and their use for inhibition of tRNA synthetase
UY32049A (en) 2008-08-14 2010-03-26 Takeda Pharmaceutical CMET INHIBITORS
JP2012501962A (en) 2008-09-10 2012-01-26 田辺三菱製薬株式会社 Aromatic nitrogen-containing six-membered ring compound and use thereof
MX2011003195A (en) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
WO2010038081A2 (en) 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
WO2010045371A1 (en) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010049731A1 (en) 2008-10-29 2010-05-06 Astrazeneca Ab Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
JP5522053B2 (en) 2008-12-03 2014-06-18 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101061599B1 (en) 2008-12-05 2011-09-02 한국과학기술연구원 Novel indazole derivatives that are protein kinase inhibitors for the treatment of abnormal cell growth diseases, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as active ingredients
MX2011006108A (en) 2008-12-08 2011-11-18 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors.
US8110265B2 (en) 2008-12-09 2012-02-07 The Coca-Cola Company Pet container and compositions having enhanced mechanical properties and gas barrier properties
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
AU2009325400A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
WO2010080503A1 (en) 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
TW201035098A (en) 2008-12-30 2010-10-01 Arqule Inc Substituted imidazolyl-5,6-dihydrobenzo[n] isoquinoline compounds
WO2010078421A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
EP3255047B1 (en) 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
EP2387315B1 (en) 2009-01-16 2015-07-15 Merck Sharp & Dohme Corp. IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
DE102009007038A1 (en) 2009-02-02 2010-08-05 Merck Patent Gmbh metal complexes
JP2010180147A (en) 2009-02-04 2010-08-19 Mitsubishi Gas Chemical Co Inc Cyanic acid ester compound and cured product thereof
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ PD-1 antibody and PD-L1 antibody and use thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
JP5615261B2 (en) 2009-03-11 2014-10-29 学校法人関西学院 Polycyclic aromatic compounds
AU2010226829A1 (en) 2009-03-18 2011-09-15 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2010111303A2 (en) 2009-03-23 2010-09-30 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
EP2411370B1 (en) 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
US8415378B2 (en) 2009-04-07 2013-04-09 Astrazeneca Ab Isoxazol-3(2H)-one analogs as therapeutic agents
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5531446B2 (en) 2009-04-20 2014-06-25 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
ES2347630B1 (en) 2009-04-29 2011-09-08 Universitat Ramon Llull SYNTHESIS AND USES OF 4-CIANOPENTANOATOS AND 4-CIANOPENTENOATS SUBSTITUTED.
JP5656976B2 (en) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド Pyrrolotriazine compounds
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
AR078411A1 (en) 2009-05-07 2011-11-09 Lilly Co Eli IMIDAZOLIL VINYL COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
JP5600891B2 (en) 2009-05-15 2014-10-08 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5604808B2 (en) 2009-05-20 2014-10-15 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5568889B2 (en) 2009-05-22 2014-08-13 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, LIGHTING DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL
JP5629980B2 (en) 2009-05-22 2014-11-26 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5499519B2 (en) 2009-05-27 2014-05-21 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
WO2010136031A1 (en) 2009-05-27 2010-12-02 Københavns Universitet Fibroblast growth factor receptor-derived peptides binding to ncam
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (en) 2009-06-24 2014-10-08 コニカミノルタ株式会社 White organic electroluminescence element, display device and lighting device
SMT201700430T1 (en) 2009-06-25 2018-01-11 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011002038A1 (en) 2009-06-30 2011-01-06 日本ゼオン株式会社 Novel diarylamine compound, and anti-aging agent, polymer composition, crosslinked rubber product and molded article thereof, and method for producing diarylamine compound
JPWO2011007819A1 (en) 2009-07-17 2012-12-27 塩野義製薬株式会社 Pharmaceuticals containing lactam or benzenesulfonamide compounds
WO2011011597A1 (en) 2009-07-24 2011-01-27 Duke University Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (en) 2009-07-30 2012-08-24 Sanofi Aventis PHARMACEUTICAL FORMULATION
TWI468402B (en) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
IN2012DN01254A (en) 2009-08-05 2015-05-15 Versitech Ltd
JP2012197231A (en) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Pyridine and pyrimidine derivative having ttk-inhibiting action
TWI464160B (en) 2009-08-07 2014-12-11 Chugai Pharmaceutical Co Ltd Amino pyrazole derivative
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
KR101721280B1 (en) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 Heterocyclic compounds and uses thereof
JP5577650B2 (en) 2009-08-24 2014-08-27 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101184115B1 (en) 2009-08-31 2012-09-18 일동제약주식회사 New peptide deformylase inhibitor compounds and the manufacturing process thereof
MX2012002274A (en) 2009-09-03 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask.
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
US8426438B2 (en) 2009-10-01 2013-04-23 Merck Sharp & Dohme Corp. Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
WO2011049987A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
KR20110043270A (en) 2009-10-21 2011-04-27 (주)씨에스엘쏠라 Organic light emitting compound and organic light emitting device having same
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120220600A1 (en) 2009-10-30 2012-08-30 Reiner Aichholz N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1--1-methyl-urea
KR20110049217A (en) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic light emitting compound and organic electroluminescent device employing the same
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
SG10201407129SA (en) 2009-11-06 2014-12-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CA2780892C (en) 2009-11-13 2017-02-14 Genosco Kinase inhibitors
MX2012005827A (en) 2009-11-18 2012-06-19 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
EP2504010A4 (en) 2009-11-23 2013-04-17 Merck Sharp & Dohme FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
CN102711470A (en) 2009-12-01 2012-10-03 雅培制药有限公司 Novel tricyclic compounds
JP2011116840A (en) 2009-12-02 2011-06-16 Fujifilm Corp Pigment fine particle dispersion, photocurable composition using the same, and color filter
AR079257A1 (en) 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME
US8759366B2 (en) 2009-12-17 2014-06-24 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
JP2013514986A (en) 2009-12-18 2013-05-02 ノバルティス アーゲー How to treat blood cancer
AU2010341573B2 (en) 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
FR2954315B1 (en) 2009-12-23 2012-02-24 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
FR2954317B1 (en) 2009-12-23 2012-01-27 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
EP2519241A2 (en) 2009-12-28 2012-11-07 Afraxis, Inc. Methods for treating autism
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8440828B2 (en) 2009-12-29 2013-05-14 Polyera Corporation Organic semiconductors and devices incorporating same
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
EP2519525A4 (en) 2009-12-30 2013-06-12 Arqule Inc SUBSTITUTED PYRROLOAMINOPYRIMIDINE COMPOUNDS
US8329705B2 (en) 2009-12-30 2012-12-11 Arqule, Inc. Substituted triazolo-pyrazine compounds
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
CN102115026A (en) 2009-12-31 2011-07-06 清华大学 One-dimensional nano-structure, preparation method thereof and method for marking by using one-dimensional nano-structure
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011082488A1 (en) 2010-01-06 2011-07-14 British Columbia Cancer Agency Branch Bisphenol derivative therapeutics and methods for their use
KR101483215B1 (en) 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
SA111320200B1 (en) 2010-02-17 2014-02-16 ديبيوفارم اس ايه Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
EP2536689A1 (en) 2010-02-17 2012-12-26 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
CN102782101B (en) 2010-02-18 2015-10-07 Ntn株式会社 Thickeners, greases, methods of making them, and grease encased in bearings
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
US9403769B2 (en) 2010-02-22 2016-08-02 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
US8986858B2 (en) 2010-02-26 2015-03-24 Nippon Steel & Sumikin Chemical Co., Ltd. Organic electroluminescent device
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
MX350010B (en) 2010-03-11 2017-08-23 Gilead Connecticut Inc Imidazopyridines syk inhibitors.
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
MX345552B (en) 2010-03-24 2017-02-02 Amitech Therapeutic Solutions Inc Heterocyclic compounds useful for kinase inhibition.
JP5752232B2 (en) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Substituted pyrrolotriazine compounds as protein kinase inhibitors
CN102153551B (en) 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 Indazole/azaindazole-based diarylcarbamide/thiocarbamide-structure antineoplastic drug
JP5724204B2 (en) 2010-04-07 2015-05-27 コニカミノルタ株式会社 Organic electroluminescence element, display device, and lighting device
WO2011130390A1 (en) 2010-04-13 2011-10-20 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
RU2012148710A (en) 2010-04-16 2014-05-27 Новартис Аг ORGANIC COMPOUND FOR USE IN TREATMENT OF LIVER CANCER
CN102939283B (en) 2010-04-22 2015-06-03 詹森药业有限公司 Indazole compounds useful as ketohexokinase inhibitors
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
BR112012026641A2 (en) 2010-04-23 2016-07-12 Kineta Inc antiviral compounds
CN103025744A (en) 2010-04-30 2013-04-03 百时美施贵宝公司 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8759398B2 (en) 2010-05-03 2014-06-24 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
EP2569012A4 (en) 2010-05-11 2013-10-30 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
TWI513694B (en) 2010-05-11 2015-12-21 Amgen Inc Pyrimidine compounds that inhibit anaplastic lymphoma kinase
AU2011252983C1 (en) 2010-05-12 2015-02-19 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US8293738B2 (en) 2010-05-12 2012-10-23 Abbott Laboratories Indazole inhibitors of kinase
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
WO2011147198A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
WO2011155983A1 (en) 2010-06-07 2011-12-15 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
JP2013532153A (en) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
FR2962437B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
FR2962438B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis INDOLIZINE DERIVATIVES, PREPARATION METHODS AND THERAPEUTIC APPLICATION
EP2590968A1 (en) 2010-07-06 2013-05-15 Novartis AG Cyclic ether compounds useful as kinase inhibitors
EP2590982B1 (en) 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
EP2595996A2 (en) 2010-07-14 2013-05-29 Merck Sharp & Dohme Corp. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
WO2012008564A1 (en) 2010-07-16 2012-01-19 協和発酵キリン株式会社 Nitrogenated aromatic heterocyclic ring derivative
EP2594566A4 (en) 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd Nitrogenated aromatic heterocyclic ring derivative
CN103384670B (en) 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 Imidazo [1, the 2-b] pyridazine replacing
EP2413140A1 (en) 2010-07-29 2012-02-01 Sanofi Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
CN103140564B (en) 2010-07-30 2015-11-25 罗门哈斯电子材料韩国有限公司 Electroluminescent devices using electroluminescent compounds as light-emitting materials
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012027239A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
ES2561277T3 (en) 2010-09-01 2016-02-25 Gilead Connecticut, Inc. Pyridinones / pyrazinones, procedure of preparation and procedure of use of the same
ES2537190T3 (en) 2010-09-01 2015-06-03 Gilead Connecticut, Inc. Pyridazinones, preparation procedure and procedures for their use
AR082799A1 (en) 2010-09-08 2013-01-09 Ucb Pharma Sa DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS
PL2614058T3 (en) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
TWI541243B (en) 2010-09-10 2016-07-11 拜耳知識產權公司 Substituted imidazopyridazines
KR20130103503A (en) 2010-09-14 2013-09-23 호도가야 가가쿠 고교 가부시키가이샤 Charge control agent and toner using same
CN102399233B (en) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 Dual PI3K and mTOR inhibitor compounds
CN102399220A (en) 2010-09-15 2012-04-04 黄振华 Tricyclic dual PI3K and mTOR inhibitors
WO2012036233A1 (en) 2010-09-17 2012-03-22 塩野義製薬株式会社 Condensed heterocyclic derivative having melanine-concentrating hormone receptor antagonistic activity
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JO3062B1 (en) 2010-10-05 2017-03-15 Lilly Co Eli Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol
WO2012054364A2 (en) 2010-10-22 2012-04-26 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
ES2592515T3 (en) 2010-10-25 2016-11-30 G1 Therapeutics, Inc. CDK inhibitors
JP2012092049A (en) 2010-10-27 2012-05-17 Sumitomo Chemical Co Ltd Pest control composition and method for controlling pest
EP2886120B1 (en) 2010-10-29 2019-06-19 Emory University Quinazoline derivatives, compositions and uses related thereto
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
MX2013005008A (en) 2010-11-10 2013-08-01 Gruenenthal Gmbh Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands.
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
JP2012116825A (en) 2010-11-11 2012-06-21 Ehime Univ Method for producing acene diimide compound
KR101171232B1 (en) 2010-11-15 2012-08-06 단국대학교 산학협력단 Spiro Compound and Organic Light Emitting Device Including the Same
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
AU2011329806A1 (en) 2010-11-17 2013-05-30 Amgen Inc. Quinoline derivatives as PIK3 inhibitors
WO2012066578A2 (en) 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US9090593B2 (en) 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
ES2650744T3 (en) 2010-12-14 2018-01-22 Electrophoretics Limited Casein kinase 1 delta inhibitors (CK1delta)
JP6007189B2 (en) 2010-12-20 2016-10-12 メルク セローノ ソシエテ アノニム Indazolyltriazole derivatives as IRAK inhibitors
AU2011348638B2 (en) 2010-12-22 2015-05-21 Leo Laboratories Limited 3-acyl-ingenols II
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
US9102687B2 (en) 2010-12-22 2015-08-11 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
MX2013007261A (en) 2010-12-23 2013-11-04 Amgen Inc Heterocyclic compounds and their uses.
JP5691508B2 (en) 2010-12-27 2015-04-01 Jnc株式会社 Diimide compound and inkjet ink and use thereof
KR101466150B1 (en) 2010-12-31 2014-11-27 제일모직 주식회사 Compound for organic photoelectric device and organic photoelectric device including the same
EP2662378B1 (en) 2011-01-06 2018-10-10 JX Nippon Oil & Energy Corporation Imide compound, method for producing same, thickening agent for grease, and grease composition
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
FR2970967B1 (en) 2011-01-27 2013-02-15 Pf Medicament AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS A MEDICINAL PRODUCT
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
TWI532742B (en) 2011-02-28 2016-05-11 艾伯維有限公司 Tricyclic inhibitors of kinases
US20130345234A1 (en) 2011-03-17 2013-12-26 Humphrey Athelstan Roy Gardner Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
CN103703000B (en) 2011-03-23 2015-11-25 安姆根有限公司 The fused tricyclic double inhibitor of CDK4/6 and FLT3
ITPD20110091A1 (en) 2011-03-24 2012-09-25 Univ Padova USEFUL INHIBITORS FOR RELATED PATHOLOGIES: PHARMACOFORIC MODELS, IDENTIFIED COMPOUNDS BY THESE MODELS, METHODS FOR THEIR PREPARATION, THEIR FORMULATION AND THEIR THERAPEUTIC USE.
WO2012134943A1 (en) 2011-03-25 2012-10-04 Abbott Laboratories Trpv1 antagonists
CN103596983B (en) 2011-04-07 2016-10-26 霍夫曼-拉罗奇有限公司 Anti-FGFR4 antibody and using method
FR2974088A1 (en) 2011-04-12 2012-10-19 Pf Medicament TRI- AND TETRACYCLIC PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS ANTI-CANCER AGENTS
ES2628385T3 (en) 2011-05-16 2017-08-02 F. Hoffmann-La Roche Ag FGFR1 agonists and use procedures
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
JP6121991B2 (en) 2011-05-17 2017-04-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Amino-substituted imidazopyridazines as MKNK1 kinase inhibitors
JP2014515353A (en) 2011-05-19 2014-06-30 ノバルティス アーゲー 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinoline-2 for use in the treatment of adenoid cystic carcinoma -ON
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
TW201316991A (en) 2011-06-03 2013-05-01 Millennium Pharm Inc Combination of MEK inhibitors and selective inhibitors of Aurora A kinase
KR101417285B1 (en) 2011-06-13 2014-07-09 주식회사 엘지화학 New compounds and organic electronic device using the same
EP2723748B1 (en) 2011-06-22 2016-10-12 Bayer Intellectual Property GmbH Heterocyclyl aminoimidazopyridazines
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
EP2742046A1 (en) 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
CN105001226B (en) 2011-08-12 2017-09-08 日产化学工业株式会社 Tricyclic heterocyclic compounds and JAK inhibitor
JP2013049251A (en) 2011-08-31 2013-03-14 Fujifilm Corp Relief printing plate original plate for laser engraving, and, relief printing plate and method for producing the same
WO2013033981A1 (en) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 2,7-naphthyridine derivative, preparation method therefor and use thereof
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US9376435B2 (en) 2011-09-23 2016-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Chromophores for the detection of volatile organic compounds
WO2013049352A2 (en) 2011-09-30 2013-04-04 Kineta, Inc. Anti-viral compounds
UA111382C2 (en) 2011-10-10 2016-04-25 Оріон Корпорейшн Protein kinase inhibitors
WO2013053051A1 (en) 2011-10-12 2013-04-18 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101897044B1 (en) 2011-10-20 2018-10-23 에스에프씨 주식회사 Organic metal compounds and organic light emitting diodes comprising the same
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
US20140288073A1 (en) 2011-10-28 2014-09-25 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
FR2985258A1 (en) 2011-12-28 2013-07-05 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
FR2985257B1 (en) 2011-12-28 2014-02-14 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
US10026905B2 (en) 2012-01-18 2018-07-17 Duk San Neolux Co., Ltd. Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (en) 2012-01-18 2013-07-25 덕산하이메탈(주) Compound, organic electronic element using same and electronic device thereof
ES2516392T3 (en) 2012-01-19 2014-10-30 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
US9475815B2 (en) 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
JP2013179181A (en) 2012-02-28 2013-09-09 Sumitomo Chemical Co Ltd Organic photoelectric conversion element
JP6431770B2 (en) 2012-03-14 2018-11-28 ルピン・リミテッド Heterocyclyl compounds as MEK inhibitors
CA2866229C (en) 2012-03-30 2020-09-15 Novartis Ag Fgfr inhibitor for use in the treatment of hypophosphatemic disorders
JP5120580B1 (en) 2012-05-14 2013-01-16 Ｊｓｒ株式会社 Liquid crystal alignment agent
LT2852354T (en) 2012-05-20 2020-09-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. MITRAL VALVE PROSTHESIS
UA125503C2 (en) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Substituted tricyclic compounds as fgfr inhibitors
BR112015000349A2 (en) 2012-07-11 2017-06-27 Novartis Ag method of treatment of gastrointestinal stromal tumors
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
KR101985259B1 (en) 2012-08-10 2019-06-03 제이에스알 가부시끼가이샤 Liquid crystal aligning agent and compound
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102000211B1 (en) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 Organometallic compound and organic light emitting diode comprising the same
US20140148548A1 (en) 2012-11-28 2014-05-29 Central Glass Company, Limited Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
RU2660349C2 (en) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Compositions and methods for treatment of malignant tumour
WO2014089913A1 (en) 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 Bicyclic compound functioning as tyrosine kinase inhibitor
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
KR102030587B1 (en) 2013-01-09 2019-10-10 에스에프씨주식회사 Asymmetric antracene derivatives having two naphthyl groups and organic light-emitting diode including the same
CN103588771B (en) 2013-01-15 2016-01-27 苏州云轩医药科技有限公司 There is the miazines antineoplastic compound of activity of hedgehog path antagonist
US9695178B2 (en) 2013-01-15 2017-07-04 Suzhou Kintor Pharmaceuticals, Inc. 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof
KR101456626B1 (en) 2013-02-01 2014-11-03 대영이앤비 주식회사 Apparatus for protecting negative pressure of refrigerator
WO2014136972A1 (en) 2013-03-07 2014-09-12 国立大学法人九州大学 Supramolecular complex, light-emitting body, and sensor element for detecting organic compound
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AR095464A1 (en) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc HETEROARILO COMPOUNDS AND USES OF THE SAME
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
TWI628176B (en) 2013-04-04 2018-07-01 奧利安公司 Protein kinase inhibitors
KR101573611B1 (en) 2013-04-17 2015-12-01 주식회사 엘지화학 Fullerene derivatives, organic solar cell using the same and fabricating method thereof
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MX2015014608A (en) 2013-04-19 2016-03-03 Covagen Ag Novel bispecific binding molecules with antitumoral activity.
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9630963B2 (en) 2013-05-09 2017-04-25 Principia Biopharma, Inc. Quinolone derivatives as fibroblast growth factor inhibitors
WO2014198942A1 (en) 2013-06-14 2014-12-18 Sanofi Pyrazolopyridine derivatives for use in the treatment of bladder cancer
EP3013797B1 (en) 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
US10939682B2 (en) 2013-07-02 2021-03-09 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
DK3019496T3 (en) 2013-07-11 2019-12-09 Acea Therapeutics Inc PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
TW201605452A (en) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 Pharmaceutical composition containing pyrimidine compound as an active ingredient
WO2015057963A1 (en) 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
FR3012330B1 (en) 2013-10-29 2015-10-23 Oreal BIPHASE COMPOSITION COMPRISING AN ESTER OF FATTY ACID AND SUGAR OR A LIQUID ALKYLPOLYGLUCOSIDE OF HLB <8, AND A C8-C18 BRANCHED ALKANE
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
MY188447A (en) 2014-08-19 2021-12-09 Shanghai Haihe Pharmaceutical Co Ltd Indazole compounds as fger kinase inhibitor, preparation and use thereof
CN104262330B (en) 2014-08-27 2016-09-14 广东东阳光药业有限公司 A kind of urea-substituted biphenyl compound and its composition and application
PE20170697A1 (en) 2014-09-19 2017-06-24 Bayer Pharma AG INDAZOLES SUBSTITUTED WITH BENZYL AS BUB1 INHIBITORS
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (en) 2015-02-20 2017-10-23 Incyte Holdings Corp BICYCLE HETEROCICLES AS FGFR INHIBITORS
PE20180021A1 (en) 2015-02-20 2018-01-09 Univ Oregon Health & Science DERIVATIVES OF SOBETHROMA
WO2016192680A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
SG10201912066SA (en) 2015-07-15 2020-02-27 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2016294426B2 (en) 2015-07-15 2018-10-18 Cabot Corporation Methods of making an elastomer composite reinforced with silica and carbon black and products containing same
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
TR201909160T4 (en) 2015-07-15 2019-07-22 Hoffmann La Roche Ethynyl derivatives as metabotropic glutamate receptor modulators.
SI3328419T1 (en) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-binding molecules and methods for their use
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017028314A1 (en) 2015-08-20 2017-02-23 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as erk inhibitors
BR112018005637B1 (en) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv COMPOUNDS DERIVED FROM QUINOXALINE, QUINOLINE AND QUINAZOLINONE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE OF SAID COMPOUNDS
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
KR20180002053A (en) 2016-06-28 2018-01-05 한미약품 주식회사 Novel heterocylcic derivatives and use thereof
MA46045A (en) 2016-08-29 2021-04-28 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
CN109641868B (en) 2016-08-30 2021-12-03 广东东阳光药业有限公司 Inhibitors of influenza virus replication and methods of use and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CA3037064A1 (en) 2016-10-05 2018-04-12 Zeno Royalties & Milestones, LLC Spirocyclic compounds
KR101755556B1 (en) 2016-11-18 2017-07-07 주식회사 케마스 Pharmaceutical composition for prevention or treatment of brain cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101834366B1 (en) 2016-11-21 2018-03-05 주식회사 케마스 Pharmaceutical composition for prevention or treatment of breast cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101844049B1 (en) 2016-12-05 2018-03-30 주식회사 케마스 Pharmaceutical composition for prevention or treatment of liver cancer comprising polymorphic form of tetraarsenic oxide
KR101844050B1 (en) 2016-12-09 2018-05-14 주식회사 케마스 Pharmaceutical composition for prevention or treatment of cancer comprising polymorphic form of tetraarsenic oxide
BR112019012993A2 (en) 2016-12-22 2019-12-03 Incyte Corporation benzo-oxazole derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
PT3558990T (en) 2016-12-22 2022-11-21 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
ES2899402T3 (en) 2016-12-22 2022-03-11 Incyte Corp Pyridine derivatives as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47099A (en) 2016-12-22 2021-05-12 Incyte Corp BICYCLIC HETEROAROMATIC COMPOUNDS USED AS IMMUNOMODULATORS
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2019037640A1 (en) 2017-08-22 2019-02-28 Js Innopharm (Shanghai) Ltd Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CA3079607A1 (en) 2017-10-19 2019-04-25 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of mnk1 and mnk2
HRP20230090T1 (en) 2018-03-30 2023-03-17 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
PE20210919A1 (en) 2018-05-04 2021-05-19 Incyte Corp SALTS FROM A FGFR INHIBITOR
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
HUE061503T2 (en) 2018-05-11 2023-07-28 Incyte Corp Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 immunomodulators
MX2021001752A (en) 2018-08-14 2021-06-23 Osteoqc Inc Pyrrolo - dipyridine compounds.
IL281212B2 (en) 2018-09-07 2023-12-01 Merck Patent Gmbh The history of 5-morpholine-4-yl-pyrazolo[[4,3-Bpyridine and their use
JP2022515197A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド 7-((3,5-dimethoxyphenyl) amino) quinoxaline derivative as an FGFR inhibitor for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113646314B (en) 2019-03-08 2023-12-08 首药控股(北京)股份有限公司 FGFR4 kinase inhibitors and preparation methods and uses thereof
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (en) 2019-12-04 2025-08-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
PE20221504A1 (en) 2019-12-04 2022-09-30 Incyte Corp DERIVATIVES OF AN FGFR INHIBITOR
TW202313611A (en) 2021-06-09 2023-04-01 美商英塞特公司 Tricyclic heterocycles as fgfr inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2008078091A1 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
WO2008078100A2 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2009050183A2 (en) * 2007-10-17 2009-04-23 Novartis Ag Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
WO2009150240A1 (en) * 2008-06-13 2009-12-17 Astex Therapeutics Limited Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
WO2010119285A1 (en) * 2009-04-15 2010-10-21 Astex Therapeutics Limited Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013041634A1 (en) * 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2014011900A2 (en) * 2012-07-11 2014-01-16 Blueprint Medicines Inhibitors of the fibroblast growth factor receptor
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170362253A1 (en) 2016-06-20 2017-12-21 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Additives", 2007, GOWER PUBLISHING COMPANY
"Pharmaceutical Preformulation and Formulation", 2009, THE PHARMACEUTICAL PRESS AND THE AMERICAN PHARMACEUTICAL ASSOCIATION
"Physicians' Desk Reference", 1996, MEDICAL ECONOMICS COMPANY
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
A. KEREKES, J. MED. CHEM., vol. 54, 2011, pages 201 - 210
ACS CATALYSIS, vol. 5, 2015, pages 3040 - 3053
ACS CATALYSIS, vol. 6, 2016, pages 1540 - 1552
ALAN F. THOMAS: "Deuterium Labeling in Organic Chemistry", 1971, APPLETON-CENTURY-CROFTS
CHEM. SCI., vol. 2, 2011, pages 27 - 50
ESWARAKUMAR ET AL., CYTOKINE & GROWTH FACTOR REVIEWS, vol. 16, 2005, pages 139 - 149
GALLO ET AL., CYTOKINE & GROWTH FACTOR REVIEWS, vol. 26, 2015, pages 425 - 449
HELSTEN ET AL., CLIN CANCER RES., vol. 22, 2016, pages 259 - 267
JENS ATZRODTVOLKER DERDAUTHORSTEN FEYJOCHEN ZIMMERMANN: "Angew. Chem. Int. Ed.", 2007, article "The Renaissance of H/D Exchange", pages: 7744 - 7765
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2
K. BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295
K. BLOMB. GLASSR. SPARKSA. COMBS: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", J. COMB. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOMB. GLASSR. SPARKSA. COMBS: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOMR. SPARKSJ. DOUGHTYG. EVERLOFT. HAQUEA. COMBS: "J. Combi. Chem.", vol. 5, 2003, article "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", pages: 670
KNIGHTSCOOK, PHARMACOLOGY & THERAPEUTICS, vol. 125, 2010, pages 105 - 117
R. XU, J. LABEL COMPD. RADIOPHARM., vol. 58, 2015, pages 308 - 312
T.W. GREENEP.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY & SONS, INC.
TETRAHEDRON, vol. 58, 2002, pages 9633 - 9695
TURNERGROSE, NATURE REVIEWS CANCER, vol. 10, 2010, pages 116 - 129

Also Published As

Publication number Publication date
US12012409B2 (en) 2024-06-18
US20210214366A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
US12012409B2 (en) Bicyclic heterocycles as FGFR inhibitors
US12083124B2 (en) Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) Bicyclic heterocycles as FGFR inhibitors
US11530218B2 (en) Spiro compounds as inhibitors of KRAS
US11591329B2 (en) Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) Tricyclic heterocycles as FGFR inhibitors
US10752635B2 (en) Indazole compounds and uses thereof
US20250188073A1 (en) Tricyclic compounds as inhibitors of kras
US11767323B2 (en) Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4352059A1 (en) Tricyclic heterocycles as fgfr inhibitors
WO2021257857A1 (en) Naphthyridinone compounds as jak2 v617f inhibitors
CA3124088A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
US20250163059A1 (en) Heterocyclic kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21708405

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21708405

Country of ref document: EP

Kind code of ref document: A1